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The Academy of Science of South Africa (ASSAf) was inaugurated in May 1996. It 
was formed in response to the need for an Academy of Science consonant with 
the dawn of democracy in South Africa: activist in its mission of using science and 
scholarship for the benefit of society, with a mandate encompassing all scholarly 
disciplines that use an open-minded and evidence-based approach to build 
knowledge. ASSAf thus adopted in its name the term ‘science’ in the singular as 
reflecting a common way of enquiring rather than an aggregation of different 
disciplines. Its Members are elected on the basis of a combination of two principal 
criteria, academic excellence and significant contributions to society.
The Parliament of South Africa passed the Academy of Science of South Africa 
Act (No 67 of 2001), which came into force on 15 May 2002. This made ASSAf the 
only academy of science in South Africa officially recognised by government and 
representing the country in the international community of science academies 
and elsewhere.
This report reflects the proceedings of the Surveillance and Response to Infectious 
Diseases and Comorbidities: An African and German Perspective workshop held 
from 12 – 13 April 2018 Durban, South Africa, unless otherwise stated.
Views expressed are those of the individuals and not necessarily those of the 
Academy nor a consensus view of the Academy based on an in-depth evidence-
based study.
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SESSION 1: OPENING 
Facilitator: Prof Roseanne Diab, Executive Officer, Academy of Science 
of South Africa (ASSAf), South Africa
Prof Roseanne Diab opened the conference and welcomed everyone, 
particularly the delegation from the German National Academy of Sciences 
Leopoldina (six young scientists, several senior scientists and members of 
the secretariat) and representatives of the Uganda National Academy 
of Sciences (UNAS), both of which had collaborated in compiling the 
programme. UNAS and ASSAf were recipients of an academy development 
initiative between 2004 and 2011 and had continued their valued 
relationship. A representative from each of the organising academies 
had the opportunity to make welcoming remarks.
Welcoming Remarks
Prof Jonathan Jansen, Academy of Science of South Africa, South Africa
Prof Jansen acknowledged the presence of Prof Jörg Hacker, President 
of Leopoldina; Dr Anban Pillay, Deputy Director-General of the South 
African Department of Health (DoH); Mr Christian Acemah, Executive 
Secretary of UNAS; Prof Sabiha Essack, ASSAf Council Member; and Prof 
Roseanne Diab, Executive Officer of ASSAf. He welcomed everyone to 
the second Infectious Diseases Symposium jointly hosted by ASSAf, the 
Leopoldina and UNAS. The first joint symposium on infectious diseases 
between Leopoldina and ASSAf was held in October 2016 at the Max 
Planck Institute for Infection Biology in Germany. 
The symposium is an opportunity to share knowledge and experience 
on this difficult topic, which confronts people around the world. ASSAf’s 
relationship with Leopoldina is one of the most productive in the South 
African science community. He thanked the German colleagues for taking 
this partnership seriously. A recent event in terms of this partnership was 
the Science, Business, Society Dialogue Conference hosted in November 
2017 in Johannesburg. ASSAf was celebrating five years of cooperation 
with Leopoldina in 2018. ASSAf was delighted to be working with UNAS 
and looked forward to a continued relationship.
Surveillance and Response to Infectious Diseases and Comorbidities
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A vast number of countries in Africa are reported to be ill-equipped in 
diagnostics, accurate reporting and providing treatment to combat known 
and emerging infectious diseases. The outbreaks of infectious diseases 
are expected to persist unless countries have proper diagnostic tools 
and surveillance responses. The unprecedented epidemic of the Ebola 
virus in West Africa highlights the need for stronger systems for response 
and prevention globally. This is a critical conference for identifying and 
coordinating outbreak action responses nationally and across borders. 
The sharing of knowledge in this regard is critical. The objective of the 
conference is to assess the prevalence, surveillance and responses to 
infectious diseases. 
Prof Jansen thanked the scientific coordinators who had compiled the 
programme for the event: Prof Quarraisha Abdool Karim (ASSAf), Prof 
Stefan Kaufmann (Leopoldina) and Prof David Serwadda (UNAS).
On behalf of ASSAf, and with gratitude to Leopoldina and UNAS, Prof 
Jansen welcomed all delegates to the symposium.
Prof Jörg Hacker, President, German National Academy of Sciences 
Leopoldina, Germany
It is a special pleasure for me to welcome you on behalf of the German 
National Academy of Sciences Leopoldina to this Inter-Academic 
Symposium on Surveillance and Response to Infectious Diseases and 
Comorbidities: An African and German Perspective jointly organised by 
ASSAf, UNAS and Leopoldina. First, I want to express my thanks to the 
scientific organisers of the meeting, especially to Prof Quarraisha Abdool 
Karim for ASSAf, Prof David Serwadda for UNAS and Prof Stefan Kaufmann 
for Leopoldina. They have taken on an additional load of work to make 
this conference a reality. Thanks to your commitment, we can look forward 
to an exciting meeting with brilliant speakers.
Leopoldina is very proud to have a close and vital partnership with ASSAf. 
In August 2013, the former President of ASSAf, Prof Daya Reddy, and I 
signed a memorandum of understanding (MoU) in Pretoria in order to 
strengthen ties between our academies and to provide a permanent 
platform for future bilateral cooperation. 
10
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Within the framework of this cooperation agreement, high-profile joint 
symposia on topics of substantial scientific, global and social relevance 
have been organised on a regular basis. Let me just mention the conference 
on Partial Differential Equations and their Applications in Stellenbosch in 
2016 or the conference on Air Pollution and Health in Düsseldorf, Germany 
in 2017. These events have already filled this MoU with life and promoted 
scientific exchange between our countries. 
Today, President Jansen and I will have the great pleasure of signing an 
addendum to the existing MoU. I am delighted that this fruitful bilateral 
cooperation will continue. In the addendum, Leopoldina and ASSAf will 
stress their willingness to continue their successful cooperation based on 
the MoU.
The conference today is part of a series that the Leopoldina and ASSAf 
have established in the area of health research. The series started with a 
joint conference on Environment and Health in Pretoria in June 2015. During 
that meeting, the participants analysed key environmental changes and 
their implications for human health in sub-Saharan Africa and Germany 
in order to identify future research needs and to assess possible solutions 
to present environmental health issues. Both academies also cooperated 
with science academies from Ethiopia and Ghana. 
In October 2016, Leopoldina and ASSAf organised the first conference 
for African and German young scientists in the area of infectious diseases 
at the Max Planck Institute for Infection Biology in Berlin. The scientific 
coordinators of the conference were Prof Stefan Kaufmann, Max Planck 
Institute for Infection Biology, Berlin, Germany on behalf of Leopoldina, 
and Prof Quarraisha Abdool Karim, University of KwaZulu-Natal, on behalf 
of ASSAf. This year, I would like to thank both of them for taking over this 
coordinating task again. 
I am most delighted that this conference will be the continuation of 
the health series. This time, it is a great pleasure for me to also welcome 
UNAS as an organising partner. I am looking forward to continuing this 
cooperation with UNAS. 
The theme of the conference is Surveillance and Response to Infectious 
Diseases and Comorbidities: An African and German Perspective. In this 
Surveillance and Response to Infectious Diseases and Comorbidities
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regard, the speakers of the conference will present research results in the 
areas of antimicrobial resistance (AMR), One Health, comorbidities, human 
immunodeficiency virus (HIV), tuberculosis (TB), malaria and hepatitis.
Over the past several years, the global emergence of infectious disease 
outbreaks has revealed that new approaches to fight and prevent 
the spread of pathogens are urgently needed. Many factors and a 
combination of factors contribute to infectious disease emergence. 
Worldwide population growth and urban migration, increasing international 
travel and trade and globalised food distribution favour the spread of 
infectious diseases. Mutations, gene transfer and recombination are 
responsible for pathogen variability, and drug-resistant infections are on the 
rise. I am pleased that the conference will bring together representatives 
from a broad range of disciplines to discuss these issues.
It is a special characteristic of this interdisciplinary conference that most 
speakers are young scientists from Germany and sub-Saharan Africa. 
ASSAf generously provided scholarships for numerous young scientists from 
South Africa and other African countries to attend. This variety of African 
and German speakers makes the current event exceptional. I would like 
to stress that the promotion of young scientists is a very relevant task of 
academies in the research area of human health and beyond. 
The current conference also promotes the discourse between young 
scientists and renowned senior scientists. On the German side, I am delighted 
that apart from Prof Stefan Kaufmann, also Prof Thomas Mettenleiter 
(President of the Federal Research Institute for Animal Health) and Prof 
Axel Brakhage (Director of the Leibniz Institute for Natural Product Research 
and Infection Biology) are attending this conference. These scientists are 
also members of Leopoldina.
The academies jointly organised a one-day workshop on Science Advice for 
the young scientists attending this conference yesterday. This workshop was 
organised in cooperation with the International Network for Governmental 
Science Advice – Africa (INGSA-Africa) and the International Council of 
Science Regional Office for Africa (ICSU ROA). The objectives were to 
strengthen the capacity of young scientists in providing science advice 
to national governments, as well as to develop and share science advice 
principles and guidelines pertaining to infectious diseases. I would like to 
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thank my African colleagues for this initiative, because in future years our 
academies will need the expertise of young scientists in the frame of their 
policy advice activities. 
My special thanks go to Prof Jonathan Jansen and ASSAf for hosting 
this conference and their great hospitality. We feel very comfortable in 
Durban. Moreover, I would like to thank all speakers as well as, again, 
the organisers of the conference for their great efforts. Finally, I would like 
to thank Dr Siyavuya Bulani from ASSAf for the excellent organisational 
management of the conference.
I wish us a successful conference as well as fruitful discussions today and 
tomorrow. 
Mr Christian Acemah, Executive Secretary, Uganda National Academy 
of Sciences, Uganda
The year 2016 was significant. In February 2016, the first Science Advice 
workshop took place and has become an important and significant 
initiative for the African continent, as shown by the event the previous 
day. In November 2016, UNAS and ASSAf signed an MoU without knowing 
that the present workshop would take place under the auspices of that 
agreement. Mr Acemah hoped that the present event signalled a growing 
relationship with ASSAf. The two academies were in discussions to launch 
several work-stream studies. 
Times were changing. It used to be rare to find two African academies 
working together in a spirit of mutual respect and accountability, but this 
was happening more and more on different sides of the continent and 
on various issues. These are signals of real change and appreciation for 
intra-continental and intercontinental partnerships. 
The title of the workshop refers to An African and German perspective. Just 
a few years ago, this would have read A German and African perspective, 
with ‘German’ appearing first. This is another positive change. Mr Acemah 
thanked the German partners for noticing the changing patterns on the 
African continent and engaging accordingly. 
Mr Acemah started his career by working on HIV/acquired immune 
deficiency syndrome (AIDS) and TB. He regarded the present conference 
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as technically stimulating and believed that participants would also leave 
with their spirits enriched, believing that they are part of something truly 
great.
Opening Remarks (Dr Anban Pillay, Deputy Director-General: National 
Health Insurance, Department of Health (DoH), South Africa)
Dr Pillay conveyed the apologies of the Director-General of the DoH.
The topic of public health surveillance and response to infectious diseases is 
opportune given the current health status in South Africa and the challenges 
experienced in the health system. Dr Pillay congratulated the academies 
on the coordination among them, which serves as a positive example and 
role model for the kind of collaboration that is possible between countries 
on issues of science in order to share research and expertise. 
South Africa faces a quadruple burden of disease, as described in the 
Lancet report: the HIV/AIDS epidemic alongside a high burden of TB; high 
maternal and child mortality; high levels of violence and injuries; and a 
growing burden of non-communicable diseases. According to the statistics 
that South Africa reports (dating from 2015), over 460 000 deaths occurred 
in that year, of which 55% were due to non-communicable diseases, while 
communicable diseases accounted for 33%, and injuries and violence 
for 11.1%. In analysing these deaths, it was found that of the ten leading 
national causes of death, six relate to non-communicable diseases, while 
the other four relate to communicable diseases (HIV/AIDS, TB, influenza 
and pneumonia, and other viral diseases). These statistics illustrate that 
prevention and control of disease remain a priority for the South African 
DoH and the global health community. 
Despite South Africa introducing free primary health care in 1994, there 
are still huge disparities in access to health care in the country. This is 
largely because of the structure of the health system in the pre-1994 
period, when during apartheid there were clear differences in the way 
the health services were structured for different racial groups. 
Improving the health system itself may not necessarily deal with many 
of the communicable diseases, since the contributors to these diseases 
include issues, such as access to safe water, sanitation, poverty, as well 
as the quality of education, which are key determinants in access to 
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good care. In trying to improve the health of all South Africans, the DoH 
has embarked on a number of legislative and other frameworks that are 
intended to improve the status of South Africans in relation to the prevention 
of disease and the promotion of healthy lifestyles. The aim is to provide 
access to health care that is equitable, efficient and of good quality.
It is important to recognise, particularly in the case of infectious diseases, 
that they know no borders. Politicians who would build walls between 
countries need to recognise that national borders do not prevent the 
spread of disease. Therefore, it is important to understand that multi-
sectoral and multidisciplinary cross-border collaboration and coordination 
with active data sharing, joint health assessment, timely and transparent 
communication are critical. Cross-border collaboration and joint simulation 
exercises can be useful tools to test countries’ prevention plans and 
enhance the collaboration and preparation for outbreaks. This cannot 
be addressed by one sector or one country alone. The past and recent 
ongoing epidemics of influenza and the Ebola virus in West Africa, the 
plague in Madagascar, the Zika virus in South and Central America, 
cholera outbreaks, malaria outbreaks, as well as the listeriosis outbreak 
in South Africa serve as a stark reminder of the unpredictable nature 
of pathogens and the importance of having resilient health systems in 
place. South Africa shares a vision of a world safe and secure from global 
health threats or infectious diseases, and recognises that in this regard 
it is not the capabilities of the strongest that count, but the combined 
effort of all. When an infectious disease overcomes the weakest among 
us, it overcomes all of us. South Africa is prone to epidemics of infectious 
diseases, such as rabies, cholera and haemorrhagic fevers.
Dr Pillay shared experiences of some critical aspects regarding South 
Africa’s status in relation to these diseases. Cholera is one of the oldest 
and best-understood diseases, and strongly linked to a culture of unsafe 
water, poor hygiene and poor sanitation. Generally, the cases reported at 
health facilities represent only 10% of those infected, while 90% of cases, 
which are potentially infectious, remains in the community. South Africa 
had its first recorded cholera outbreak in 1973. In August 2000, KwaZulu-
Natal experienced one of the biggest cholera epidemics nationwide in 
history. In July 2001, over 106 000 people were infected and 232 died. 
Subsequent to this epidemic, several sporadic small outbreaks were 
reported in several provinces, accompanied by the loss of life. In November 
2008, a suspected imported case from outside South Africa resulted in a 
Surveillance and Response to Infectious Diseases and Comorbidities
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cholera outbreak in the Limpopo province. In 2008, other provinces also 
reported deaths related to cholera. Some of the contributing factors 
include the migration of possibly infected persons from other countries 
into South Africa, increased travel during the festive periods, inadequate 
water and sanitation, unsafe water sources, and the rainy season, which 
exacerbate vulnerability to cholera outbreaks. Accordingly, multi-sector 
and multidisciplinary stakeholders are critical in ensuring mitigation 
against epidemics. Every epidemic affords an opportunity to learn and 
improve for future epidemics. The cholera epidemic taught two things: (1) 
epidemic preparedness and response are critical in mitigating the impact 
of outbreaks, and (2) a multi-sector and multidisciplinary approach is 
critical in order to deal with epidemics through a cross-border approach. 
Emerging zoonotic diseases
Emerging zoonotic diseases have potentially serious human as well as 
economic impacts, and the current upward trends are likely to continue, for 
example, of avian influenza. Some of the lingering zoonoses are re-emerging 
in some regions, although they seem to attract less public awareness; these 
include brucellosis and canine rabies. Increasing awareness, providing 
information for prevention and applying strict biosecurity measures are 
essential. Zoonotic diseases are a result of the strong association between 
human and animal health. Surveillance and biosecurity are key points to 
ensure the control and prevention of zoonotic diseases. It is thus necessary 
not only to implement biosecurity rules, but it is also important to ensure 
that they are correctly and strictly applied. The only way to prevent public 
health hazards related to emerging and re-emerging zoonoses is to adapt 
the human and animal health systems in a harmonised and coordinated 
way using the One Health approach. This would expand multidisciplinary 
collaborations and communications with all aspects of health care for 
human and animal public health. Understanding the mechanisms and 
the underlying causes of emerging and re-emerging infections is one of 
the most important scientific challenges that society must face today. If 
these diseases are to be monitored over time, health surveillance systems 
will have to be put in place with high sensitivity for detection and high 
specificity for diagnosis. The work of ASSAf is important to support these 
endeavours. Cross-border mechanisms are also critical in complying with 
the requirements of the International Health Regulations of 2005. One of 
the key concerns remains the frequent travel between South Africa and 
other endemic areas. Extensive travel through ports of entry creates the risk 
of importation and exportation of diseases. For this reason, South Africa’s 
16
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ports of entry, airline companies, as well as various provinces along the 
borders are requested to be on the alert and identify the importation of 
infectious diseases.
There was an outbreak of plague in Madagascar in 2017 in which 194 
cases were reported (including both suspected and confirmed cases) in 
20 districts across the country, with 30 deaths. An imported case of plague 
was reported in South Africa through the surveillance system, and it was 
possible to effectively identify and contain this case. During the Ebola 
virus outbreak in West Africa, South Africa was successfully able to prevent 
the importation of Ebola through the ports of entry and by implementing 
robust measures, such as screening for authorisation of travel between 
South Africa and other countries. In the spirit of humanitarian action, the 
South African government recruited two teams of volunteers who were 
deployed in the Ebola treatment centre in Sierra Leone. These volunteers 
were able to identify those who were ill and offer treatment. The South 
African National Institute for Communicable Diseases and National 
Health Laboratory Services developed a mobile laboratory unit, which 
was established in Freetown, and was a key point at which services were 
delivered in the Ebola-infected areas. 
South Africa continues to play an important role in trying to support countries 
to deal with epidemics that occur outside national borders. Prevention 
and control of epidemics remain a priority for South Africa. It is important 
to appreciate the enormous social and economic consequences in a 
closely connected and interdependent world. It is often difficult for the 
Ministry of Health to get the budget that it requires to manage many of 
these diseases. Colleagues in National Treasury have a better appreciation 
of the impact of managing infectious diseases when there are economic 
consequences of not doing so. Another best practice is the One Health 
approach to manage the outbreak of various infectious diseases in South 
Africa. 
Antimicrobial resistance strategy
South Africa has implemented an AMR strategy. Adopting and implementing 
the strategy are critical for government to take account of. Access to 
effective basic treatment to manage infectious diseases is critical to the 
Surveillance and Response to Infectious Diseases and Comorbidities
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success of the AMR strategy. There is currently a shortage of vaccines, 
such as Bacillus Calmette–Guérin vaccine (BCG) and basic antibiotics, 
such as penicillin, largely because these are not commercially attractive 
for companies to produce. The consequence is that far more expensive 
drugs are used to manage diseases, with significant consequences for 
the success of the AMR strategy. It is important to focus energy on dealing 
with these matters. 
Listeriosis
South Africa is currently experiencing the largest listeriosis outbreak recorded 
internationally. At a recent G20 meeting, there was considerable concern 
about the extent of the listeriosis outbreak. Coming just after the Joint 
External Evaluations in relation to the World Health Organisation (WHO) 
International Health Regulations, the outbreak afforded South Africa the 
opportunity to implement some of the recommendations. The South African 
DoH has published regulations on notifiable medical conditions, which 
now include listeriosis. The DoH has also implemented a multidisciplinary 
team that includes the departments of Trade and Industry; Agriculture, 
Forestry and Fisheries; Cooperative Governance and Traditional Affairs; 
the Consumer Council; WHO and others. The intention is to create an 
integrated approach to manage listeriosis outbreaks. The integration of 
services will help manage the investigation and identify the sources of 
this bacterial infection, recall infected products and monitor outbreaks 
from other sources. The outbreak called for intensive communication. The 
DoH appreciates the lessons it is learning in terms of developing a more 
resilient process.
This conference comes at a good time. Professionals have the opportunity 
to identify their roles and possible contribution to prevent, protect, control 
and provide public health responses to the international spread of disease 
in the light of the International Health Regulations.
The importance of cross-border surveillance, and professionals from three 
countries coming together at this conference, as well as the opportunity 
for scientists to give advice to government on infectious diseases, was 
emphasised.
18
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Keynote Address I: Future Prospects in Infectious Diseases: Critical 
Tools to Manage Outbreaks on the Continent (Dr Izukanji Sikazwe, 
Centre for Infectious Disease Research in Zambia, Zambia)
The Centre for Infectious Disease Research (CIDRZ) was founded in 
2001 as a collaboration between the Zambian Ministry of Health, the 
University of Zambia and the University of Alabama, Birmingham. Its 
activities were centred on clinical trials mostly for prevention of mother-
to-child transmission, working mostly with nevirapine. In 2011, CIDRZ 
was established as an independent local organisation, with Zambians 
making up most of senior management and the board of directors. The 
centre is mostly grant-dependent (competitive or solicited), with funding 
from the United States (US) government (President’s Emergency Plan for 
AIDS Relief (PEPFAR)/Centres for Disease Control and Prevention (CDC), 
National Institutes of Health (NIH)), European and Developing Countries 
Clinical Trials Partnership (EDCTP), United Kingdom (UK) Department for 
International Development (DFID), European Union (EU), Bill and Melinda 
Gates Foundation, ELMA Foundation, TB Alliance and others. CIDRZ has a 
footprint across four provinces in Zambia, two of which have the highest 
prevalence of both HIV and TB. The centre supports the delivery of high-
quality health care services for hundreds of thousands of Zambians within 
the public health system, conducts groundbreaking research, and has 
become a local and international training ground and resource. CIDRZ 
is the biggest research institute in Zambia.
CIDRZ has a strong commitment to answering key research questions 
relevant to Zambia and the region. Its key activities are:
• Supporting local financial and technical ownership of high-quality, 
complementary and integrated health care services within the public 
health system.
• Facilitating clinical, research and professional development training. 
• Partnering with multiple leading universities and institutions to ensure 
that the latest methodologies are used to answer locally relevant 
health questions.
Historical review of infectious disease outbreaks on the African continent
Since the 1980s, the global number of disease outbreaks has risen, while 
the variety of diseases has also increased. The proportion of diseases 
transmitted by animals and other vectors has also risen relative to those 
that are human-specific. The map of global emerging and re-emerging 
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diseases has become busier over the years. The ‘deliberately emerging’ 
infectious diseases are of particular concern. This refers to the anthrax 
outbreak in the United States of America (USA), where a group of individuals 
deliberately sent out an infectious pathogen. This is particularly worrying in 
the current global context. There have recently been alleged chemical 
releases in Syria that killed hundreds of men, women and children. 
Between 1976 and 2017, the Zairian Ebola virus strain was the most 
prevalent. In the most recent Ebola virus outbreak in Guinea, Liberia and 
Sierra Leone in 2016, there were 28 616 cases and 11 310 deaths. 
The drivers of infectious diseases, particularly HIV, hepatitis and TB, are 
clearly visible, including crowding and a lack of hygiene, but countries do 
not seem to be very active in controlling them. Asylum seeking is a human 
right, but systems have to be instituted to accommodate refugees and 
ensure that they have access to safe water, housing and health care. 
Prison systems are a source of overcrowding and infection. 
Recent outbreaks in Africa
Recent outbreaks of infectious diseases in Africa include Lassa fever in 
Nigeria, hepatitis E in Namibia, Rift Valley fever (RVF) in The Gambia, 
Chikungunya in Kenya, listeriosis in South Africa and cholera in the 
Democratic Republic of the Congo, Mozambique, Tanzania, Somalia 
and Zambia.
The listeriosis outbreak in South Africa began in January 2017 and was 
still ongoing because of its long incubation period of 70 days. There had 
been 982 cases with 28% fatalities, which was one of the largest outbreaks 
worldwide to date. Listeriosis had been isolated from blood cultures, as 
well as cerebrospinal fluid. The most affected group were neonates, 
accounting for 41% of cases. The source of the infection was fortunately 
identified, although it took more than 14 months from the initial cases. 
Measures had been instituted to recall products and clean up the meat-
processing plants responsible for the outbreak. Several neighbouring 
countries banned the import of meat products from South Africa. The 
listeriosis outbreak has been accompanied by considerable hysteria, 
fuelled by social media and fake news or alternative facts. Tiger Brands, 
the majority shareholder in the company that produced the infected 
products, suffered a drop in its share price. 
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Cholera has re-emerged in Zambia. The defence force was called in to 
clean up and move vendors off the streets. Some types of the seventh 
cholera epidemic, imported from Indonesia in the 1960s, continue to 
proliferate across the African continent. Cholera accounted for about 9% 
of cases of diarrhoea worldwide in 2013. Zambia has suffered recurrent 
outbreaks of cholera since the early 1990s, driven by government transition 
during the departure of President Kaunda and the consequent negative 
impact on the economy. The cholera outbreak was one of the factors 
that led to the wide-scale public disaffection that drove Kaunda out. 
The most recent outbreak began in September 2017 and is still ongoing 
with recent spikes in some sub-districts in the Lusaka province. The source 
was contaminated shallow water wells in high-density areas, mostly in 
the capital city of Lusaka, due to the lack of sufficient sanitation systems 
for the large urban population. By March 2018, there had been 4 443 
cumulative cases and 82 deaths, and a case fatality rate of 1.85%. The 
outbreak was being treated with Ciprofloxacin, and the usual emergency 
management responses were being instituted to contain it. 
Although the focus of the work of CIDRZ has been on HIV, the centre is 
involved in cholera research funded by mostly by DFID, with some WHO 
funding:
• Immunological characteristics of a population at risk of cholera are 
being profiled before and after the first and second doses of the oral 
cholera vaccine. 
• The Extended Dose Interval Study (EDIS) determines changes in the 
vibriocidal geometric mean titers in subjects who receive the second 
dose of oral cholera vaccine at different intervals: two weeks or six 
months after the first dose of vaccine. 
• Cholera surveillance is being strengthened through hotspot mapping.
• The relationship of cholera strains between historical and new outbreaks 
is being investigated.
Critical tools to manage outbreaks on the African continent
Critical tools for managing outbreaks are centred on being able to 
detect and monitor an outbreak and institute timely responses. A vibrant 
multidisciplinary workforce is required. During the listeriosis outbreak in 
South Africa, integrated teams were instituted, made up of different 
professionals including not only health care workers, but also engaging with 
the community. The thinking that only infectious disease physicians should 
be involved in managing a disease outbreak is wrong. Multidisciplinary 
Surveillance and Response to Infectious Diseases and Comorbidities
Proceedings Report 12 – 13 April 2018
21
teams could be made up of epidemiologists, clinical microbiologists, 
laboratory technicians, pharmacists, public health advocates, other clinical 
providers and social workers. There is also a critical role for communication 
specialists and community leaders.
During an outbreak, the role of infectious disease physicians and clinicians 
is to:
• Recognise that a new outbreak is taking place.
• Collaborate with laboratory staff with respect to correct sampling and 
interpretation of results.
• Conduct appropriate isolation and treatment.
• Interact with public health advocates and governments to communicate 
correct and appropriate information.
Technology must be effectively used to extend electronic health record 
capabilities by providing real-time access to clinical and non-clinical data 
from multiple data sources, for example, coupling geographic information 
system (GIS) data with mobile health to map outbreak hotspots in field 
settings. Targeted data analytics need to be employed to detect emerging 
disease threats by monitoring the incidence and prevalence of conditions 
and pathogens. Communities must be mobilised and communication 
improved. 
Active and passive surveillance is needed to detect infectious diseases. 
Infectious disease intelligence is the best defence, which entails systematic 
ongoing collection, collation and analysis of data for public health. 
Surveillance networks include:
• Global Outbreak Alert and Response Network (GOARN) launched by 
WHO in April 2000, which links real-time networks with data, expertise 
and skills needed to keep the international community alert and able 
to respond.
• Africa Centres for Disease Control and Prevention (Africa CDC), which 
started in in January 2016 and has established the Regional Integrated 
Surveillance and Laboratory Network (RISLNET) with five regional 
collaborating centres in Egypt, Nigeria, Gabon, Zambia and Kenya.
• Global Health Security Agenda (GHSA) launched in 2014 with funding 
from the Group of Seven (G7) countries.
Zambia recently established its first public health institute and plans to 
build its first public health laboratory but lacks the right laboratory support 
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needed in the country. Surveillance is facing funding challenges with 
the reduction in the work of the CDC, including its work on the African 
continent.
Laboratory capacity plays a critical role before, during and between 
outbreaks with respect to early warning signals, outbreak response and 
management and trend monitoring. The establishment of as many reference 
laboratories as possible with international accreditation in key localities 
across the African continent is essential. Africa has several biosafety level 
(BSL) 4 and BSL 3 laboratories, which play a role in early warning, supporting 
the outbreak response, and the monitoring and management of outbreaks. 
Laboratories should be well networked with country-specific focal point 
persons in each one to coordinate the information flow during and after 
outbreaks. In order to respond appropriately, public-private partnerships 
must be maximised. This cannot be a government responsibility alone, but 
close collaboration is needed between various diagnostic centres, clinical 
teams and public health institutions. Training initiatives and innovative 
programmes must be created to support exposure to infectious diseases. 
Resources are required to improve access to training programmes 
and internships, as well as improved compensation. Investment and 
political will are needed to support a prepared and vibrant workforce. 
A behaviour change approach should be utilised to limit exposure to 
infectious pathogens.
The challenges include:
• Surveillance systems are currently inadequate.
• There is a dwindling pipeline of new antibiotics and antivirals, continued 
emergence of resistant pathogens, and non-existent or ineffective 
antimicrobial stewardship.
• There is a lack of creative training initiatives in relation to infectious 
diseases with respect to emerging topics and outbreaks, undergraduate-
level training, combined certification pathways (e.g. infectious diseases 
and clinical microbiology, or infectious diseases and critical care) and 
public health training.
• There is a dwindling pipeline of new infectious disease trainees 
entering programmes in the USA, and positions are vacant because 
the compensation is not equivalent to what counterparts in surgical 
or other medical specialisation fields receive.
Surveillance and Response to Infectious Diseases and Comorbidities
Proceedings Report 12 – 13 April 2018
23
• There is a lack of vaccines due the cost and long turn-around time to 
produce safe and effective vaccines. The Ebola vaccine is a case in 
point. Researchers, specialist scientists and policymakers had to move 
quickly to address ethical considerations, obtain financing and increase 
the pace of production to get the vaccine to the population.
• Resources are required to improve access to training programmes and 
internships.
• Investment and political will are needed to support a prepared and 
vibrant workforce to address the unrelenting infectious threats.
• Other cadres of health care works should support detection, monitoring 
and response to possible outbreaks.
• Point-of-care diagnostics must be used to detect new pathogens.
• Microbial-resistance patterns must be improved.
• Accredited clinical labs are required with functional microbiology and 
virology systems.
• Hubs and referral networks must be mapped.
• Human resource gaps need to be addressed.
• Communication and information systems are inadequate.
There is currently a fourth HIV epidemic driven by HIV-1 drug resistance, 
and primary resistance is increasing. 
The future of combating infectious diseases is promising, given the 
environment of technology and the brilliant minds who are working on 
the challenges.
Keynote Address II: Metabolism and Pharmacokinetics of Anti-
Parasitic Drugs: Implication for Treatment, Safety and Efficacy (Dr 
Collen Masimirembwa, African Institute of Biomedical Sciences 
and Technology, Zimbabwe)
The previous presentation emphasised the importance of response 
mechanisms to infectious diseases, one of which is treatment. The field of 
pharmacokinetics deals with the way in which the body handles medicines, 
as well as issues of drug safety, efficacy, affordability and access.
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The African Institute of Biomedical Sciences and Technology (AiBST) focuses 
on drug safety, efficacy and cost/benefit analysis. The institute conducts 
translational research in the following areas:
• Drug metabolism and pharmacokinetics, which are major determinants 
of the outcomes related to safety, efficacy and affordability. When the 
major impediments to drug discovery and development were reviewed, 
it was shown that poor pharmacokinetics in the 1990s was a major reason, 
accounting for 40% of the failure due to the poor way in which drugs 
were absorbed, distributed, metabolised and excreted in the body. 
If these issues could be addressed, drugs could be developed with 
better efficacy and safety profiles. When the pharmaceutical industry 
introduced pharmacokinetic analysis in 2005, the failure rate due to 
poor pharmacokinetics was reduced to less than 10%. Drugs that were 
discovered and developed before the advent of pharmacokinetic 
integration still carry liabilities that could compromise their use. AiBST 
addresses these issues and what could be done to rescue the situation. 
The ultimate outcome of drugs depends on the complex interplay of 
many factors. Pharmacokinetics looks at the concentration of drugs 
over time, and the levels at which they are most effective against 
disease without side effects. In these investigations, AiBST collaborates 
with partners in medicinal chemistry and pharmacology.
• Pharmacogenetics, since the genetic makeup of people impacts on 
the way in which they respond to medicines.
The institute also conducts clinical trials.
Much of the work of AiBST is done in vitro, and some entails computational 
modelling. Animal studies are decreasing as they are not very predictive 
of the human response. The liver is the key organ for the breakdown of 
drugs, and the major determinant of the pharmacokinetics of a drug. 
In some cases the drug itself could be effective, but in other cases the 
medication, after administration, is metabolised into a pharmacologically 
active drug, resulting in a prodrug, and it must then be ensured that 
enzymes produce enough of the active compound. A danger is that 
the metabolites could be very reactive and result in toxicity. The major 
enzymes responsible for metabolising compounds are cytochrome P450s, 
either to facilitate excretion or by bio-activation.
Most of the drugs for parasitic diseases were discovered in between the 
1940s and 1970s, and there have not been new drugs since then. There are 
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big challenges to young people to discover new medicines, particularly 
for neglected tropical diseases. AiBST investigates the efficacy of drugs 
(amodiaquine, praziquantel and efavirenz) and ways of addressing their 
liabilities and reintroducing the drugs to the market.
Amodiaquine for malaria has serious neutrocytosis and liver toxicity issues, 
but was put back on the market after the development of widespread 
resistance to chloroquine. The approach was to rescue the drug through 
designing away from toxicophores. Isoquine had been found to be a 
promising analogue devoid of potential for liver toxicity, but it failed in 
clinical trials due to agranulocytosis. The research at AiBST began by 
analysing the enzymes responsible for metabolising the compounds. 
The metabolism of amodiaquine was then looked at in more detail. It 
was realised that amodiaquine was also being metabolised through an 
aldehyde, which was a very reactive compound circulating in the blood. 
Another mechanism for the toxicity was thus discovered. The initial work 
thus only solved the liver toxicity but not the blood toxicity. Molecular 
modelling was then done to try to design analogues that could bypass 
the bioactivation pathway. AiBST collaborated with Prof Kelly Chibale 
at the University of Cape Town and synthesised a number of analogues, 
which were tested for anti-malarial activity. They proved to be more 
potent than amodiaquine or chloroquine. The compounds were tested 
for reactivity, and it seemed that the aldehyde formation was not taking 
place. It seems that an analogue has been developed that has anti-
malarial activity but does not carry the reactive capacity of the aldehyde. 
Future work would investigate whether a variant of compound 19 could 
replace amodiaquine in malaria combination drugs.
Praziquantel, which is used to treat a number of types of parasitic worm 
infections, has variable efficacy because it is rapidly removed from the 
body. However, it is still the only drug available to treat schistosomiasis, 
which affects over 207 million people in 78 countries. In countries where 
schistosomiasis is endemic, annual mass drug administration is done (i.e. the 
drug is administered to four million children within a week). There are many 
complaints about adverse drug reactions and poor treatment outcomes. It 
is the R form of praziquantel that is effective, and not the S form. The drug 
is administered as a mixture of the R and S forms, which means that of the 
600 mg dose, only 300 mg are actually required. The research looked at 
what causes the R form to be metabolised and removed from the body. 
Rifampicin (RIF), which is used to treat TB, was found to markedly decrease 
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concentrations levels of praziquantel. This means that when praziquantel is 
administered to patients who are coinfected with TB and schistosomiasis, 
the praziquantel is ineffective. Concentrations of (R)-praziquantel need 
to be raised. The approach was to rescue the drug by using a boosted 
regimen. The research at AiBST was inspired by work with HIV drugs in 
which protease inhibitors are administered together with retinol V, the 
purpose of which is to inhibit the enzyme that removes protease inhibitors 
for sustained exposure levels. The research at AiBST began by looking 
at the kinetics of praziquantel and identifying compounds that could 
inhibit the enzymes, so that by administering them together the exposure 
levels of praziquantel could be boosted for better treatment outcomes. 
Metabolic studies have been done to identify the biotransformation routes. 
With that knowledge, the research team can look for other compounds 
that can be co-administered. It has been found that exposure levels are 
boosted if praziquantel is administered together with a cytochrome P450 
(CYP)1A2 inhibitor. This could be a quick solution to ensure that the use 
of praziquantel among the population is not compromised through co-
administration with a compound that ensures sustained exposure and 
maintenance of effective concentrations.
Efavirenz is currently the drug of choice for treating HIV but carries severe 
neuropsychiatric side effects, particularly in the African population. AiBST 
focused on how to minimise the toxicity and maximise the benefit of the 
drug. There is a genetic variable associated with reduced capacity to 
remove the drug. Higher exposure levels are associated with higher severity 
of the adverse drug reaction. The research found that the African population 
was distinct from Caucasians and Asians in terms of genetic variance for 
drug response, and that there are also complex variations among the 
African population with clinical implications. Eighty per cent of people 
treated with efavirenz had at least one severe adverse reaction. More 
than half of patients were outside the therapeutic concentration range. 
It was concluded that the dose of 60 mg was too high. Some of the results 
were published in 2008, but the government did not listen. In 2013, when 
efavirenz became first-line therapy and patients kept complaining, the 
government began to show interest in the findings. By 2016, efavirenz was 
ranked second among the drugs causing adverse reactions throughout 
Africa and a solution was required through personalised dosing. AiBST 
looked at their data and developed a model to try to understand how 
best to use efavirenz in the African population. It was shown that a patient 
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must be genotyped for enzyme status and those with reduced capacity 
to remove the drug must be given doses of only 200 mg instead of 
600 mg. The weight and gender of the patient are also taken into account. 
The approach was to rescue the drug through use of a pharmacogenetic-
based dosing algorithm.
This research gives rise to the question of whether Africa is ready for 
precision personalised medicine. AiBST believes that this is possible, and 
that Africa is ready. Efavirenz is an example that this approach can be 
actively deployed. Polymerase chain reaction (PCR) machines are not 
expensive, so the issue of cost should be removed from the equation and 
the focus should be on the benefits. The Zimbabwean government has 
asked for a cost/benefit analysis of the proposed efavirenz personalised 
medicine regime. 
Apart from its work on rescuing drugs, AiBST is working on building 
infrastructure, developing technologies and training the next generation of 
biomedical scientists to support the whole drug discovery and development 
value chain.
AiBST has set up a laboratory in Harare with the capacity for genomic 
analysis as well as biomimetics for drug concentrations and pharmacokinetic 
and pharmacodynamic modelling, benchmarked against best practice 
in industry. Building the facilities is a slow and expensive process. A 400 m2 
phase I clinical trial unit that meets international standards has recently 
been set up with 28 beds, data-capture facilities, archive room, board 
room, offices and a research pharmacy. This facility enables AiBST to do 
clinical trials in partnership with pharmaceutical companies that are trying 
to introduce drugs into Africa.
AiBST believes that the future lies in forming strong partnerships with drug 
discovery and development companies so that Africa is taken into account 
at an early stage when the drugs are developed.
Discussion
Question: What are the statistics for resistance to HIV drugs and are 
there alternative drugs? What are the statistics for the prevalence of HIV 
type 2 in Zambia?
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Response (Dr Sikazwe): There is about 12% resistance to the first-line non-
nucleoside reverse transcriptase inhibitors (NNRTI) drug used in lower-
income countries in the region. Local data from Zambia from 2009/10 found 
resistance to efavirenz to be 5 – 6%. Zambia has been working since 2010 
to establish a drug-resistance surveillance system, but it has not yet been 
set up. The protocol is almost ready for submission, and funding is now 
available for primary resistance surveillance work. Zambia is getting ready 
to roll out an alternative first-line drug to overcome primary resistance.
Zambia mostly has HIV-1 (subtype C), and HIV-2 rates are low. There has not 
been any work to specifically identify the rates of HIV-2. From work done 
in the late 1990s and early 2000s, the rates of HIV-2 are less than 1%, and 
this type usually occurs in individuals who have come from West Africa.
Question (Prof Stefan Kaufmann): Is there any evidence that the activation 
of CYP molecules is induced by the drugs and how they are induced, 
mostly by praziquantel? What is the receptor of the transcription that 
activates the CYP molecule?
Question (Prof Axel Brakhage): Would it be possible to try to inhibit the 
enzyme?
Response (Dr Masimirembwa): These enzymes are mainly non-hepatic 
(i.e. not in the liver) but occur in the lungs or blood cells. The expression 
of CYP1A1 and CYP1B1 in the lungs or blood bio-activates amodiaquine, 
which is induced by polycyclic aromatic hydrocarbons going through 
the hydrocarbon receptor. 
The enzymes involved in the metabolism of praziquantel are CYP3A4 
and CYP2C. For CYP3A4, the pregnane X (PX) receptor is the mechanism 
through which induction takes place. There are many drugs that are 
inducers of CYP3A4; RIF is an important inducer. Nevirapine is therefore not 
given together with RIF because RIF will cause CYP3A4 levels to shoot up.
Boosted regimens are good clinical examples. For some P450s, specific 
potent inhibitors are known. In the case of expensive drugs, such as 
cyclosporine, smaller doses could be administered together with 
ketoconazole, itraconazole or fluconazole, which would block CYP3A4. 
AiBST is looking at whether that kind of mechanism could be borrowed to 
boost exposure levels of praziquantel without side effects to reach levels 
that kill schistosomiasis.
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Round-Table Discussion I: Challenges of Diagnosis and Management 
of Comorbidities
Moderator: Dr Izukanji Sikazwe, Centre for Infectious Disease Research 
in Zambia, Zambia
Panellists:
Dr Shevin Jacob, Infectious Diseases Institute, Uganda/Liverpool School 
of Tropical Medicine, United Kingdom
Dr Alex Sigal, Africa Health Research Institute, South Africa
Dr Jackson Marakalala, University of Cape Town, South Africa
Prof Gayle Sherman, National Health Laboratory Service, South Africa
Dr Norbert Heinrich, University Hospital, LMU, Munich, Germany
The moderator introduced the session. Africa is facing several epidemics. 
The epidemic of non-communicable diseases (NCD) intersects the 
epidemics of HIV and communicable diseases. 
Dr Shevin Jacob, Infectious Diseases Institute, Uganda/Liverpool School 
of Tropical Medicine, United Kingdom 
Dr Jacob gave a presentation on Uganda’s experience with HIV and 
non-communicable disease comorbidities.
NCDs kill approximately 40 million people each year, accounting for 
about 70% of all deaths globally. The four most common NCDs are: 
cardiovascular (17.7 million deaths per year year), cancers (8.8 million), 
respiratory diseases (3.9 million) and diabetes (1.6 million). Over 80% of the 
deaths that are deemed ‘premature’ (i.e. between the ages of 30 and 
69 years) occur in low and middle-income countries (LMICs).
In a quote from a 2014 article: “We are now in an era when people living 
with HIV may experience a reduction in quality of life or die, not from HIV 
itself, but from a preventable NCD that may be a consequence of HIV-
related immunosuppression, antiretroviral drug toxicities, or HIV-related 
inflammation and hypercoagulation.” Specific considerations for HIV 
and NCDs in LMICs include higher prevalence of infections such as TB 
and hepatitis.
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The Infectious Diseases Institute (IDI) in Kampala, Uganda looked at 1 000 
patients in the antiretroviral treatment long-term cohort between May 
2014 and September 2015. This cohort comprised adults who had been on 
antiretroviral (ARV) treatment for ten consecutive years: 345 (34.5%) of the 
patients were from a pre-existing IDI research cohort and 655 (65.5%) from 
a routine clinic. Eighty-one per cent of the cohort was on first-line ARVs: 
• AZT/3TC/NVP (44%)
• AZT/3TC/EFV (22%)
• TDF/3TC or FTC/EFV (10%).
About 21% of the cohort suffered from hypertension; fewer than 5% had 
cardiovascular disease (CVD) or diabetes. Almost 23% engaged in tobacco 
use and 73% in alcohol consumption.
The Integrated Management of Adolescent and Adult Illness (IMAI) Package 
of Essential Non-communicable Intervention Tools (PEN) framework has 
been established by the WHO to integrate NCD care within primary health 
centres in LMICs. Tools to implement this framework have been developed 
by two NGO: the IMAI Alliance based in the USA, and Walimu (co-founded 
by Dr Shevin Jacob) in Uganda. These tools are currently being piloted 
in primary health centres within Uganda through collaboration with the 
Ugandan Ministry of Health and include the following:
• Acute care involving screening/early detection for CVD risk, hypertension, 
diabetes mellitus (DM), and breast and cervical cancer. This focus area 
includes a systematic approach to acute care for severe hypertension, 
diabetic ketoacidosis (DKA), myocardial infarction and heart failure 
involving emergency assessment and then essential pre-referral 
treatments.
• Integrated NCD chronic care, with a focus on sequence of care, task-
shifting and a modular approach involving three protocols:
o Protocol 1 (HEARTS for CVD/DM): fully technically compatible with 
and operationalises the Global HEARTS programme. It involves 
training for physicians, nurses and auxiliary staff and task-shifting in 
the case of limited human resources to auxiliaries (nursing assistants, 
health educators, trained expert patients). The longitudinal patient 
monitoring system, which is similar to the HIV system, can support 
HIV-NCD co-management;
o Protocol 2 (for asthma and chronic obstructive pulmonary disease): 
symptom-based management of chronic respiratory illness;
o Protocol 3 (for rheumatic heart disease): assessment, tracking and 
secondary prophylaxis.
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The sequence of care in integrated NCD chronic care draws on Ugandan 
experience of scaling up HIV care and ARV treatment. It entails clear 
integration of work within the clinical team and clarifies which tasks can 
be performed by auxiliaries, which require a clinician, and when and how 
to refer. It is aimed at feasible scale-up to manage a large number of 
patients (given the large NCD burden) and works in settings with limited 
human resources.
The tools developed for implementation of the WHO IMAI-PEN Protocols 
include:
• NCD card (similar to the HIV card used in many outpatient clinics), which 
provides a summary of the patient, their encounters and counselling.
• NCD register, which is a longitudinal analysis of hypertension, diabetes 
and elevated CVD risk.
The reports allow one to look at specific indicators and longitudinal care.
There is much research still to be done on how best to address the growing 
burden of NCDs in sub-Saharan Africa.
Dr Alex Sigal, Africa Health Research Institute, South Africa
At the Africa Health Research Institute, Dr Segal was involved in research 
on how necrosis occurs in a lung infected with TB. The findings were 
surprising. Macrophages perform well if they are infected with single 
Mycobacterium tuberculosis (Mtb) but die when they are infected by a 
clump. The TB is not eliminated during cell death, and will be taken up by 
the next cell, which will die in turn and so on. It is believed that this process 
of successive cells being infected and dying leads to the damage in the 
lung as a result of an active TB infection. 
Dr Sigal’s background was not as a clinician but as a computational 
biologist. As a basic scientist, he was gaining increasing appreciation of 
the importance of surveillance. It is important to be able to straddle the 
population. Within a population of HIV-infected individuals on antiretroviral 
therapy, there may be different types, for example: some may be failing 
therapy due to lack of adherence, while others may be partially adhering 
and still suppressive. The difference between these two groups with respect 
to the HIV reservoir is a key question for surveillance epidemiology, leading 
to further research.
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Dr Jackson Marakalala, University of Cape Town, South Africa
Dr Marakalala is an immunologist who looks at the interaction between 
immunology and infectious diseases. He had done research on TB 
biomarkers. 
In 2005/06, the first outbreak of extensively drug-resistant tuberculosis 
(XDR-TB) in the region occurred in Tugela Ferry. The deaths associated with 
this outbreak point to the lack of proper surveillance procedures being 
in place. There is a need for thorough preparedness to avoid outbreaks 
of infectious disease. 
Hippocrates, who lived around 400 BC and is known as the father of 
medicine, observed a tumour-like structure in the lungs (now known as a 
granuloma). At the time, many people believed that it was hereditary and 
did not connect it with a causative agent. Aristotle, his fellow countryman, 
mentioned his belief in about 340 BC that when a consumptive coughs, 
something heavy in the air is transmitted to other people causing 
consumption (TB). However, no-one knew at that stage that there was 
a strong connection between a causative agent and the granuloma. A 
granuloma is an aggregate of immune cells that come together when 
the bacteria that cause TB are inhaled into the lungs. The bacteria settle in 
spaces in the lungs known as alveoli. Within the alveoli, the microphage cells 
capture the TB bacteria, and many other mononuclear cells are recruited 
from nearby blood vessels to the site of infection. Adaptive immunity arrives 
in the form of T-cells and P-cells. The bacteria are contained at the centre 
of the aggregate granuloma. Many people believe that the bacteria 
could be contained and confined at the centre of the granuloma so that 
people could survive without the bacteria causing disease. 
Two thousand years after Hippocrates and Aristotle reported the first 
observations of granulomas, Robert Koch, working in in Heidelberg in 
1882, cultured bacteria from a pathogen connected to TB. The Nobel 
Prize in Physiology or Medicine 1952 was awarded to Selman Abraham 
Waksman for his discovery of streptomycin, the first antibiotic effective 
against tuberculosis. Despite extensive research, TB remains a challenge in 
that 1.7 million people still die from TB each year. Sub-Saharan Africa has 
the highest TB burden of disease, compounded by increasing numbers 
of immuno-compromised individuals in the last 35 years due to HIV. Those 
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with HIV have a 30 times higher chance of contracting active TB due to 
depleted CD4 T-cells needed to structure the granuloma so as to contain TB. 
One of the most important things to understand now with respect to 
diagnosis is how to accurately predict the disease activation from latent 
to active status. Granulomas that solidly contain bacteria are used to see 
how the structure dissolves to form caseations (i.e. cheese-like structures 
with cavities in the lung) through which the bacteria can be spread 
throughout the lung and coughed out. Research looks at the spectrum of 
disease at tissue level that mirrors disease progression and tries to identify 
molecules at each step that could help predict disease progression and 
be used in point-of-care diagnostics. However, not everything present in 
the lung circulates in the blood. 
An exciting study at the South African Tuberculosis Vaccine Initiative (SATVI) 
at the University of Cape Town is conducting longitudinal studies for 800 
days before diagnosis. Molecules have been identified that reliably show 
latent infection. Some of these molecules are present in blood signatures. 
This avenue can be explored for developing diagnoses that would catch 
people on the brink of developing active TB for better interventions.
Prof Gayle Sherman, University of the Witwatersrand, Centre for HIV & 
STI, National Institute for Communicable Diseases, South Africa
The presentation would highlight diagnostic challenges of rolling out the 
early infant diagnosis programme for HIV (i.e. in the first 18 months of life). 
It is fairly easy to diagnose adults with HIV; by taking a drop of blood from 
the finger and using a rapid test, an individual can be diagnosed within 
one to 20 minutes. Infants at risk are born to mothers who are already HIV-
infected; through passive immunisation, those babies will test positive at 
birth regardless of whether they are infected or not if an antibody test is 
used. For diagnosis of HIV during the first 18 months of life, a PCR HIV viral 
detection assay is required, which is much more costly. Approximately 
300 000 of the one million babies born in South Africa each year are 
born to HIV-infected women. It is essential to identify infected infants for 
treatment and to monitor the prevention-of-mother-to-child-transmission 
(PMTCT) programme. 
The first challenge faced in around 2000 was ‘it can’t be done’ due to 
the technology being costly and requiring considerable expertise in a 
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low-resource setting. The view was to rather use clinical skills and/or other 
biological markers with suboptimal positive predictive values to make 
diagnoses. When South Africa implemented the roll out of ARVs in 2004, 
the Antiretroviral Roll Out Guidelines did not include HIV PCR as a way of 
diagnosing infants. 
The next challenge is to demonstrate how it can be done. This entailed 
developing protocols, raising funding and showing that HIV PCR testing 
in a local setting, albeit used less frequently than in the developed world, 
can achieve a definitive diagnosis, improve care and is affordable. In 
2006, HIV PCR testing was adopted for other low-resource settings by the 
WHO in HIV Early Infant Diagnostic (EID) guidelines.
The next challenge was that of implementation. It had been overlooked 
that it is difficult to get a blood sample from a six-week-old infant, and 
there are not enough people trained to do so. In order to address this, new 
studies had to be done on how to do the diagnostics on dried blood spots 
from a heel prick, for which there is experience. After the introduction of 
dried blood spot testing in 2005, EID could be scaled up in locations other 
than tertiary hospitals where it was traditionally being done. Additional 
issues arose in how to deal with dried blood spot tests in the laboratory. 
The next challenge was to train people to conduct the diagnoses.
The early infant diagnosis programme for HIV is monitored using laboratory 
test data from the National Health Laboratory Service, where all data go 
into a single data warehouse. From 2004 when only about 2 000 HIV PCR 
tests were done, usually as part of research studies, the number of children 
under the age of two months who were tested with PCR rose to 450 000 
by 2015. As PMTCT was rolled out in South Africa, there was a decrease in 
mother-to-child transmission to only 1.8% in 2014. This was a year ahead 
of the target of below 2% set in the National Strategic Plan (NSP) for 2015. 
Other challenges remained. The HIV epidemic had been evolving; there 
was more ARV drug pressure; more sensitive HIV PCR assays became 
available; and there was more knowledge about the poor outcomes that 
infants infected with HIV experienced. These factors led to the introduction 
of new HIV EID Guidelines in 2015. 
New truths about HIV emerged. It used to be taught that once an HIV 
PCR was positive in a child, it would remain positive; however, this is no 
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longer the case. With the ARV drug pressure, can be more difficult to 
make a definitive diagnosis of HIV in children now than it was 15 years 
ago because of lower viral reservoirs and/or viral loads. Clinicians have 
to deal with many indeterminate tests in which they are not sure whether 
the patient is HIV-positive or not. 
Dr Norbert Heinrich, Division for Infectious Diseases and Tropical 
Medicine, University of Munich, Germany
Dr Heinrich gave a presentation on TB diagnostics and sequelae. 
According to WHO statistics, there are ten million new cases of TB per 
year, but of these an estimated four million cases are not reported to the 
health system, do not receive diagnosis and treatment opportunities, and 
continue to spread the disease. Without treatment, mortality is about 50% 
within two years. In the past, microscopy was the only diagnostic tool with 
widespread availability; and its high limit of detection of 105 TB bacilli per 
millilitre of sputum, often contributes to missed or delayed diagnosis. Other 
factors also played a role in late diagnosis, including access to health 
care. Delay in diagnosis makes the greatest contribution to morbidity, 
mortality and transmission.
A lung function impairment study in a Maputo cohort found that about 
one-third of patients still had some lung impairment in spirometry at the 
end of their treatment. The long-term consequences in terms of sequelae 
are not well researched. 
The diagnostic situation for children with TB is difficult. Respiratory samples 
are difficult to obtain, especially in small children, due to low volumes 
and low bacterial burden, which are sub-optimally sensitive. In terms of 
TB epidemiology, there are one million new cases with 209 000 deaths 
annually
A number of new approaches are being investigated, ranging from PCR 
to biomarker signatures and immunological tests. WHO has developed 
target product profiles for new tests:
• A point-of-care biomarker test.
• A point-of-care triage test.
• A point-of-care sputum-based test to replace smear microscopy.
• A rapid drug-susceptibility test at the microscopy-centre level. 
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The rapid and accurate diagnosis of paediatric (RaPaed) TB project is 
about to establish a paediatric diagnostic consortium to validate new 
child-friendly tests among a cohort of 800 children with TB symptoms. 
Discussion
Question (Dr Collen Masimirembwa): Are dry blood samples being bio-
banked for other research purposes?
Response (Prof Sherman): There were initially efforts to biobank samples, 
but samples are now discarded according to a routine programme within 
a few weeks to a year, depending on how much space the laboratory 
has available. The samples from a South African PMTCT evaluation study 
over three years, which produced 10 000 dried blood spot samples, is 
looking for a home. 
Response (Dr Segal): The Africa Health Research Institute has a demographic 
surveillance site where the individuals who are being monitored are asked 
for blood spots at least once a year. This is a valuable resource not only 
for DNA sequences of the donor but also viral sequences and levels of 
antiretroviral drugs including tenofovir phosphate, for example, which 
indicates adherence. There needs to be consideration of bio-banking 
samples, because there is potential to return to the individuals and see 
how successful the outcomes were.
Question: What is the correlation between babies that are born HIV-positive 
serologically and those who are found to be PCR positive? 
Response (Prof Sherman): The mother-to-child transmission rate is currently 
less than 2%, which means that almost all the babies would be serologically 
positive at birth and they would gradually lose maternal antibodies. Up 
to the age of about six weeks, fewer than 2% would be PCR positive for 
HIV infection.
Question (Dr Sikazwe) enquired about the implementation of integrated 
clinics and how many patients they were seeing. 
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Question: How do you intend to monitor an HIV-infected population?
Response (Dr Jacobs): The work on integration is funded by the WHO 
Regional Office for Africa (WHO-AFRO). It is currently being piloted in five 
health care centres, which are relatively small units that see about 1 400 
patients with NCD over a three-month period. With respect to feasibility, 
the main question in the context of diminished human resources for 
health is how to manage patients with a burden of HIV disease inside 
and outside the HIV context. Of the five health care units, only one is 
specifically an HIV clinic, but all are using the same model that has been 
used in Uganda for HIV care.
Question: Are granulomas an indicator for preventative action?
 
Response (Dr Jackson): When patients are treatment refractory (i.e. they 
do not respond to currently available drugs) and there is severe damage 
to the lung, they generally undergo surgery to remove infected tissue from 
the lung. When the granuloma is still intact, latently infected individuals tend 
to have a disease that is well contained. Only 5 – 10% of infected people 
with bacteria in the lungs develop active TB. The presence of bacteria in 
the lung provides the potential for granuloma to develop, within which 
the disease may be protectively contained. The disease is only spread 
through the lung if the granuloma structure dissolves to form caseations.
Question (Dr Sikazwe) enquired about experience of disease progression 
in other comorbid conditions among HIV patients.
Response (Dr Jackson): With respect to comorbidity, emerging data show 
that lifestyle diseases such as diabetes triple the chances of developing 
active TB. The high inflammation that may occur when a patient is taking 
medication for both HIV and TB also increases the chances. For effective 
projection of the outcome of treatment, it is necessary to understand the 
patient and the underlying diseases. 
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Question (Dr Sikazwe) asked whether microphages are killed in the same 
way in patients with drug-sensitive or resistant TB.
Response (Dr Segal): This has not yet been tested. XDR and MDR-TB strains 
are difficult to make fluorescent. From a clinical perspective, XDR and 
MDR infections do not seem to be completely cured with chemotherapy, 
but the individuals can still function for a while. 
Response (Dr Heinrich): There is a question of whether MDR is generated 
through failing treatment or transmitted. Modelling studies have shown that 
two-thirds of MDR is transmitted, not generated. In these circumstances, 
it is unrealistic to hope that MDR will subside just by optimising first-line 
treatment in those demonstrating resistance. 
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SESSION 2: ANTIMICROBIAL RESISTANCE
Facilitator: Prof Charles Wiysonge, South African Medical Research Council, 
South Africa
Keynote Address III: Antibiotic Resistance in Africa: Challenges 
and Strategies (Prof Sabiha Essack, University of KwaZulu-Natal, 
South Africa)
There are controversies around antibiotic resistance related to the over-
use of antibiotics in livestock and fish farming, poor infection prevention 
and control in hospitals and clinics, lack of hygiene and poor sanitation, 
poor coverage of vaccination within communities, as well as the lack of 
new antibiotics in the pipeline. Of the new antibiotics undergoing clinical 
trial, none have a novel mechanism of action. The current approach is 
mainly to look at combination therapy and repurposing older drugs. 
Antibiotic resistance happens when bacteria change and become 
resistant to the antibiotics used to treat the infection they cause. It occurs 
as the result of selection pressure with the warranted and justified use of 
antibiotics, as well as indiscriminate use or misuse. The greater the exposure 
to antibiotics, the greater the chance of mutation to become resistant to 
the antibiotics. Antibiotic resistance can be spread via the food chain or 
from person to person. The time period between the introduction of a new 
antibiotic and the development of resistance is reducing. In the case of 
antibiotics introduced since 2000, antibiotic resistance developed within 
less than five years in the case of Linezolid and Daptomycin. Very few 
antibiotics have enjoyed a long period of efficacy in the clinical setting. 
Antibiotic resistance (ABR) has extensive health, economic and societal 
implications. For the last three years, the Global Risk Report published 
annually by the World Economic Forum has identified ABR as a threat to 
the world economy. The implications of ABR are that infected people are 
sick longer, stay away from work longer and have a greater potential of 
spreading the infection so that more people get sick. Not only does the 
individual suffer loss of income, but also the industry. ABR knows no borders 
and affects both developed and developing countries.
A review of AMR by economist Jim O’Neill commissioned by the UK prime 
minister found that unless AMR is addressed by 2050, there will be ten 
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million deaths as a result of AMR with an international cost of US$10 trillion. 
The implications are that even a simple ear infection will not be able to 
be cured with antibiotics. A disproportionate mortality rate is anticipated 
for Africa and Asia at the epicentre of AMR: Africa (4.1 million) and South 
East Asia (4.7 million). 
Because of the implications of ABR, it has generated unprecedented 
political attention among the G8, G20 and G77, and it even featured 
in the UN General Assembly in 2016. This was only the fourth time that a 
health issue was tabled at the UN. The first occurrence related to HIV, 
the second to NCD, the third to Ebola, and the fifth occurrence will be 
TB in 2018. The UN formed a task force comprising an alliance of several 
important global role players to address AMR. The UN has endorsed 
the Global Action Plan on Antimicrobial Resistance, a tripartite alliance 
between the WHO, Food and Agriculture Organisation (FAO) and the World 
Organisation for Animal Health (OiE), which have committed themselves 
to addressed AMR collectively because antibiotics and other AMRs are 
used in all three sectors of human, animal and environmental health. 
The environmental component is somewhat lacking but does have an 
important role to play especially with respect to the disposal of AMRs or 
the use of animal litter to fertilise agricultural soil. 
AMR or ABR has been described as the quintessential One Health issue 
because of its prevalence and transmission between the three sectors of 
human, animal and environmental health. As long ago as 1977, there was 
awareness that AMR was a complex issue that could only be effectively 
addressed through a holistic approach as opposed to focusing on each 
sector individually. The huge investment by pharmaceutical companies in 
the development of new antibiotics has waned and few pharmaceutical 
companies are currently working in this area. 
An alternative to the epidemiological framework is the Collective Action 
and the Risk Ecosystem (CARE), which takes the perspective of exposure. 
People are exposed to AMR through various interactions with food, water, 
wild animals, companion animals, sewage, rivers, pesticides, hormone 
and other compounds, pests, impact of travel, climate and weather. 
Africa is the leader with respect to causes of death due to HIV, TB, malaria, 
diarrhoeal diseases, lower respiratory infections and other infections. AMR 
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confounds the successful management of infectious diseases. The collateral 
damage of HIV occurring together with other communicable diseases 
has been mentioned, but there is collateral damage related to HIV and 
AMR. An HIV patient has a compromised immune system and is thus more 
prone to infections. The higher the rate of infection, the more antibiotics 
are used, which increases selection pressure and the further development 
of ABR. The collateral damage of HIV is thus ABR. Capacities related to 
surveillance of antimicrobial use and resistance, infection control, drug 
legislation and distribution, veterinary sciences and health economy are 
often limited in sub-Saharan Africa. It is not possible to motivate huge 
investment in a surveillance system when there is little understanding of 
AMR. Death registers may state that a patient died of TB, pneumonia or 
a bloodstream infection, but it is seldom known whether the infection was 
caused by resistant bacteria. 
WHO has been working on AMR since 1959, but despite the AMR Strategy 
of 2001, there has not been much uptake by countries to take substantial 
steps to address AMR. Only in 2011, with the adoption of the WHO stance 
of “no action today no cure tomorrow” did political will start to quicken. 
WHO published a six-point policy package, which required governments 
to start taking AMR seriously. In 2014, WHO published the Antimicrobial 
Resistance Global Report on Surveillance in various regions. All these 
initiatives have been focused on ABR. This does not mean that other 
microbial resistance is not important, but ABR programmes have enjoyed 
considerable investment. The Global Action Plan and other initiatives 
focused on common causative organisms of community and hospital-
acquired infections. 
Since 2016, implementation guidelines have been published as well as 
the Global Framework for Development and Stewardship to Combat 
Antimicrobial Resistance, the WHO Methodology for a Global Programme 
on Surveillance of Antimicrobial Consumption, and a revised WHO Model 
List of Essential Medicines. The list provides new advice on which antibiotics 
to use for common infections and which to preserve for the most serious 
syndromes, based on a thorough review of all essential antibiotics. Intended 
to optimise antibiotic use and reduce antibiotic resistance without 
restricting access, the list categorises antibiotics into three groups: Access 
(for treating common infections), Watch (for potential development of 
resistance) and Reserve (for treating serious syndromes).
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The WHO Global Surveillance Report published the following data on 
AMR in Africa:
0–87% to third-generation cephalosporins in Escherichia coli (ESBL+);
0–98% to fluoroquinolones in E. coli;
8–77% to third-generation cephalosporins in Klebsiella pneumoniae (ESBL+); 
0–4% to carbapenems in K. pneumoniae (CRE); 
0–100% to methicillin in Staphylococcus aureus;
1–100% to penicillin in S. pneumoniae;
0–35% to fluoroquinolones in non-typhoidal Salmonella; 
0–9% to fluoroquinolones in Shigella spp.; 
0–12% to third-generation cephalosporins in Neisseria gonorrhoeae.
The country situational analysis for Africa showed that:
• eight out of 47 member states in the region participated;
• all eight countries stated that resistance to treatments for malaria and 
TB are their greatest challenges;
• poor-quality medicines are a general problem, further contributing to 
the spread of AMR;
• data are incomplete due to lack of information;
• the results suggested that AMR is a growing problem.
A paper co-published by Prof Essack in the Journal of Public Health in 
2016 looked at how member states in the African region are performing 
on the WHO Policy Package, but many African countries did not submit 
data on all the aspects:
• Availability of national action plans (NAPs) to combat AMR, with 
aims, objectives, funding sources, responsibility, accountability and 
timeframes: The report found that 38% (18/47) countries have developed 
NAPs and 40% (19/47) have NAP development in progress.
• Percentage of member states in which reports on surveillance for AMR 
had been prepared in the last five years: 23% (11/47) have enrolled in 
the Global Antimicrobial Resistance Surveillance System (GLASS); 17% 
(8/47) countries have initiated GLASS enrolment; no African countries 
have representative national surveillance systems. South Africa has 
a national laboratory-based surveillance programme on selected 
bacterial and fungal pathogens. Several countries have instituted pilot 
surveillance projects.
• Access to quality medicines: 85.1% (40) countries have access to quality 
essential medicines and expert opinion-based treatment guidelines.
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• Infection prevention and control policies (IPC): 14.9% (7) have national 
IPC policies, which are crucial to prevent the dissemination of any 
infection, especially in relation to AMR infections.
• Rational medicine use: 87.2% (41) have rational drug use policies.
Two non-profit organisations have been working on AMR in Africa:
• Centre for Disease Dynamics, Economics and Policy (CDDEP), which 
is part of the Global Antibiotic Resistance Partnership (GARP). It is US-
based and funded by the Bill and Melinda Gates Foundation. GARP 
advances policy analysis and policy development capacity in AMR. 
GARP chapters are national multi-sectoral working groups in low and 
middle-income countries. The aim is to conduct situational analyses on 
antibiotic use and resistance in humans and animals to inform evidence-
based, country and context-specific interventions to preserve the 
effectiveness of antibiotics, decelerate the spread of resistance, and 
ensure access to antibiotics. GARP is active in Kenya, Mozambique, 
Namibia, Tanzania, Uganda, South Africa and Zimbabwe.
• ReAct Africa is Swedish-based and brings together experts and key 
stakeholders to form technical working groups on AMR. It provides 
technical assistance in the development and implementation of NAPs, 
and raises awareness of AMR among the general public and the health, 
veterinarian and agricultural sectors. ReAct has a toolbox that speaks 
to various ways in which ABR can be addressed, including awareness, 
surveillance, education and policy. ReAct facilitated Ghana’s National 
Policy on AMR; partnered with the Global Alliance against Chronic 
Respiratory Diseases (GARD) and CDDEP GARP to support the NAP 
process in Zimbabwe, Zambia and Rwanda; and also partnered with 
GARP-Kenya. 
CDDEP GARP and ReAct are now discussing how they can work together 
rather than duplicating their efforts by working in the same countries.
The UK government has committed £265 million to the Fleming Fund until 
2020/21 in order to build capacity in surveillance networks and AMR 
response capacity in low and middle-income countries. AMR plays a 
role in Universal Health Coverage, International Health Regulations, in 
achievement of the Sustainable Development Goals and in the Global 
Health Security Agenda. These are timebound external funds, and it 
is incumbent on African governments to take responsibility for AMR 
surveillance and investing in changing behaviour and antibiotic use.
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Antibiotic resistance is a tragedy of the commons, in that individuals act 
independently and in self-interest to the detriment of the best interests of 
a whole group by depleting a common resource. Antibiotic conservation 
requires coordinated, multi-pronged, multi-stakeholder, multidisciplinary 
partnerships underpinned by national and international policies that 
suspend sectoral interests for the public good.
Long-Term Bedaquiline-Related Treatment Outcomes in Patients 
with Extensively Drug-Resistant Tuberculosis from South Africa (Dr 
Olatunde Olayanju, University of Cape Town, South Africa)
The global burden TB amounted to 10.4 million cases reported in 2016. It is 
the leading infectious cause of death worldwide. In 2016, there were 1.7 
million estimated deaths from TB. Drug-resistant TB continues to threaten TB 
control, with 600 000 new cases of rifampicin-resistant (RR-TB), of which 490 
000 were multiple drug resistant (MDR)-TB reported in 2016. Approximately 
10% of global MDR-TB strains are XDR-TB. 
In South Africa in 2016, 3.4% of all notified TB cases were MDR/RR-TB, and 
8.1% was XDR-TB. It was estimated that M/XDR-TB will consume over 80% 
of TB treatment cost in South Africa in 2017/18 despite MDR-TB making up 
less than 10% of the total caseload.
The treatment outcome is still poor due to lack of effective treatment. 
The culture conversion rate in patients with XDR-TB between 2002 and 
2008 in South Africa was only about 19%. Seventy per cent of XDR-TB 
patients dies within five years of diagnosis. In 2017, WHO estimated the 
favourable outcome for XDR-TB in South Africa to be 27%. Patients who 
failed treatment are discharged home. Migration to developed countries 
continues unabated. The EU urged members to take in 160 000 refugees 
between 2015 and 2017.
Primary transmission of XDR-TB has been proven. New and repurposed 
bactericidal drugs such as linezolid (Lzd), delamanid (Dlm) and bedaquiline 
(Bdq) have offered new hope for patients with XDR-TB. A phase II trial on 
Bdq reported a cure rate of 61%, 6.8% mortality, and significant adverse 
events including QT prolongation and hepatitis, raising concerns about 
efficacy and safety. Long-term prospective outcome data comparing XDR-
TB regimens, with and without Bdq, from an endemic setting are lacking.
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A study was undertaken to compare long-term treatment outcomes 
between XDR-TB patients who received a Bdq-containing regimen and 
those who did not. The study followed up 272 patients with laboratory-
confirmed XDR-TB; 204 patients received a non-Bdq-based regimen, while 
68 received a Bdq-based anti-TB regimen. All patients were admitted to 
Brooklyn Chest Hospital, Cape Town. Demographic and clinical information 
were obtained by a trained health care worker. The treatment outcomes 
that were evaluated were cure/treatment completion, deceased, 
treatment failure, treatment default and lost to follow-up.
Multivariate analysis of patients in both groups suggested that receiving 
Bdq (p=0.05; HR=0.24) was an independent predictor of survival. Patients 
who were HIV-infected (p=0.02; HR=1.51) and those who weighed less 
than 50 kg at admission (p<0.001; HR=1.96) were more likely to die. 
The Bdq-based regimen resulted in substantial and remarkable improvement 
in outcomes in patients with XDR-TB. The Bdq survival effect remained 
significant in HIV-infected persons irrespective of CD4 count. Initial fears 
about Bdq adverse events were not substantiated. These data make a 
strong case for the accelerated roll-out of Bdq-based regimen for the 
treatment of XDR-TB in endemic settings.
Discovery of New Anti-Infectives from Fungal and Bacterial Sources 
(Dr Kathrin Wittstein, Helmholtz Centre for Infection Research, 
Germany)
AMR is an increasing problem worldwide, while the number of new drugs has 
been decreasing over the last few decades. The pace of new discoveries 
in the field of anti-infectants has slowed down, especially since many 
large pharmaceutical companies have stepped back from this research 
because of the low potential for profit. Many of the drugs launched in this 
field over the last 30 years are mainly analogues, derivatives of already-
established compounds with improved pharmacokinetics or a broader 
spectrum of activity. However, the evolution of resistance against these 
analogues is much faster because of cross-resistance. Compounds with 
new mechanisms and modes of action are needed. This is not an easy 
task. Almost 80% of anti-infective agents are still derived from natural 
sources, mainly bacteria and fungi. The compounds have to be chemically 
optimised to fulfil the requirements of a drug, but it seems that nature is 
still a very effective source for providing diverse new lead structures. 
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The presentation would focus on efforts of the Department of Microbial 
Drugs at the Helmholtz Centre for Infection Research to identify potential 
new lead structures from fungal and bacterial strains. 
The screening for new bioactive compounds is a very work-intensive and 
time-consuming process. Redundancies are a big issue. To avoid the 
isolation of already-known compounds, the focus is on new species from 
different kinds of natural habitats that have not been well investigated. For 
example, the research team recently started to work on spider-associated 
fungi. Another option is to look at genomic data if available to check 
biosynthetic gene clusters in order to identify a particular strain for selection. 
The pre-selection of strains is crucial. Selected strains are cultivated in various 
liquid media as well as solid media in varying conditions. This is a key step 
to the production of diverse secondary metabolites in microorganisms. 
Cultures are extracted by organic solvents, and the crude extracts are 
investigated in different biological assays, mainly against Gram-positive 
and Gram-negative bacterial and fungal strains. In parallel, the strains 
are being investigating using high performance liquid chromatography – 
ultraviolet/ mass spectroscopy (HPLC-UV/MS) dereplication. This provides 
specific characteristic data of each compound in the extract mixture, 
which can be compared with internal and external databases to identify 
already-known compounds and to evaluate whether it is worth working 
on the extract. This is a bio-activity guided approach, but the focus is also 
on chemical diversity. 
New antifungal compounds from Favolaschia
The Favolaschia calocera species is a good example, obtained from 
cooperation with Kenya. The fungus provided extracts with strong and 
selective anti-fungal activity. The mixture was fractionated into a 96-well 
plate using HPLC, and afterwards the test organism was applied, in this 
case Candida tenuis. In this way, there is direct correlation of activity and 
a specific peak in the HPLC chromatogram. For the isolation, the focus 
was only on the active compounds. In order to have enough material 
for the isolation of single compounds, the replication process has to be 
scaled up. This is followed by purification using chromatographic methods, 
mainly preparative HPLC, and structure elucidation and characterisation 
of pure compounds using NMR microscopy and further analysis of the 
purified compounds. It was possible to isolate 18 new compounds from 
the species, among which were four new strobilurin derivatives, which 
are responsible for antifungal activities. Strobilurins are a known class of 
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antifungal compounds. It was also possible to isolate four fairly uncommon 
chlorinated metabolites, which showed cytotoxic effects on mouse cells 
and human cancer cells. 
New fungal species with nematicidal metabolites
There is also a search underway for new fungal species with nematicidal 
metabolites. Recently, active compounds were obtained from a new 
species collected in northern Thailand. The fungi will be screened on 
culture plates together with nematodes, and the corresponding extracts 
will be tested in solution on 24-well plates. The collecting trip to Thailand 
was very productive and several new species were discovered (one of 
which represents a new genus). Regular exchange takes place between 
the Helmholtz Centre and two institutes in Thailand (BIOTEC and Mae Fah 
Luang University). The new fungal genus and species, Pseudobambusicola 
thailandica, was isolated from a plant twig. Extracts show nematicidal 
and antifungal activity. From this fungus, six new metabolites and two 
known ones with nematicidal activity were isolated. 
Natural products with anti-biofilm activity
Through internal collaboration, several groups at the Helmholtz Centre 
are investigating natural products with anti-biofilm activity in order to find 
new natural products with anti-biofilm activity. Biofilms are large colonies 
of bacteria (e.g. staphylococcus) that protect the bacteria and make 
them less susceptible to drugs and combative organisms. A compound 
that inhibits the formation of biofilms, while at the same time not interfering 
with bacterial growth, is unlikely to induce resistance, or at least very slowly, 
because it does not directly alter the phenotypes. Such a compound is 
a valid potential alternative to classical antibiotics. The researchers are 
particularly interested in quorum sensing, the communication of single 
bacteria during the formation of biofilm. 
More complex bioassays cannot be used in the initial bioscreening. 
Submissions to the internal natural product library recently obtained two hits. 
One of these was microporenic acids A and B, isolated from the Kenyan 
fungi, which inhibited the biofilms of pathogenic Staphylococcus. aureus 
and C. albicans. The other was erinacine C (ErC), which was evolving a 
protection mechanism against S. mutans biofilms, which are present in 
dental plaque, for example. Mutacins were being produced, which are 
small antibiotic peptides that kill competitors of S. mutans. ErC inhibits the 
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production of three mutacins (IV,V,VI), weakens the biofilms of S. mutans 
and makes them susceptible to competitor organisms. 
Large-scale production
If a new metabolite with particularly strong activity is discovered, the next 
step would be up-scaling of fermentation. Such projects usually involve 
strain optimisation for a specific metabolite and media optimisation. The 
cultivation parameters have to be transferred from screening shaking flasks 
to large bioreactors, which is a difficult process. Large-scale fermentation 
produces kilogrammes of biomaterial that has to be processed. The 
purification process also has to be optimised. 
Corallopyronin A: novel antifilarial drug candidate
Currently, the Department of Microbial Drugs at the Helmholtz Centre is 
producing one compound on a very large scale, namely Corallopyronin 
A, which was isolated in 1985 from the soil myxobacterium Corallococcus 
coralloides and is effective against some Gram-positive bacteria. It has 
the same target as RIF but not the same mode of action. RIF binds to 
the active site of DNA-dependent ribonucleic acid (RNA) polymerase, 
whereas Corallopyronin A binds to the outside region that is responsible 
for opening and closing the active site of the enzyme. Corallopyronin A 
is therefore still active against RIF-resistant S. aureus strains. Corallopyronin 
A is being investigated as a potential agent against diseases caused by 
filarial nematodes such as river blindness. Two drugs are currently used 
for treatment: ivermectin which kills the nematode, and doxycycline 
which kills the Wolbachia bacteria associated with these nematodes. 
If the Wolbachia bacteria are killed, the nematodes are sterile and not 
able to reproduce, and they will gradually die. Doxycycline is effective, 
but problematic for pregnant women and children. Corallopyronin A also 
decreases the population of Wolbachia bacteria. Collaboration partners 
were able to show that Corallopyronin A demonstrates very significant in 
vivo activity, even higher than doxycycline, depleting and blocking the 
development of Wolbachia. The Department of Microbial Drugs at the 
Helmholtz Centre has established a large-scale fermentation process and 
thus far isolated 20 g of the natural products. 
Cystobactamids: novel broad spectrum antibiotics
Another collaborative project in which the Department of Microbial Drugs 
at the Helmholtz Centre was involved was on cystobactamids, a new 
class of antibiotics with strong activity against Gram-positive bacteria as 
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well as some Gram-negative strains in the micro and even nano range. 
Cystobactamids was discovered through LC-HRMS-assisted bioactvity-
guided screening. The target was identified as DNA gyrase. The binding 
pocket has only partial overlap with the quinolone antibiotics. There is thus 
a good chance that resistance would develop very slowly. The challenge 
in this project was the low concentration. After the identification of the 
biosynthetic gene cluster, alternative myxobacterial strains were used, 
which were also producing derivatives of cystobactamids. By combining 
genomic data, it was possible to identify a strain that was producing 
derivatives in slightly larger amounts. A new derivative was isolated 
which is also active against P. aeruginosa. This kind of activity has not 
been observed before. Cystobactamids are being investigated in vivo 
to evaluate their potential for further development.
Towards the Development of the Next Generation of Antibiotics 
from Fungal Sources (Dr Patrick Arthur, University of Ghana, Ghana)
The research activities are in the area of chemical systems biology of 
infectious pathogens including infection biology of tuberculosis, chemical 
biology of fungal metabolites, advanced imaging techniques and mass 
spectrometry-based proteomics of the perturbations caused in infectious 
pathogens by novel bioactive compounds. The research is aimed at the 
discovery and development of new antibiotics against tropical infectious 
diseases. Towards the discovery of novel anti-infective agents, the research 
group has isolated and screened more than 3 000 distinct fungal species. 
The surprisingly high rate of the occurrence of anti-infective activities 
in the culture extracts of these fungi has led the group to develop a 
phenotypic array-based workflow as a key strategy. This allows for the 
comparison of the bioactive extracts with many standard antibiotics 
on the basis of their pattern of activities across different physiological 
conditions of the test organisms. The group is currently in the process 
of isolating pure compounds from fungal extracts from the priority list. 
These compounds will be extensively characterised using NMR-structural 
elucidation, advanced imaging techniques and mass spectrometry-based 
proteomics to provide understanding of their mechanism of action to 
support preclinical development.
The research was funded by German Academic Exchange Service (DAAD)-
Germany, Grand Challenges Canada, The World Academy of Sciences 
(TWAS)-Italy, the International Foundation for Science (IFS)-Sweden and 
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the Gates Foundation/Noguchi Memorial Institute for Medical Research 
(NMIMR).
Discussion
Question (Dr Collen Masimirembwa): Once the molecules have been 
identified, what strategy does the research group at the Helmholtz Centre 
use to decide whether to take the approach of synthesis or fermentation? 
Is the target differentiation from docking experiments or co-crystallisation 
data?
Response (Dr Kathrin Wittstein): The target differentiation was done 
by cooperation partners, and she could not give details of how they 
proceeded. Regarding the strategy, her research group is interested in 
bioactive compounds, especially new compounds with new modes of 
activity. They usually work on small molecules. The synthesis is done by 
cooperation partners. 
Question (Dr Collen Masimirembwa): Screening provides numerous 
hits, but these are not being translated into new drugs. Is there a target 
product portfolio that guides Dr Arthur’s research and provide a sense 
of progression? 
Response (Dr Patrick Arthur): There is no organisation that guides the 
process of drug development. In 2015, Dr Arthur attended at TB drug 
discovery conference in Italy, where the keynote speaker had led the 
development of a drug by Johnson & Johnson that took a frustrating eight 
years, during which he had almost abandoned the work. The scientific 
world has not worked out how to guide the process of drug development 
in a logical manner. 
Question (Dr Collen Masimirembwa): What provides confidence to pursue 
a ‘black box’ approach using a whole organism, without a molecular 
mechanism to guide optimisation? 
Response (Dr Patrick Arthur): Their usual approach is to sample about 20 
compounds in one assay. Any extract that passes all 20 is considered a 
top hit. The work focuses on those that maintain or improve the activity 
under tried and proved conditions. In this way, confidence is gained to 
proceed with product isolation. 
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Question: Dr Olayanju’s research found that bedaquiline does not have 
side effects, but according to the literature it has considerable toxicity. 
How big was the sample to reach the conclusion that reported toxicity 
to be false? How are patients who weigh less than 50 kg treated?
Question: Given the positive effects of Dr Olayanju’s research, have there 
been any efforts to include the new drugs in treatment?
Question (Dr Norbert Heinrich) asked Dr Olayanju’s views on potential 
biases in his research (e.g. the non-randomised way in which the data 
are generated) that might lead to the conclusion that bedaquiline is 
effective. He would like to believe the data but is sceptical.
Comment (Prof Charles Wiysonge): Before any recommendations can 
be made on therapy and treatment, there has to be a randomised trial 
and systematic review.
Question (Dr Olatunde Olayanju): All patients in Cape Town diagnosed 
with XDR-TB are referred to Brooklyn Chest Hospital for treatment. When 
they show improvement as evidenced by culture conversion, chest X-ray 
improvement and general wellbeing, they are discharged to day-hospitals 
closer to their place of residence where the treatment continues. All 
patients referred to Brooklyn Chest Hospital qualified for recruitment into 
the study. Participants were recruited between 2008 and 2016. Because 
of the sporadic nature of outpatient care after discharge, it was difficult 
to get a large group to consent to participate in the study. Only patients 
who have completed 24 months of treatment were included in the study, 
several other patients were exempted due to this reason. 
With respect to toxicity, in randomised clinical trials as well as short-term 
studies mostly for six months, the major adverse effects reported were 
mild toxicity or mild QT interval. In the study of patients who completed 
24 months of treatment, no major toxicity effects were observed. Only 
seven had a marginally prolonged QT interval of 450 – 470 ms, but not 
so high as to recommend discontinuation of the treatment. None of the 
patients had a QT interval as high as 500 ms.
With respect to weight, multivariate analysis, showed that patients who 
weighed less than 50 kg were more likely to die within the whole cohort of 
272. This finding was not limited to patients who received the Bdq-based 
anti-TB regimen.
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Facilitator: Prof Sabiha Essack, University of KwaZulu-Natal, South Africa
Antibiotic Resistance and Molecular Epidemiology of Shingella 
Isolates from Children under Five Years in Manhiça, Southern 
Mozambique (Mr Delfino Vubil, Manhiça Health Research Centre, 
Mozambique)
The Manhiça Health Research Centre (Manhiça HDSS) is a biomedical 
research centre in a rural area in southern Mozambique that conducts 
research in several areas including malaria, HIV, TB, respiratory infections, 
diarrhoeal diseases and others, clinical and molecular epidemiology and 
pathology, assessment of drugs and vaccines, monitoring and evaluation, 
and social science projects among the community. The population 
of the study area of Manhiça HDSS comprises 184 000 people living in 
43 000 households. 
Among the thematic areas researched at Manhiça HDSS, diarrhoeal 
diseases continue to be the most common in children, and are the major 
causes of infant mortality in developing countries. Species of Shigella 
remain among the main causes of childhood diarrhoea in both developing 
and developed countries. Annually, 165 million cases of shigellosis were 
estimated to occur worldwide, with over one million associated deaths. 
The burden of disease due to Shigella is partially explained by the diversity 
of Shigella species, with more than 50 serotypes. S. dysenteriae, S. flexneri 
and S. sonnei are endemic. There is no effective vaccine against Shigella. 
Antibiotic resistance is increasingly reported worldwide in relation to 
the most commonly used antibiotics, including ampicillin, tetracycline, 
chloramphenicol, sulfonamides, sulphamethoxazole-trimethoprim and 
nalidixic acid as well as new-generation antibiotics such as fluoroquinolones. 
Antibiotic resistance is a serious threat to patient management.
Manhiça HDSS launched a study to evaluate the trends of antibiotic 
resistance and molecular epidemiology of childhood Shigella-diarrhoea 
from a case-control study conducted among children under the age 
of five in Manhiça from December 2007 until November 2012. The study 
used the following methods:
• Shigella identification: Species identification was based on culture, 
colony morphology, biochemistry and serotyping.
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• Antimicrobial susceptibility: All isolates were tested for antimicrobial 
susceptibility using the Kirby-Bauer disk diffusion method following 
Clinical and Laboratory Standards Institute guidelines.
• Mechanisms of resistance: PCR-based techniques were applied for 
detection of mechanisms of AMR.
• Genetic diversity: To evaluate whether the isolates were genetically 
related, pulsed-field gel electrophoresis (PFGE) was done according 
the PulseNet standardised protocol for typing of foodborne pathogens. 
A clone was defined with 85% similarity.
The study reached the following conclusions:
• There is a high diversity of Shigella spp causing diarrhoea in Mozambican 
children. 
• Multidrug resistant isolates follow clonal spreading. 
• The presence of MDR carriers in the community is an alert for the 
importance of community-based interventions for infection prevention 
and control. 
• Continuous disease surveillance is required to track changes over time.
The proposed next steps entail virulence studies for the identification of 
virulence genes and clonal studies, possibly multi-locus sequence typing 
analysis or whole genome sequencing.
Flavonoids with Significant Antibacterial Activity from Pseudathria 
hookeri (Fabaceae) (Mr Joseph Tchamgoue, University of Yaounde 
I, Cameroon)
The research that is done today is for the benefit of the next generation. 
It is therefore surprising when people demand to see immediate results 
from the investment in research into new drugs.
Despite the extensive use of antibiotics and vaccination programmes, 
microbial infections (including bacterial, fungal, and viral infections) 
continue to be a leading cause of morbidity and mortality worldwide. The 
reasons include antibiotic resistance, the emergence of new pathogens, 
lack of effective new therapies and the resurgence of old pathogens.
Medicinal plants, through the variety of their secondary metabolites, can 
constitute a vast source for new bioactive compounds to fight against 
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such resistance: 25% of drugs are derived from natural products, and 61% 
of the 877 new chemical entity introduced between 1981 and 2002 can 
be traced to natural product origin. Several medicinal plants are used in 
folk medicine for the management of microbial infections, but few have 
received scientific attention to ascertain their efficiency and safety.
Pseudarthria hookeri Wight & Arn is used in folk medicine for the treatment 
of microbial infections including pneumonia, cough, diarrhoea and 
abdominal pains. It was investigated for its antibacterial activity against 
pathogenic bacterial strains involved in diarrhoea and respiratory infections.
The study isolated and identified the active principles, which involved 
collection, extraction, filtration, thin layer chromatography (TLC), 
purification of compounds, analysis, structure elucidation and bioassays. 
The antibacterial assay used the broth microdilution method: minimum 
inhibitory concentration (MIC) and minimum bactericidal concentration 
(MBC). Acute toxicity was measured following Organisation for Economic 
Co-operation and Development (OECD) guidelines. The application of 
these methods resulted in quantification (LC-QqQ-MS).
The study reached the following conclusions:
• Chemical investigation of P. hookeri (Fabaceae) led to the discovery of 
five new compounds. Five flavonoids out of the 22 isolated compounds 
showed moderate to significant antibacterial activity (MIC < 10 μg/
mL).
• The tested compounds showed no toxic effect on MIN-6 and 3T3 cell 
lines up-to 400 μM, suggesting their safety profile.
• The crude extract of the whole plant of P. hookeri showed no in vivo 
acute toxicity up to the highest tested dose (2 500 mg/kg).
• A rapid, sensitive and accurate method was developed for the 
quantification of bioactive flavonoids in P. hookeri. This method could 
be used for the quality control of herbal drugs prepared from P. hookeri. 
An improved phytomedicine is currently being processed from the extract 
of this plant.
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Actinobacteria Biosynthetic Potential: Bridging in Silico and in Vivo 
(Prof Andriy Luzhetskyy, Helmholtz Institute for Pharmaceutical 
Research Saarland, Germany)
In 1928, when penicillin was discovered, scientists believed that they 
had conquered pathogens, but Louis Pasteur (1822 – 1895) had already 
realised that ‘the microbe always has the last word’. Soon after antibiotics 
were introduced to the market, drug-resistant pathogens evolved. The 
speed of antibiotic resistance has accelerated. A year or two after a 
new antibiotic is introduced to the market, resistant pathogens are now 
developing. The growing resistance towards established antibiotics presents 
a serious problem especially with infectious diseases. Pathogens that are 
multidrug-resistant pose a huge threat, since there are no drugs on the 
market to fight them. 
New antibiotics can be developed through chemical synthesis or 
biosynthesis. Natural products have been particularly successful for the 
development of antibiotics. Actinobacteria have been an important 
source of different drugs. 
There was a large gap in developing new antibiotics between 1962 and 
2000. It is still possible to isolate new compounds, but there are associated 
problems, which discouraged industry from working on antibiotics, namely 
the huge range of rediscovery of known compounds. The research is 
very expensive, involving considerable screening, isolation and structure 
elucidation, and it is frustrating after all this work to keep coming up with 
known compounds. Industry concluded that the sources of antibiotics 
had been exhausted and there was nothing new to look for. This was the 
dominant idea for several decades until the start of the genomic era. It 
was realised that there was huge genetic potential through gene clusters 
for actinobacteria to produce many more drugs and natural products 
than had been discovered thus far. 
Two examples of actinomycetes genome projects are:
• S. coelicolor A3(2): 23 secondary metabolite gene clusters are predicted 
(4.5% of genome). 
• S. avermitilis ATCC31267: 30 secondary metabolite gene clusters are 
predicted (6.6% of genome).
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Genomes were sequenced and compared, and some were found to be 
especially talented. Streptomyces, for example, has up to 50 biosynthetic 
gene clusters, from which 50 new natural products could be produced. 
Frankia is not known as a producer of antibiotics, but a number of 
biosynthetic gene clusters were discovered in the genome. The discovery 
of huge potential in the genomic era attracted industrial interest and 
there was huge investment. 
As a small research group, the Helmholtz Institute for Pharmaceutical 
Research Saarland decided not to become involved in sequencing or 
analysing the data, as they could not compete with large role players. 
They decided instead to develop a genetic method for exploiting the 
potential. 
The regulatory cascade is very complex. There has to be a signal from 
the environment, and then the biosynthetic gene cluster is activated 
through the regulatory cascade. The gene cluster will be transcribed. It 
is very difficult to reconstitute the conditions present in the environment 
in the laboratory in order to induce this expression. Another approach is 
thus that of synthetic biology, which entails decoupling the biosynthetic 
gene cluster from the environment and from the complex regulatory 
cascade, which is unique to every strain and could take thousands of 
years to understand. 
Genomes contain many gene clusters that are potentially responsible for 
antibiotic production. The gene clusters are expressed and decoupled 
from the regulatory cascade. Synthetic regulatable controlling elements 
are taken, such as promoters, ribosome binding sites or terminators. 
Genetic clusters are then engineered, and brought into a chassis or host 
where they will be expressed and new compounds can be isolated. The 
following three components are required for this process: 
• Synthetic controlling elements, which are predictable and not dependent 
on any controlling signal from the environment, and which guarantee 
the expression of particular gene clusters in the host.
• Heterologous host to which the biosynthetic gene cluster is brought 
(of which there are now several thousand).
• Actinobacteria genome mining.
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Some bacteria behave in a domesticated way and are easy to work 
with, while others are difficult to handle. There was an idea to move 
from domesticated to engineered bacteria that can be more readily 
controlled. After looking through the whole Streptomyces collection, 
S. albus was found to be suitable for domestication. It has a small genome 
and produces a variety of different natural products, which means that 
it has all the precursors that are necessary on which to synthesise natural 
products or antibiotics. 
Work began on S. albus. The first step was simple and straightforward. A 
biosynthetic gene cluster will consume the precursors (e.g. amino acids). 
By combining the simple precursors, an antibiotic can be built. There are 
many different ways to successfully clone the gene cluster.
About 20 000 natural products have been discovered from actinobacteria, 
but only about 1 000 gene clusters have been characterised. 
Refactoring of the gene cluster with synthetic controlling elements 
and bringing this into the host will yield the new compound. Many new 
compounds have been discovered, which will hopefully lead to the 
discovery of active compounds against MDR bacteria. 
Discussion
Question (Dr Patrick Arthur): Are you willing to go to the next level and 
teach the new clusters new tricks?
Response (Prof Luzhetskyy): Through biosynthesis, the specificity of the 
enzyme can be changed. Genes can be combined from different gene 
clusters in order to create new chemistry. 
Question (Prof Sabiha Essack): Has there ever been an outbreak of 
diarrhoea due to Shingella isolates? 
Response (Mr Delfino Vubil): The research did not go into detail in looking 
at the period to see if there was an outbreak.
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Question: Have you considered using tRNA as a chassis for all genes?
Response (Prof Luzhetskyy): S. albus was explored first because of its large 
variety of biosynthetic gene clusters, but in principle it would be possible 
to try to adapt to other clusters from different organisms.
Question (Dr Patrick Arthur): Is it possible to take clusters from fungi into 
Streptomyces?
Response (Prof Luzhetskyy): This would be difficult. It would involve re-
synthesis and would entail laborious work with a low rate of success. It 
would be better to develop new hosts based on fungi.
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SESSION 3: DINNER 
Facilitator: Prof Quarraisha Abdool Karim, Associate Scientific Director, 
Centre for the AIDS Programme of Research in South Africa (CAPRISA)
Prof Karim opened the event and welcomed everyone. She acknowledged 
funding for the event from ASSAf, Leopoldina, ICSU ROA and the South 
African Department of Science and Technology (DST). ASSAf and Leopoldina 
were celebrating five years of successful collaboration and had just signed 
another MoU for a further five years. 
Keynote Address IV: Building Research Capacity and Transformation 
in Health Research (Prof Glenda Gray, President and Chief Executive 
Officer (CEO), Medical Research Council, South Africa (MRCSA))
State of science in Africa and rationale for investing in science
The South African Medical Research Council (SAMRC) is the custodian for 
medical research in South Africa and the biggest funder (and government 
funder) of medical science in Africa. Scientific excellence is central to 
everything that the SAMRC does, and the science that it funds is always 
internationally peer-reviewed and competitive. The SAMRC funds research 
based on local development priorities and the ten most common causes 
of mortality in the country, given the funding limitations. The research 
also looks at disability and quality of life. The SAMRC focuses its efforts on 
developing scientific capacity and transforming the pipeline of researchers 
in South Africa. 
There is a problem of lack of local investment in research. South Africa 
spends only 0.9% of its gross domestic product (GDP) on research and 
development (R&D). Only 1% of global investment in research and 
development (R&D) is spent in Africa, and only 0.1% of world patents are 
held in Africa.
Scientific productivity is a much better predictor of economic wealth 
and human development than any other variables. Africa has a lack of 
critical mass among researchers. In Africa there are only 198 researchers 
per million inhabitants, compared to over 4 000 researchers per million 
inhabitants in the UK or USA. It is alarming that 20 000 professionals leave 
Africa per annum to high-income countries. It is a challenge to try to keep 
professionals and researchers in African countries. 
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The unequal contribution and participation in science in Africa needs to be 
addressed and changed. The collaboration between ASSAf and Germany, 
as well as ASSAf and Uganda, is important in the efforts to proliferate 
scientific research in Africa. Africa has 12% of the global population, but 
produces less than 1% of total science output. The increase in research 
in Africa between 2003 and 2012 was driven by health science research 
(4% annual growth), which represents 45% of all research in sub-Saharan 
Africa. Africa has a disproportionately large share of global AIDS deaths. 
If important diseases are to be addressed, science will have to grow on 
the African continent.
The SAMRC is committed to changing this picture by:
• Administering health research effectively and efficiently.
• Leading the generation of new knowledge.
• Supporting innovation and technology development to improve health.
• Building capacity for the long-term sustainability of the country’s health 
research.
There is no reason why South Africa should not lead the world in many 
areas of health research, and the country is not short of problems to solve 
or lacking in innovation. South Africa has a quadruple burden of disease 
through four colliding epidemics: 
• Maternal, new-born and child health.
• HIV/AIDS and TB.
• Non-communicable diseases.
• Violence and injury.
Scientific research leads to new knowledge, technologies and clinical 
treatment along the spectrum from basic science, to the development 
of new paradigms, and the impact of translational science leading to 
products, discoveries and innovations that will have a direct impact on 
society. 
Addressing capacity development in health sciences research 
Addressing capacity development in health sciences research in South 
Africa entails:
• Building capacity for the long-term sustainability of the country’s health 
research.
• Capacity development in health research.
• Addressing succession and sustainability.
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• Training clinical scientists to respond to South Africa’s health needs.
• Developing highly skilled researchers for global competitiveness.
The ASSAf consensus study of clinical medicine and clinical research in 
2011 identified the paucity of clinician scientists (MD PhDs). This needed 
to be addressed by increasing the number of PhD-holders involved in 
clinical research. The SAMRC therefore moved from a focus on funding 
Masters to funding doctoral programmes, with a target of funding 100 
health science-related PhDs per annum. There has been gradual progress 
towards this target, with 61 PhDs funded in 2016/17 (an increase from 16 
in 2011/12).
The SAMRC has also invested in building the next generation of black 
scientists and addressing the discrepancies in transformation. South Africa 
now has a vibrant group of future black scientists.
Gender and science have been another challenge in order to keep 
women in science, ensure that they are valued and address the issues 
that cause attrition, which include:
• A one-way career flow with no interruptions does not reflect the lived 
experience of women.
• Senior women are often more vulnerable in their positions than men.
• Many women choose technical careers rather than academic or 
managerial careers.
• Women may have to move backwards in their career to accommodate 
their family.
• Women often say they have to out-perform men to advance and be 
taken seriously.
• Leaks of women from scientific careers correspond to family formation 
but may not be chosen freely. Women face long hours at work, are 
required to be mobile, and the demands of the career of a spouse 
are often incompatible with family responsibilities.
Unless there is a critical mass of women or black scientists, the gender and 
racial stereotypes are reinforced, namely that good scientists tend to be 
white men. This is a particular challenge for South Africa. Science often 
has a very masculine and very Western model of success characterised by 
long working hours, uninterrupted scientific career and active participation 
in extracurricular activities, such as advisory boards and panels. 
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The SAMRC is committed to gender transformation and supporting women 
to become science leaders. In 2018, three-quarters of the SAMRC’s capacity 
development grants were awarded to women, and half to black African 
scientists. There has also been transformation in self-initiated research 
grants. Two streams of research grants were created (one for early-stage 
investigators and one for mid-career and advanced investigators), so 
that like could compete with like. The variables of race, gender and 
graduating from a historically disadvantaged institution were weighted. 
These interventions helped to open the field for transformation. By 2018, 
41% of SAMRC grants were awarded to African researchers, compared 
to 11% in 2012. All the SAMRC’s grants are internationally peer-reviewed 
following an NIH review process. 
The SAMRC began an intervention to build mid-career scientists and 
mentor them to becoming science leaders in the interests of succession 
planning. The programme is currently supporting five mid-career medical 
scientists with a focus on clinical researchers and women. 
The SAMRC is committed to supporting clinical research among early to 
mid-career scientists. The South African Clinician Scientists’ Society would 
be launched on 11 May 2018 with the following objects:
• To create a platform for clinicians to develop as scientists.
• To establish an environment for clinician scientists to discuss research 
ideas and collaboration.
• To liaise with national and international stakeholders.
This society would be the first of its kind. It is the initiative of Dr Salome 
Maswime, a young and committed SAMRC fellow.
In order to address the shortage of support for postdoctoral internships, 
the SAMRC created programmes for the development of research skills, 
including:
• NCD basic science support through the relationship between the 
University of Zululand and SAMRC supporting 30 interns.
• Intramural postdoctoral interns.
• Extramural postdoctoral interns.
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The DST-NRF-SAMRC South African Research Chairs Initiative (SARChI) 
Chair in Biostatistics was recently launched with co-funding for five years to 
address the paucity of biostatisticians in South Africa. The chair is aimed at 
developing postdoctoral fellows, doctoral, Masters and honours students. 
In 2015, the SAMRC launched a programme to strengthen institutional 
research capacity at eight historically disadvantaged institutions with 
the following objectives:
• To strengthen research capacity at selected universities.
• To leverage funding for research projects and programmes (collaborative), 
and for essential infrastructure to conduct research.
• To create an enabling research environment. 
• To gear the universities for self-sustainability.
• To initiate, maintain and grow a robust and sustainable research culture.
Each university receives R1 million per annum for five years. There are 18 
investigators at these universities, with more than 20 research projects, and 
several Masters and doctoral candidates. The first papers were published 
in 2016 within a year of the start of the programme, and the first cohort 
of graduates graduated in 2017. This programme has been particularly 
successful because of the mentoring to enable investigators to become 
successful and competitive.
The SAMRC has developed international collaboration to improve health 
outcomes in South Africa. The idea was to develop collaborative networks, 
improve grant-writing capacity, conduct world-class research and 
produce world-class scientists. The most ambitious of these programmes 
was SAMRC-NIH collaboration, which brought together USA and South 
African researchers at a joint Summit on HIV/AIDS, TB and HIV related 
Malignancies, held in Durban on 17 – 18 June 2013. Each country dedicated 
US$40 million to the programme, which has been very fruitful and is about 
to be renewed. In the next call, collaboration with other African scientists 
will be introduced. 
Another exciting initiative was the launch of the Whole Genome Sequencing 
Research Institute in South Africa in 2018, in collaboration with the Beijing 
Genome Institute. The institute is developing the field of bioinformatics 
at the country level. 
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Research capacity enhancement and sustainability require a multi-
factorial approach with engagement in all the following areas in order 
to be successful:
• Building research capacity along the whole value chain of individuals, 
departments and institutions.
• Improving, refining and growing research expertise and portfolios by 
identifying research niches that fit into the national burden of disease 
but are also globally relevant.
• Forming collaborative research networks and partnerships.
• Establishing independent researchers, departments and institutions, 
including successful grantsmanship from diverse sources to fund research 
and attract new partnerships.
• Realising the development of skilled researchers, globally competitive 
departments and excellent institutions and leveraging research capacity 
for research translation contributing to the knowledge economy and 
GDP.
Science has the power to save lives, particularly in South Africa.
Prof Kaufmann thanked Dr Gray on behalf of colleagues at Leopoldina, 
the UNAS and ASSAf.
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SESSION 4
Facilitator: Dr Oladoyin Odubanjo, Nigerian Academy of Science, Nigeria
Keynote Address V: Novel Biomarkers and Vaccines for Tuberculosis 
Control (Prof Stefan Kaufmann, Director, Max Plank Institute for 
Infection Biology, Germany)
In pursuing the Millennium Development Goals and later the Sustainable 
Development Goals, the UN decided to convene high-level meetings on 
health and other issues related to the goals in order for partners to take 
responsibility. Four meetings have thus far taken place on health issues:
2011: High-level meeting on non-communicable diseases.
2014: High-level meeting on Ebola.
2016: High-level meeting on ending AIDS.
2016: High-level meeting on AMR.
The fifth high-level meeting on tuberculosis is scheduled for 26 September 
2018 in New York. This meeting was preceded by pre-meetings: the Global 
TB Ministerial Conference in Moscow in November 2017, and the STOP 
TB Partnership Board meeting in Delhi in March 2018. This is intended to 
encourage global commitment to end TB as the leading infectious killer 
and one of the top ten causes of death worldwide. Annually, 10.4 million 
people fall ill with TB, 1.8 million die of TB, and 0.5 million develop multidrug-
resistant TB. Multi-sectoral action is required to accelerate global and 
national TB responses, involving the health, finance, labour, justice and 
social development sectors, and all stakeholders including government, 
civil society, NGOs, the private sector and academia. New intervention 
methods are needed. The presentation addresses two interventions: TB 
biomarkers that measure host responses rather than the epidemiological 
agent, and a new TB vaccine.
The immunopathology of TB follows several stages:
• If a TB-infected person coughs, there is a strong likelihood of infecting 
other people, because the pathogen is transmitted by airborne particles.
• The bacteria enter the alveoli, where they are engulfed by monocytes 
and granulocytes, but most importantly also by the dendritic cells in 
the epithelial layer, which transport the bacterial load into the lymph 
nodes.
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• The T cells are activated, and after several weeks CD4 T cells and CDA 
T cells contribute to the development of a lesion, known as a sold 
granuloma, in which the bacteria are contained. These lesions often 
last life long, affecting between 1.7 and 2 billion people in the world 
who have latent TB infection but are healthy. Sometimes the lesions 
disappear, but the bacteria stay elsewhere; for example, the bone 
marrow is thought to be a major reservoir.
• After a year or even several decades, in 5 – 10% of individuals, a 
cancerous lesion develops, a caseating granuloma (first necrotic 
caseating and then cavitory) develops and cavities are formed, and 
the bacteria multiply and may be spread to other organs, and to other 
individuals through contagious disease. 
TB biomarkers could be a diagnostic tool for the future, even at the point 
of care. A study was launched with funding from the Gates Foundation 
to investigate host biomarkers in TB and compare the differences in the 
host response between people exposed to TB who never become sick 
(1.7 billion) and those who develop serious disease (>10.4 million 2016). The 
study looked at blood cell transcriptomics (i.e. gene expression profiles). The 
presentation focuses on transcripts, and metabolites are only mentioned. 
Biomarkers are very successful for diagnosing TB, with biosignature with 
high sensitivity and specificity for differential diagnosis between active TB 
and latent tuberculosis infection. Biosignature is then used with a predictive 
marker for the disease prognosis (i.e. how soon a person with latent TB 
infection will develop active TB).
The process can be simplified. Only three to four biomarkers are required 
to reliably diagnose TB. The top markers for tailored diagnostic signature 
in a peripheral blood mononuclear cell are:
• FcgR I, an antibody Fc binding receptor.
• Lactoferrin, which is involved in iron uptake.
• Guanylate-binding proteins, which are induced by type I and type II 
events.
This combination has been shown to work well, but other combinations can 
be used. This approach was used with 85% specificity and 85% sensitivity 
in The Gambia, Uganda and South Africa under the Grand Challenges in 
Global Health research initiative launched by the Bill and Melinda Gates 
Foundation. It was then validated in Bangalore, India and Eastern Europe 
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with the same results. Different combinations of three to four markers 
combined in decision trees also work well.
Having solved TB diagnosis, the core activity of the Grand Challenge 
programme is now to investigate TB prognosis, which Prof Kaufmann 
headed as the principal investigator until 2013. It was then decided to 
move the research to South Africa, with Stellenbosch University and the 
University of Cape Town as major players. 
The index case involved 1 098 newly diagnosed TB patients at seven sites 
across Africa, and 4 462 household contacts. Household contacts that 
are willing to participate in the study are followed over two years. Blood 
is taken immediately after exposure to TB, which is at approximately the 
time of diagnosis of the index case, and six, 18 and 24 months later. At 
the end of the two-year period, 2.2% of household contact individuals 
developed TB, and 97.8% remained healthy. The rate of infection was 
lower than the expected 4 – 5%, which is the average in South Africa. 
With over 80% sensitivity and specificity, it is possible to predict which 
individuals with latent TB infection will develop TB disease within the next 
12 to 24 months using a transcript-based GC6 biosignature.
It is possible to further minimise the risk by introducing pair ratios (upregulated 
marker/downregulated marker), so that two pairs of two selected 
biomarkers can predict TB in latently infected individuals. There is the 
potential to develop a PCR test using just a few biomarkers for point-of-
care prognosis of TB. 
This work was based on transcripts. It was hoped that a dipstick could be 
developed in order to use metabolites for diagnosis. This proved to be 
difficult, but it does work, although with less sensitivity and specificity in 
the range of 70 – 80%. 
Metabolomic and transcriptomic signatures can be harnessed for both 
diagnosis and prognosis of TB. Prognostic signatures in reality detect 
disease progression six to 12 months prior to active disease. The original 
signature used 16 transcripts, and the decision trees and pair ratios have 
now been reduced to two marker pairs (i.e. four markers). Multiplatforms 
are now being analysed for further optimisation of the system and yield 
higher sensitivity and specificity.
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The issue is what we are really looking at. It was realised that another 
group of individuals needed to be defined, namely those with subclinical 
disease. These people are healthy, but the markers are so sensitive that 
light inflammation can be detected. Since most of those with subclinical 
TB will eventually develop active TB, TB prognosis can be determined by 
diagnosing subclinical TB. This is relevant for preventive therapy before 
the onset of the clinical disease and transmission. The University of Cape 
Town is testing whether identifying subclinical individuals and offering them 
preventive therapy can succeed in preventing active TB and transmission of 
the disease. This would involve drugs that prevent transmission. Diagnosing 
subclinical individuals could be used for stratification for clinical trials. 
It might be asked why there is a need for a new TB vaccine, since BCG 
is available. BCG protects against extrapulmonary TB in neonates, but 
poorly against pulmonary TB in any age group, notably in developing 
countries with the highest TB incidences. Better vaccines are therefore 
urgently needed. 
It was decided to use BCG as a platform and improve it using Vakzine 
Projekt Management (VPM) 1002, the most advanced live TB vaccine 
candidate. Next-generation BCG has been produced, improved by 
genetic modification. This vaccine has now reached phase II and phase III 
trials as a pre-exposure BCG replacement for neonates. It will be tested 
for pre and post-exposure Mtb as a BCG boost for adults, and as a post-
exposure Mtb for prevention of recurrence. The vaccine will be used for 
prevention of infection, prevention of disease and prevention of recurrence. 
This is quite ambitious. 
The new vaccine was developed by introducing the gene for listeriolysin 
not as an antigen but as the molecule that perforates the phagosomal 
membrane. When the listeriolysin perforates the membrane, proline 
antigens form the recombinant vaccine, egress into the cytosol, and 
CD4 and CD8 T cells are stimulated (whereas BCG primarily stimulates 
CD4 cells). Perforation also allows egress of listeriolysin and cathepsins 
inducing apoptosis, which leads to the release of vesicles that contain 
mycobacterial components. Cross-priming, which is much better than 
primary priming, is induced, and a broad spectrum of CD8 T cells, Th17 
cells, inflammatory CD4 cells, Th1 cells, central memory T cells and helper 
cells are induced. Ultimately, autophagy and inflammation are induced, 
because double-stranded DNA is released, which is sensed by the STING 
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(stimulator of interferon genes) molecule, resulting in autophagy or 
xenophagy and much stronger immunity.
The vaccine has been shown to be efficient and safe in preclinical studies. 
P1-level was approved Large-scale GMP production (fermentation) has 
been achieved. Safety and toxicity have been approved. The hygromycin 
resistance marker has been removed. The vaccine was licensed worldwide 
to VPM and has been renamed VPM1002. Recently it was sub-licensed 
to the Serum Institute of India, the largest vaccine producer in terms of 
doses, which is continuing with the trials of the vaccine.
The vaccine has undergone the following clinical trials:
• Phase I trial in Germany NCT 00749034: successfully completed in 
2009; three escalating doses were given to young adults (104, 105, 106 
rBCGΔureC::hly, comparator 106 BCG).
• Phase I trial in South Africa NCT 01113281: successfully completed 
in 2011; three escalating doses given to young adults (104, 105, 106 
rBCGΔureC::hly, comparator 106 BCG).
• Phase IIa trial in South Africa NCT 01479972: successfully completed 
in 2013; three escalating doses given to newborns (104, 105, 106 
rBCGΔureC::hly, comparator 106 BCG).
• Phase II trial in South Africa NCT02391415: 416 HIV-exposed/unexposed 
neonates; the first baby was vaccinated on 11 June 2015; recruitment 
was completed in September 2016, and unblinding was expected late 
in 2018.
• Multicentric phase I/II therapy trial for bladder cancer NCT02371447 in 
Switzerland: first instillation on 21 September 2015; phase I had been 
completed, and phase II had started.
The issue was then to design a phase III clinical trial with limited financial 
resources. If one in 100 people are assumed to develop TB, and 200 cases 
are required in the control group for statistical reasons, a minimum of 20 000 
participants are required per group, and hence 40 000 participants in total 
over five years. A clinical trial of this magnitude would cost US$200 million. 
TB vaccine trial design could be slightly improved by using household 
contacts. With this approach, approximately 6 000 participants would be 
required per group, totalling 12 000 over three years and costing US$36 
million. This approach would be followed from 2019. The Indian Council 
of Medical Research had decided to test the efficacy of the VPM1002 
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vaccine in a household context study together with a competitor. The study 
had been submitted and the results were expected in 2023. This would 
involve both pre and post-exposure individuals. Most of the household 
contacts (an estimated 90%) would already be infected. 
Another way to improve TB vaccine trial design would be through 
stratification for TB high risk. This study would comprise neonates, since about 
five in 100 develop TB disease despite BCG vaccination. This would involve 
4 000 participants per group, with a total of 8 000 over two years, costing 
US$16 million. A phase III multicentre efficacy trial was being prepared 
in HIV-exposed/unexposed neonates in sub-Saharan Africa. BCG is not 
endorsed for HIV-exposed neonates. The trial is expected to start in the 
third or fourth quarter of 2018, funded by the EDCTP, and the results are 
expected by 2024. The objective of the trial would be pre-exposure BCG 
replacement, with the end points of safety and efficacy against infection 
and prevention of disease over BCG.
Prevention of recurrence was another area of focus in improving TB vaccine 
trial design. In India, about 10% of those who have been cured using TB 
drugs will develop TB again after one year, whether through reinfection (30 
– 40%) or relapse (60 – 70%). A trial of this group would require only about 
2 000 participants, totalling 4 000 over one year, at a cost of US$4 million. 
The trial on the prevention of recurrence began in 2018. The first vaccine 
was administered on 5 January 2018, and the trial will be concluded by 
the end of 2019, with unblinding in 2020. This group is highly susceptible. 
Another way of designing a clinical trial would be to recruit people with 
subclinical TB (i.e. those predicted to develop the disease within a year). 
This would require 300 participants per group, totalling 600 over one year, 
at a cost of US$0.6 million.
WHO has set the ambitious target of reducing morbidity by 90% and 
mortality by 95% by 2030 – 2035. Now that biomarkers are available to 
identify and introduce individuals into preventive treatment, and with a 
new TB vaccine on the horizon, the goal is starting to become somewhat 
more realistic. 
Surveillance and Response to Infectious Diseases and Comorbidities
Proceedings Report 12 – 13 April 2018
71
Discussion
Question: If subjects are reliably identified at subclinical level before they 
develop the active disease, could the vaccine be administered to stop 
the disease?
Response (Prof Kaufmann): There were concerted efforts to find a few 
metabolically stable markers. Individuals have to be screened each 
year. A surveillance study can be conducted in populations at high risk 
to identify those who are likely to develop TB in the next year and offer 
treatment. This is a very expensive approach. A study of this nature is 
being conducted at the University of Cape Town with funding from the 
Gates Foundation, the data from which will soon become available. Four 
biomarkers are now used for a simple low-cost assay. 
Question (Dr Norbert Heinrich): It was mentioned that there is specificity 
of 80% one year before diagnosis with TB, and that this increases in the six 
months before diagnosis. What does this indicate about the incubation 
period, and when does the infection event actually occur?
Response (Prof Kaufmann): This is not known. Investigating this would 
involve non-human primate studies such as those conducted by Flynn in 
the USA. In Prof Kaufmann’s study, all individuals who developed TB within 
three months of the index case diagnosis were discarded. Individuals are 
infected by the index case and give out latent TB; fewer than 3% continue 
to direct TB. TB has the highest rate of infection in the first year two years. 
The literature reported that 5% continued to direct TB, but Prof Kaufmann’s 
study found this to be much lower, and recruitment continued up to 100 
cases. The initial goal was to recruit 3 500 participants, but this rose to 
4 500 in order to get 100 cases. Prof Kaufmann’s research was a complex 
pan-African study with better bioinformatics.
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Keynote Address VI: Virulence Factors of the Human-Pathogenic 
Fungus Aspergillus fumigatus and Novel Antibiotics (Prof Axel 
Brakhage, Leibniz Institute for Natural Product Research and Infection 
Biology – Hans Knöll Institute, Germany)
Germany has four non-university research institutes, including the Max 
Planck Society, the Helmholtz Association of German Research Centres 
and the Leibniz Association, which comprises 90 institutes in five sections, 
with 17 200 employees and an annual budget of €1.5 billion, half of which 
comes from the federal government and half from federal states.
The Leibniz Institute for Natural Product Research and Infection Biology 
has 440 employees, including ten professors, 130 doctoral researchers, 150 
students and ten start-ups that emerged from the institute. The institute 
works very closely with universities, to the extent that it is almost part of 
the university system. 
The motivation of the institute is that its research must have relevance 
for society. Its research focuses on multi-resistant pathogens and human-
pathogenic fungi that cause high mortality because diagnosis tends to 
be unspecific and is often too late, and therapy is ineffective. New anti-
infectives are needed. Another aspect of the research is active compounds 
in natural products, which form the basis for many pharmaceuticals. The 
pipelines for new anti-infectives are empty, pointing to a major societal 
need. 
Fungi infect billions of people every year, including:
• Superficial infections of the skin, mucosal surfaces and nails. About a 
quarter of the world’s population is infected with dermatophytes. Ninety 
per cent of HIV-infected patients are infected with oral Candida.
• Life-threatening fungal infections. Fungi have become a major problem 
in the clinical setting and kill at least as many people as tuberculosis 
or malaria.
Significant invasive fungal infections include:
• Aspergillosis (Aspergillus fumigatus), which accounts for over 200 000 
infections per year, with 30 – 95% mortality rates in infected populations. 
Invasive aspergillosis infections are often associated with TB because 
of the defect of the lungs.
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• Candidiasis (Candida albicans), which accounts for over 400 000 
infections per year, with 46 – 75% mortality rates in infected populations.
• Cryptococcosis (Cryptococcus neoformans), which accounts for over 
one million infections per year, with 20 – 70% mortality rates in infected 
populations. Cryptococcosis occurs particularly in sub-Saharan Africa, 
often associated with HIV.
The mortality rates for these infections are extremely high.
Prof Brakhage works on A. fumigatus, a common fungus. People inhale 
the spores, and can become infected, especially immune-suppressed 
patients, with mortality rates of up to 90% because it is very difficult to 
treat. Prof Brakhage’s laboratory is particularly interested in the interaction 
between the fungus and immune cells. When conidia are inhaled, 
many immune cells are involved in preventing infection, but the fungus 
has immune-evasion mechanisms. Two such mechanisms have been 
discovered involving macrophages. The fungus has surface molecules, 
which are the first contact with the immune system. Two surface molecules 
were mentioned:
• Rodlet layer: Spores have distinctive proteins known as rodlets, which 
are like a shell for the spore to protect it against adverse environmental 
conditions. The rodlet layer consists of a protein called Hydrophobin 
RodA, which prevents immune recognition of airborne fungal spores by 
humans. It is difficult to isolate this protein, requiring very harsh conditions, 
and only resting conidia are found, not swollen or germinating conidia.
• Dihydroxy naphthalene (DHN) melanin: A gene cluster was discovered, 
and when the genes were deleted, white conidia were obtained. 
When these conidia are introduced to mice, they are avirulent (i.e. they 
have lost their virulence). It was found that the pigment is important 
for virulence and is similar to mycobacteria, in that the melanin inhibits 
the acidification of fungal lysosomes. If the pigment is missing, the 
phagosome fuses with the lysosome and kills the conidia. This work has 
not yet been published.
The mechanism of DHN-melanin interference with macrophages was 
investigated. Membranes form lipid rafts, which are an accumulation 
of cholesterol, glycosphingolipids, and proteins that keep the lipid raft 
together. The lipid rafts are essential for receptors to be positioned in a 
membrane, and are important for signalling processes. Melanin interferes 
with the formation of lipid rafts in macrophages. The phagolysosomal 
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membrane surrounding conidia showed a reduced assembled vATPase 
when they had melanin. 
The three-step mechanism works as follows:
• Conidial proteins mask immunogenic structures and bind human 
immune regulatory proteins.
• DHN-melanin prevents apoptosis.
• DHN-melanin prevents full acidification of the phagolysosome by 
interference with lipid rafts.
Recognition of DHN-melanin by a C-type lectin receptor is required for 
immunity to Aspergillus.
Discovery of novel antibiotics
The focus would be on natural products and antibiotics from fungi. 
Fungi are chemical factories. It is estimated that they produce millions 
of compounds, most of which are not yet known. Penicillin, cyclosporine 
and statins, for example, were derived from fungi. 
The biological problem of natural product research is that microorganisms 
do not use their full genetic potential to produce natural products under 
laboratory conditions; they need the ecological context to activate the 
gene clusters because ecological triggers are required. The challenge 
was to find a way of activating the gene clusters.
Natural products can be discovered through genome mining. In one 
example of a silent gene cluster in the genome of Aspergillus nidulans, a 
regulatory gene that formed part of the gene cluster was fused with an 
inducible promoter and put back into the fungus. When the regulatory 
gene was activated, all the genes of the cluster were activated. New 
peaks appeared. It was reasoned that new compounds were formed, 
which were then isolated, and the structures were elucidated. Through 
synthetic biology or genetic engineering, there is now access to many 
silent gene clusters. 
Researchers are interested in the ecological conditions that activate 
gene clusters to produce antibiotics. It is believed that natural products 
are the chemical language of the microorganism. In order to find such 
compounds, the Aspergillus nidulans fungus was co-cultivated with 50 
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different actinomycetes that live in the soil. All the gene clusters in the 
fungus were analysed for activation of silent gene clusters. A single bacterial 
strain, S. rapamycinicus, activated a silent fungal gene cluster. Activation 
of the ors gene cluster requires intimate physical contact between 
A. nidulans and S. rapamycinicus. 
Jagaricin was presented as an example of using the ecological context to 
discover new compounds. Jagaricin, a novel antifungal compound, was 
developed by Dr Christian Hertweck’s group. Jagaricin is produced by a 
bacterium that infects mushrooms such as white button. The compound 
belongs to the group of lipopeptides. Apart from aiding in the infestation 
of the mushroom, it is active against a variety of other fungi including 
human pathogens such as A. fumigatus and C. albicans.
The investigators became aware of less-investigated bacteria that can 
infect mushrooms and assumed that the bacteria probably employ small 
compounds that weaken or kill the fungus. They reasoned that such 
compounds would be potentially active against other fungi and thus 
perhaps also useful for treating mycoses.
Sequencing the genome of the bacterium proved to be very helpful 
because with the genomic inventory at hand they were able to predict 
its potential for metabolite production. They noted that the candidate 
genes were silent under standardised culture conditions in the laboratory. 
Thus, they wanted to catch the bacterium in action and monitor how it 
infects the mushroom.
Using a modern method to visualise the production of metabolites (imaging 
mass spectrometry), they discovered that a compound with a particular 
molecular mass accumulates in lesions of the mushroom tissue. They 
succeeded in finding growth conditions to produce sufficient amounts of 
the antifungal agent for a full structural elucidation and biological testing.
BTZ043 (Benzothiazinone) is a new drug against tuberculosis. It is extremely 
active against Mycobacterium tuberculosis. The structure was isolated, 
the compound was synthesised and a patent was filed. A consortium 
comprising experts from the Leibniz Institute for Natural Product Research 
and Infection Biology and other specialists in the field discovered that 
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan 
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synthesis. Inhibition of this enzymatic activity abolishes the formation of 
decaprenylphosphoryl arabinose, a key precursor required for the synthesis 
of the cell-wall arabinans, thus provoking cell lysis and bacterial death. 
Industry is no longer willing to invest in development research to the 
extent that they did in the past. Academia needs structures in order to fill 
the gap between research and industry. Fortunately, InfectControl 2020 
was prepared to support the further development of the compounds. 
InfectControl 2020 is a consortium of representatives from enterprises 
and academia that jointly aims at developing solutions regarding these 
problems on a national and global level. It is funded by a grant from 
the Federal Ministry of Education and Research in Germany. The Leibniz 
Institute for Natural Product Research and Infection Biology together with 
the Friedrich Löffler Institute developed a transfer group for anti-infectives 
with the role of filling the gap between research and industry by managing 
novel compounds, developing novel animal models, preclinical trials 
and supporting clinical trials of the clinical partner, Prof M Hölscher at 
the University of Munich. 
The clinical trials of the BTZ043 compound have been completed, and 
funding is available to enter the preclinical phase once the work has been 
approved. All this work has been publicly-funded; €14 million were raised. 
Discussion
Question (Dr Collen Masimirembwa): What is the failure rate of antibiotics 
in these programmes? In most drug discovery programmes, the attrition 
rates are high. What gives you optimism on the basis of preclinical data 
that these new antibiotics will succeed?
Response (Prof Axel Brakhage): The institute isolates 50 new classes of 
compounds per year and most are excluded. Only when a compound 
is found that is very effective in vivo in animal models with low toxicity is 
there consideration of taking it further. The metabolites that are derived in 
the bloodstream also have to be analysed. The Leibniz Institute for Natural 
Product Research and Infection has specialists in the compounds for this 
type of work, but there are very few such experts throughout the world. 
The success rate is higher if these issues are addressed by the same team 
from discovery right through to the eventual development of the drug.
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Keynote Address VII: Refocusing on STIs (Prof Koleka Mlisana, 
University of KwaZulu-Natal, South Africa)
The way in which sexually transmitted infections (STIs) have been managed 
is altogether inadequate. Prof Mlisana would like to see the South African 
government change this. 
Epidemiology and HIV risk
The complications of STIs include:
• Infertility (male and female): In sub-Saharan Africa, untreated genital 
infections are responsible for 85% of infertility among women seeking 
infertility care.
• Pelvic inflammatory disease (PID) in women.
• Urinary tract complications.
• Cervical cancer: human papillomavirus (HPV) infection causes 530 000 
cases of cervical cancer and 275 000 cervical cancer deaths each 
year.
• Pregnancy-related morbidities such as ectopic pregnancies and pre-
term labour.
• HIV transmission and acquisition: If these are to be reduced, STIs cannot 
be ignored.
• Genital inflammation.
• Psychological impact.
The causative agents of the most common STIs include viruses and bacteria. 
Common viral STIs include warts, herpes, hepatitis and AIDS, and bacterial 
STIs include chlamydia, gonorrhoea and syphilis.
More than one million STIs are acquired every day worldwide, including 
an estimated 357 million new infections with one of the following four STIs 
each year: chlamydia, gonorrhoea, syphilis and trichomoniasis. More than 
500 million people are estimated to have genital infection with herpes 
simplex virus (HSV). More than 290 million women have HPV infection. 
There are high prevalence rates in Africa, particularly chlamydia and 
trichomoniasis. In South Africa, there are chlamydia and trichomoniasis 
prevalence rate of 10 – 18%. 
A person with one STI is more likely to become infected with another 
one. A study in South Africa by D Moodley et al. found a high rate of STIs 
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among pregnant women, including both those with HIV and those who 
were uninfected with HIV. 
STIs, bacterial vaginosis and HIV risk
• The vaginal environment greatly alters the likelihood of HIV transmission.
• The presence of STIs, epithelial disruptions and any factor that increases 
inflammatory cytokines increases the likelihood of HIV transmission.
• In women, the acidification of the vagina by lactic acid from lactobacilli 
provides protection from vaginal infections.
• BV or the absence of vaginal lactobacilli is an independent risk factor 
for STIs such as HIV, HPV and HSV infections.
• Women with bacterial vaginosis (BV) as well as men whose female 
partners have BV have a more than two-fold higher risk of transmitting 
HIV.
• Most STIs are curable (especially bacterial STIs), but if untreated lead 
to significant morbidities such as ectopic pregnancies, infertility, foetal 
and neonatal complications.
Lactobacillus species as biomarkers and agents can promote various 
aspects of vaginal health. A healthy ‘normal’ vaginal environment 
is dominated by Lactobacillus species with a pH of less than 4.5. This 
description may not be perfectly applicable to women of African descent, 
who have diverse microbial communities. Loss of Lactobacillus may lead 
to bacterial vaginosis, a microbial dysbiosis, rather than an STI.
Bacterial vaginosis occurs in over 50% of sexually active women and is 
associated with increased risk for HIV transmission or acquisition. Bacterial 
vaginosis is also associated with reproductive and obstetric sequelae, 
including PID, spontaneous abortions and pre-term labour. As many as 
75% of women may be asymptomatic.
Current management of STIs
Like most poorly resourced countries, South Africa uses syndromic 
management of STIs, because STIs signs and symptoms are rarely specific 
to a particular causative agent due to dual and multiple infections. 
Most STI organisms are fastidious and difficult to culture for susceptibility 
testing. Laboratories for diagnosis are either non-existent or non-functional 
due to lack of resources. Dual infections are quite common, and both 
clinician and laboratory may miss one of them. In poorly resourced 
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circumstances, there are benefits to treating patients syndromically, in 
that it is not necessary to wait for laboratory results; patient management 
is improved through treatment at first contact; and this approach allows 
for the decentralisation of the management of STIs to primary health care 
levels. Syndromic management thus makes sense, but is only possible in 
patients who are symptomatic.
A study in Kenya evaluated syndromic management of STIs in the Kisumu 
incidence cohort study. The findings suggest that syndromic management 
of STIs is not a sufficient tool for STI diagnosis in this setting; development and 
improvement of STI diagnostic capabilities through laboratory confirmation 
is needed in resource-limited settings. 
Prof Mlisana and her group conducted a study to follow women in an acute 
infection cohort study. Any of the participants with clinical symptoms were 
treated syndromically, and all the participants were tested for STIs every 
six months. Women with symptomatic diagnosis of STIs were compared 
with the laboratory diagnosis of STIs. The result was 12.3% sensitivity, which 
means that almost 87.7% of patients were missed who had laboratory-
diagnosed STIs but no clinical symptoms. Among those who were treated 
syndromically (e.g. because they had a vaginal discharge, which could 
be due to causes other than STIs), 65.8% did not have STIs according to the 
laboratory results. Current syndromic management thus not only under-
diagnoses, but also results in over-treating. There is a place for syndromic 
management for patients who are symptomatic, but there is a need to 
look beyond this approach. 
Asymptomatic infections and genital inflammation
A study compared cytokine levels and genital inflammation in women 
with and without symptoms of STIs. It was found that cytokines were 
increased in both symptomatic and asymptomatic women. This means that 
asymptomatic women also had inflammation and were thus susceptible 
to the risk of HIV infection. Another study found that biological susceptibility 
in the female genital tract alters the protective efficacy of tenofovir gel. 
Genital inflammation in women increases the risk of HIV transmission and 
acquisition, and this is seen in both symptomatic and asymptomatic 
infections. Genital inflammation may be caused by factors other than 
STIs, such as vaginal douching. The findings undermine the effectiveness 
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of tenofovir gel in preventing HIV acquisition in women, especially for 
those with genital inflammation. Genital inflammation therefore needs 
to be managed.
Screening is an important approach for identifying and treating infected 
individuals with asymptomatic STIs who would otherwise go undetected, 
but routine screening for all potential STIs in all patients is cost-prohibitive. 
Targeted screening of asymptomatic patients in specified risk groups is more 
feasible. Screening for chlamydia has been the most extensively studied. 
The benefits of screening are to reduce the personal risk of reproductive 
sequelae in women, to reduce the likelihood of reinfection of sex partners, 
and to reduce overall transmission of these infections in men.
For the purposes of targeted screening, the risk for STIs can be assessed 
on the basis of behavioural risk factors, including:
• New sex partner in past 60 days.
• Multiple sex partners or sex partner with multiple concurrent sex partners.
• No or inconsistent condom use when not in a mutually monogamous 
sexual partnership.
• Trading sex for money or drugs.
• Sexual contact (oral, anal, penile or vaginal) with sex workers.
• Meeting anonymous partners on the internet.
Risk groups associated with high STI prevalence include:
• Young age (15 to 24 years old).
• Men who have sex with men.
• History of a prior STI.
• Unmarried status.
• Lower socioeconomic status, or high-school education or less.
• Admission to correctional facility or juvenile detention centre.
• Illicit drug use.
Better diagnostics are available for targeted screening of high-risk groups. 
Pregnant women have been screened for syphilis for a long time. It is now 
possible to screen for hepatitis B or hepatitis C. Nucleic acid amplification 
tests are available for screening for N. gonorrhoeae, C. trachomatis and 
T. vaginalis using less invasive samples such as urine, especially men. 
There is enough evidence to show that self-collected vaginal swabs give 
reliable results.
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Resistance in gonococcal infections
The majority of gonococcal infections are in low-income and middle-
income countries. Gonorrhoea has no symptoms in about 80% of women 
and 50% of men. Between 2012 and 2016, gonorrhoea notification rates 
increased by 63% (62 to 101 per 100 000), with an increase in both males 
(72%) and females (43%). 
Penicillin was used to treat STIs until resistance to penicillin developed. 
Resistance also developed to tetracycline and spectinomycin, and there is 
increasing resistance to azithromycin. South Africa previously used penicillin 
to treat STIs. When resistance developed, there was a move to using third-
generation cephalosporins (both oral and via intramuscular injection), such 
as ceftriaxone. Ceftriaxone in combination with azithromycin is currently 
the recommended treatment for gonorrhoea in most places, but there was 
decreased susceptibility to ceftriaxone of 1.7 – 4.3% between 2012 and 
2016. With increasing resistance to cephalosporins, there is a threat that 
there will be no drugs available to effectively treat gonococcal infections. 
There is a need for new drugs for multidrug-resistant N. gonorrhoeae. This 
could entail repurposing known drugs (e.g. gentamicin, ertapenem and 
fosfomycin) or developing new drugs with in vitro data (e.g. sitafloxacin 
and delafloxacin). New compounds are ready for investigation (e.g. 
solithromycin, zoliflodacin and gepotidacin). A clinical trial of zoliflodacin 
would be starting soon.
The Lancet Infectious Disease Commission in 2017 addressed challenges for 
research, practice and policy and identified the following major areas for 
attention: chlamydial infections, emerging drug resistance in gonococcal 
infections, bacterial vaginosis, STIs in low-income and medium-income 
countries, and epidemics of STIs in high-income countries in the population 
of men who have sex with men. Partner management strategies also 
need urgent attention.
The WHO Global Health Sector Strategy (2016 – 2021) looks specifically 
at STIs, with a focus on universal health coverage. Services have to 
be provided to vulnerable populations. A public health approach of 
integrating services is required so that vulnerable people can be reached 
and properly managed. 
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South Africa is entering the second year of its NSP for HIV, TB and STIs (2017 
– 2022). Previous strategic plans hardly addressed STIs at all, so the current 
NSP is a sign of significant progress. The priority areas cover the whole 
continuum of care: prevention, testing, treatment and care, health systems 
and surveillance, research and innovation. Laboratory diagnostics need 
to be improved, because this capability has declined through the focus 
on syndromic management. High-risk populations need to be identified. 
There is an urgent need for baseline data so as to set meaningful targets, 
and to scale up expertise (clinical and laboratory) and resources.
Round-Table Discussion II: One Health
Moderator: Prof Thomas Mettenleiter, Friedrich-Loeffler-Institut, Federal 
Research Institute for Animal Health, Germany
Panellists:
Prof Thumbi Ndung’u, University of KwaZulu-Natal, South Africa
Dr Alison Lubisi, Agricultural Research Council (ARC), South Africa
Dr Kristina Roesel, International Livestock Research Institute, Kenya
Prof Marietjie Venter, University of Pretoria, South Africa
Prof Rose Hayeshi, North-West University, South Africa
One Health is gaining increasing attention.
In the 1960s, people believed that the world was on the brink of victory 
over infectious diseases. There were significant advances that eliminated 
smallpox and rinderpest, which were highlights in the health and veterinary 
profession. However, the reality is different. Infectious diseases have 
reached the highest political level as a major concern. The term ‘One 
Health’ was taken up in the G20 Summit Declaration of 2017, together 
with a commitment to strengthen the One Health approach within the 
G20 while fully respecting the specific mandates of the WHO, OiE and 
FAO. The political climate is favourable to introducing the topic of One 
Health to the primary political agenda.
The One Health concept recognises that human health is connected 
with the health of animals and the environment. This holistic approach is 
not new but is novel in combatting infectious diseases. 
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In 2017, directors of G20 public health and veterinary health institutions met 
for the first time in Berlin to discuss issues related to the One Health concept. 
For high-income countries, the major One Health issue is AMR. AMR has 
implications for interactions between human and veterinary medicine, 
and implications for food and food products, and the environment. AMR 
is thus clearly a One Health issue. However, for lower and middle-income 
countries, zoonotic infections are particularly important. More than 60% of 
existing human infections is zoonotic (i.e. they have an animal source), and 
the percentage among newly emerging infectious diseases is estimated 
to be 75%. Five new human diseases appear every year, of which three 
on average are of animal original. Eighty per cent of agents with potential 
bioterrorist use are zoonotic pathogens.
The WHO Blueprint of Priority Diseases is a special tool for determining 
which diseases and pathogens to prioritise for research and development 
in public health emergency contexts. It seeks to identify those diseases 
that pose a public health risk because of their epidemic potential and 
for which there are no, or insufficient, countermeasures. On the 2018 list 
of diseases to be prioritised under the R&D Blueprint, seven of the eight 
infectious diseases are zoonotic: Crimean-Congo haemorrhagic fever, 
Ebola viral disease and Marburg viral disease, Lassa fever, Middle East 
Respiratory Syndrome (MERS) and severe acute respiratory syndrome 
(SARS), Nipah and henipaviral diseases, RVF, Zika disease and Disease X. 
Disease X represents the knowledge that a serious international epidemic 
could be caused by a pathogen currently unknown to cause human 
disease, and so the R&D Blueprint explicitly seeks to enable cross-cutting 
R&D preparedness that is also relevant for an unknown Disease X as far 
as possible.
The 13 most important zoonoses account for 2.2 million fatalities and 
2.4 billion morbidities annually. On average, every third person in the world 
is infected once a year with a zoonotic agent, which is a huge burden 
of disease. The most important zoonoses are primarily gastrointestinal 
infections (mostly parasitic) but include also zoonotic tuberculosis and 
rabies. The outlook is not expected to improve in the short term. In terms of 
human and animal interaction, the global demand for meat is predicted 
to increase drastically within the next few decades, because of rising 
income levels in increasing numbers of countries. This is particularly relevant 
for the demand for poultry, which is predicted to more than double in 
the next 30 years. 
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The health burden of zoonoses is primarily in low to middle-income countries, 
and these countries have the least means to address the challenges. 
High-income countries have a responsibility to help low to middle-income 
countries combat zoonotic infections. 
Zoonotic diseases also have an impact on human nutrition. Food sources 
can be lost through zoonotic diseases that kill animals used for food. High-
income countries can compensate for the loss, but low-income countries 
cannot. This puts the One Health concept into perspective as extending 
more widely than the human-animal interface. 
We live in a globalised world in which infectious diseases do not respect 
national diseases. An infection that arises in one place has the potential to 
spread worldwide within 24 hours. The epidemiology of infectious diseases 
has thus changed radically in the last few decades due to trade, travel, 
passive vectors (e.g. vehicles, objects in contact with animals or animal 
products) and active vectors (e.g. arthropods and birds). 
There is a need for more coordinated activity within the G20 and with 
countries that suffer from the burden of infectious diseases through 
epidemiology, monitoring, surveillance, research and coordinated best 
practice.
The G20 Summit Declaration on One Health undertook to support and 
facilitate the regular exchange of evidence and science-based knowledge 
in the field of human and animal health, agriculture and the environment. 
The present conference is one aspect of building what is required to 
deal with One Health. The last century was characterised by incremental 
advances, but there is a need to speed up.
Prof Thumbi Ndung’u, University of KwaZulu-Natal, South Africa
Prof Thumbi Ndung’u presented evidence of transmission-virulence 
evolutionary trade-offs in the spread of HIV-1 subtypes. 
HIV viral diversity presents an opportunity to understand how pathogens 
are transmitted and persist. There are significant differences in replication 
capacity among subtypes. HIV-1 subtypes show a hierarchy of Gag-
protease-driven replication capacity consistent with reported differences 
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in rates of disease progression and paradoxically with reported differences 
in transmissibility.
Understanding the genetic characteristics of viruses and other pathogens 
associated with transmissibility and virulence has important implications 
for controlling epidemics and predicting outbreaks.
Dr Alison Lubisi, Agricultural Research Council, South Africa
Dr Lubisi gave a presentation on One Health needs for effective RVF 
control in endemic areas. RVF is an emerging and re-emerging zoonotic 
disease affecting domestic ruminants (mainly camels) and man. It is 
caused by RVF virus, a Phlebovirus in the Bunyaviridae family. Widespread 
abortions, hepatitis, death among young animals and teratogenic effects 
characterise the disease in animals. Humans develop self-limiting flu-like 
symptoms, which may progress to retinal damage, hepatitis, nervous 
symptoms and haemorrhagic disease. When RVF affected Somalia in 
1997/98, more than half a million people died, and the economy suffered 
because of its dependence on the export of small livestock.
The transmission cycle of RVF shows that cattle are a big culprit. The disease 
is also spread by mosquitoes (Aedes mosquito). The major cause of RVF in 
humans is handling aborted material, carcasses, excretions or secretions 
from infected animals. There are also believed to be wildlife reservoirs of 
RVF as some wildlife animals have shown symptoms, but these are not as 
overt as in domestic animals. 
The prevention of RVF involves:
• Use of sentinel animals to monitor viral activity in the inter-epidemic 
period, which is the responsibility of veterinary officials.
• Early-warning satellite imagery involving climatic data collation (i.e. 
sea-surface temperature fluctuations, resultant high rainfalls and 
normalised difference vegetation index measurement), which is the 
role of climatologists.
• Vector control by conservationists and environmentalists.
• Vaccination by veterinary and medical officials (live attenuated, 
inactivated or clone 13); however, there are still no vaccines against 
RVF for humans.
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The control of RVF during an outbreak entails:
• Safe carcass disposal by veterinary officials and environmentalists.
• Quarantine and movement restrictions, which is the function of law 
enforcement.
• Ban on livestock slaughtering, enforced by veterinary officials.
• Ring vaccination by veterinary officials.
• Education by veterinary officials and social groups.
The gaps with respect to knowledge and control of RVF include:
• Virus maintenance hosts during the inter-epidemic periods. In East Africa 
it is believed that there must be other inter-epidemic hosts other than 
mosquito eggs that act as reservoirs, leading to outbreaks occurring 
when the environmental conditions are conducive.
• Drivers of emergence and re-emergence in different geographic 
regions. In Southern and East Africa, it is known that RVF outbreaks 
occur after high rainfalls, but the epidemiology in West Africa is not 
well understood.
• Laboratory diagnostic tests are needed. There are still no rapid tests 
available; the tests lack markers to differentiate infected from vaccinated 
animals; and there is a need for tests with application in all species. 
Only one company has commercialised RVF serological tests, but the 
tests need to be more sensitive.
• Effective vaccines for application in all susceptible animals and man.
• Vaccine banks for emergency responses.
One Health needs in relation to RVF include:
• Joint projects for simultaneous execution spatio-temporally for meaningful 
epidemiological studies.
• Resource sharing (e.g. transportation and manpower).
• Development and use of multi-species tests.
• Development and use a single vaccine in all susceptible species, 
including man (e.g. MP12 is promising and clinical trials are ongoing).
• Logistical and coordinated execution of control measures during 
outbreaks, with clear responsibilities and commitment.
• Sharing of samples for research purposes and laboratory test validation 
exercises; 
• Regular inter-laboratory test comparisons (ISO17025 compliance).
• Skills transfer, including research methods, insect identification and 
clinical sign recognition.
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• Regular information sharing, including early warning information and 
new epidemiological information.
The One Health approach could address the challenges with RVF.
Dr Kristina Roesel, International Livestock Research Institute, Kenya
The International Livestock Research Institute in Kenya is part of a consortium 
of 15 agricultural research institutes that came together in the 1970s to 
conduct agricultural research to improve global food and nutrition security 
and to reduce poverty in low and middle-income countries. Most of the 
centres focused on crop-based foods. The International Livestock Research 
Institute is the only one that looks at livestock and is thus by default a One 
Health institute through securing human access to food and income by 
improving animal health. In the first 30 years of the existence of the institute, 
the focus was on haemoparasites (East Coast fever and trypanosomiasis, 
which are cattle diseases). Developing vaccines and control strategies 
can be a lifelong activity; in the past 15 years the institute has therefore 
broadened its approach to include work on food safety, zoonoses and 
emerging infectious diseases. For the past two years, the institute has had 
an Animal and Human Health Programme that follows a multidisciplinary 
and multisectoral approach. 
For instance, the approach to food safety has been to look at the livestock 
value chains, from production to consumption, together with animal 
nutritionists, human nutritionists, economists and sociologists, using risk-
based methods developed in high-income countries, and adapting social 
science methods to close data gaps. Jointly with scientists working on 
climate change and data managers, the International Livestock Research 
Institute works on RVF, for which climate-based data are important in 
predicting outbreaks. Models have been developed to forecast RVF 
outbreaks in Kenya. 
Moreover, the International Livestock Research Institute is working with 
national and international institutions on emerging infectious diseases 
in pigs, which are of growing importance in Africa. The institute is also 
involved in abattoir-based surveillance. The social sciences are important in 
assessing the human health burden, animal health burden and economic 
burden of disease. 
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Prof Marietjie Venter, University of Pretoria, South Africa
Most zoonotic diseases circulate in the environment during inter-epidemic 
stages. Unless the diseases are addressed at that stage, they can cause 
major outbreaks among animals, which spill over into the human population. 
There are very short opportunities to act to combat the diseases. If outbreaks 
can be predicted in the environment before humans are infected, it 
is possible to take steps against the disease, and there is more time to 
respond (e.g. by vaccinating animals or controlling mosquitoes).
One of the problems with zoonotic diseases is that many of them present 
symptoms similar to common diseases. South Africa has experienced many 
epidemics of zoonotic diseases, including brucellosis, Crimean-Congo 
haemorrhagic fever, Q-fever, West Nile fever, rabies and avian influenza, 
but these are often missed because they present like common diseases. 
It takes a specialist to be aware of and diagnose these zoonoses, as well 
as specialised surveillance to fight the diseases. 
The approach at the University of Pretoria is to do surveillance in sentinel 
animals and humans. In animals this surveillance looks for neurological signs 
in horses, livestock and wildlife; bird fatalities; abortion and death in young 
animals; and signs or viral haemorrhagic fever (VHF). Human syndromic 
surveillance includes febrile disease, neurological signs, arthralgia and 
VHF. If signs are found among humans, there is a search for vectors in the 
area where the cases occurred. This approach has been very successful 
in describing West Nile virus (WNV). 
South Africa has several One Health initiatives to try to bring together 
human and animal aspects. The National One Health Forum was launched 
in 2014 involving the Department of Agriculture, Forestry and Fisheries, the 
DoH, the ARC Onderstepoort Veterinary Institute, the National Institute 
for Communicable Diseases, state veterinarians from across the country, 
medical schools, academia and some private veterinarians and doctors. 
The forum meets quarterly, and outbreak response teams meet monthly 
with representatives of the various sectors. There was an exercise in 2016 to 
prioritise some of the zoonotic diseases, which proved complicated, as it is 
difficult to decide which diseases are more important than others; however, 
it is important to decide which diseases the government should focus on 
and invest in. The Annual One Health Conference was launched in 2016 
to coincide with celebrating International One Health Day. In November 
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2017, the forum participated in a WHO Joint External Evaluation as required 
by the International Health Regulations. In the evaluation, South Africa 
was commended for having many things in place for zoonotic disease 
preparedness and response. The areas identified for action were training 
and awareness for doctors in early detection of zoonoses in humans, and 
an approved official policy for One Health.
Prof Rose Hayeshi, North-West University, South Africa
The DST/North-West University (NWU) Preclinical Drug Development Platform 
is a state-of-the art national facility for the innovation of pharmaceutical 
development focusing on preclinical drug development, formulation and 
diagnostics. This is a joint initiative between the DST and NWU.
Preclinical drug development was identified as a strategic development 
area for NWU. The platform is based on the implementation of expertise; 
it is at heart an initiative that is intended to teach postgraduates and to 
supply expertise and innovation to scientists and businesses, both locally 
and internationally. This includes education in the One Health concept.
The development of a vibrant pharmaceutical industry in South Africa 
forms part of the DST’s Bio-economy Strategy. Preclinical studies are a 
crucial step in the development and registration of any therapeutic 
product. Pharmaceutical companies want to avoid late-stage failures or 
drugs labelled for restricted use following approval. Thorough preclinical 
studies can contribute to early decisions about further development, thus 
saving time and money and increasing the success rate of the project.
Discussion
Question (Prof Thomas Mettenleiter): Is there a gap in education with 
respect to One Health in order to make the concept a household name? 
Does this require more emphasis on education at graduate, postgraduate 
and continuing education levels?
Response (Dr Alison Lubisi): We are doing well in veterinary public health. 
Veterinary students understand that One Health is where human and 
animal health meet. One Health features well in the veterinary curriculum 
in South Africa, but it seems that more effort may be required to emphasise 
the importance of One Health in training in other disciplines.
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Response (Prof Marietjie Venter): The concept of One Health is often 
presented at undergraduate level and then forgotten. In the medical 
context, there is a gap in that doctors do not always appreciate the role 
of One Health. Even after a decade of surveillance and explaining to the 
DoH why it is important to look at neurological cases, there is still a lack of 
understanding. There is a need to raise awareness, and for medical and 
veterinary scientists and practitioners to meet and talk more. From the 
perspective of animal science, there is an effective surveillance system 
for rabies, for example, but there are still human deaths from rabies, which 
represents a failure of public health and points to lack of communication 
between doctors and veterinarians. One Health receives sufficient attention 
at undergraduate level, but at postgraduate level it is important to keep 
reminding professionals in different associated disciplines to communicate 
with one another.
Response (Dr Kristina Roesel): Undergraduate and postgraduate students, 
as well as scientists need to be more open to communication, collaboration 
and working with scientists in other fields towards the common vision and 
goal of One Health. Specialists sometimes lose touch with the overall vision 
for their work and what other disciplines could contribute.
Response (Prof Thumbi Ndung’u): The One Health issues are well covered 
in veterinary curricula, but there may be a gap in the approach of human 
medicine colleagues, where there seems to be a lack of emphasis on 
cross-disciplinary One Health issues. The animal and human health fields 
need to work together better.
Question (Prof Thomas Mettenleiter): Medical doctors tend to define One 
Health in terms of human health. This attitude needs to change. Veterinarians 
tend to be the leaders in One Health because they are used to working 
with multiple species. However, the environmental aspects of One Heath 
are generally completely overlooked. How can this gap be closed?
Response (Prof Rose Hayeshi): One of the gaps in the curricula for life and 
natural scientists is that the translation aspects of fundamental research 
are not discussed, which may be why there is so little awareness of One 
Health. Collaboration with scientists in different areas should feature more 
prominently in research strategies. 
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Question (Prof Thomas Mettenleiter): How embedded is the One Health 
concept in veterinary, medical and natural science curricula? 
Response (Prof Marietjie Venter): Students in medical and veterinary 
science at her university learn the One Health concept. It would definitely 
help to introduce the concept to curricula in the natural sciences, such 
as microbiology, zoology and biochemistry. Basic scientists need to see 
the wider implications of their field for addressing human, animal and 
environmental issues.
Response (Dr Alison Lubisi): Veterinarians are aware of the implications of 
animal disease for human health, but there is less focus on environmental 
aspects, which ought to become ingrained (e.g. discarding of drugs). 
Perhaps there is a need for a tailor-made One Health subject in university 
curricula that encompasses the broad scope of the concept and shows 
how issues are interlinked. 
Response (Prof Marietjie Venter): The aim of the International One Health 
Day is to encourage students to participate in events or compete in 
competitions in teams that include veterinary, human science and 
environmental students or practitioners. The initiative is being advertised 
on social media. Since being launched in 2017, there have been 17 events 
across Africa, 20 in Europe and 20 in the USA. This is a way of involving 
students and encouraging participation online.
Question (Prof Thomas Mettenleiter): Hardly any of the audience members 
have heard of the International One Health Day, which falls on 3 November. 
Academics should bring this to the attention of their students and 
colleagues.
Question (Dr Shevin Jacobs): There is a need for infection prevention 
and control initiatives at both pre-service and in-service levels. In human 
health pre-service training, there is considerable emphasis on infection 
prevention and control, although this does not happen quite so well in 
practice, as seen in outbreaks in West Africa, for example, of human-to-
human infections. In the case of zoonotic diseases, transmission occurs from 
animals to veterinarians, or from veterinarians to other human subjects. 
From the human health perspective, WHO has a number of initiatives to 
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prevent human-to-human transmission, for example 5 May is World Hand 
Hygiene Day. Uganda has strong governmental support for a One Health 
platform, but it is not certain that what is learnt in pre-service institutions 
is practised by veterinarians in the field. Are there One Health tools for 
colleagues in animal health that can be used for in-service training to 
ensure best practice in infection prevention and control and to minimise 
the transmission of infection from animals to humans?
Response (Dr Alison Lubisi): The only way to address the human, animal 
and environmental aspects of One Health is to establish clear and binding 
policies. Individual egos often hinder research and hamper progress. It is 
heartening that One Health forums are in place. There is now a need for 
legislation, regulations and protocols (e.g. how to sample bats without 
driving them to extinction). Bureaucracy also often inhibits research.
Response (Prof Marietjie Venter): Politicians and government officials need 
to take more responsibility for promoting and institutionalising the One 
Health approach. Veterinarians are at greatest risk of zoonotic infections. 
There are training materials specifically from Uganda developed by the 
Field Epidemiology and Laboratory Training Programme, and there is 
willingness to implement this in other African countries as well. The US 
Defense Threat Reduction Agency is keen to do One Health training. 
Ultimately One Health is the responsibility of national governments in order 
to protect their populations. When veterinarians go into the field, they 
often forget that they can be infected by zoonoses. Basic training to use 
gloves and masks when handling animal samples is very important. This 
is perhaps the responsibility of state veterinarians.
Question (Prof Sabiha Essack): One Health is cross-cutting and requires 
coordinated implementation from the various sectors that are responsible. 
One Health initiatives tend to be reactionary. Very few countries have 
a One Health policy or overarching national health plan. Is there merit 
in an assistance-based approach, ranging from policy and legislation to 
practice on the ground? If so, how would this be implemented? Another 
factor is that without enforcement capability or accountability measures, 
One Health legislation would not be effectively implemented. 
Response (Prof Thumbi Ndung’u): The issues are difficult. The first thing would 
be to create awareness of One Health and the need for interdependence 
between disciplines. Such an approach would lead to people from 
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different disciplines interacting more, and to communication between 
the veterinary, medical and environmental fields. It should be considered 
work in progress for disciplines to work together. When there is an outbreak, 
the various disciplines are forced of necessity to work together. We are 
making progress in the right direction, but we still have a long way to go.
Response (Prof Rose Hayeshi): The One Health concept is inherently 
interdisciplinary. Teams that work across the One Health continuum already 
exist and need to be strengthened.
Response (Dr Kristina Roesel): Apart from legislation and policy, there is a 
need for creating an enabling environment for One Heath, for instance, to 
facilitate implementation and enforcement. There are already regulations 
for food safety, which is a One Health topic, but these are not always 
enforced because of issues such as high-level corruption, and lack of 
human capacity and laboratories.
Response (Prof Marietjie Venter): There are many policies in place, especially 
in South Africa, but education is also required starting at school level. South 
Africa has school education initiatives associated with International One 
Health Day. There are also initiatives to educate individuals. In KwaZulu-
Natal, for example, rabies has been a big issue, but individuals drove the 
rabies campaign and have made a big difference in trying to eradicate 
rabies in animals. Similar actions are required in other parts of the country. 
One Health is a governmental responsibility, but individuals also have a role 
to play. Universities and institutions should find champions for One Health.
Question (Prof Quarraisha Abdool Karim): In addition to awareness raising, 
there is a need for training for preparedness for medical or zoonotic 
outbreaks, rather than preparing for disaster management. There is a need 
to bridge the gap of training for medical interns who are appointed in 
areas other than where they were trained, with a different disease profile. 
Once they become familiar with the diseases that occur in the area, they 
are better able to deal with them. This needs to be done annually with 
each new group of interns to ensure that they are fully prepared to deal 
with disease outbreaks. Some interns, for example, do not know how to 
take samples for rabies. With closer networking, the One Health concept 
can be achieved. Veterinarians have skills that medical practitioners could 
use. There is a need to assist one another.
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Summary of issues raised (Prof Thomas Mettenleiter):
• Thanks to the panel members for their participation and serving 
as multipliers to raise awareness of the One Health concept. It is a 
recommendation to the academies to embrace the One Health 
concept and act as multipliers themselves.
• One Health issues need to be featured more prominently in education 
at university and school levels. Current education initiatives need to 
be expanded and include practical advice.
• One Health is not just a combination of medicine and veterinary 
science, but also involves environmental and societal issues.
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SESSION 5: BIG FOUR: HIV, TB, MALARIA, HCV
Facilitator: Prof Koleka Mlisana, University of KwaZulu-Natal, South Africa
Malaria and West Nile Virus Co-Infection Amongst Febrile Patients 
Attending a Tertiary Hospital in Abuja, Nigeria (Mr Aina Kehinde 
Oluwasegun, University of Ilorin, Nigeria)
Arboviral diseases have risen considerably, increasing the risk of co-
infection with other endemic diseases. Epidemiological data suggest a 
greater incidence of negative effects on pathogen-specific host immune 
responses during co-infection. Among the prevalent infectious diseases in 
the world, mosquito-borne parasites and viruses are frequently co-endemic 
in subtropical areas. Malaria transmission still persists in 95 countries, 
accounting for over 214 million new cases worldwide in 2015 alone. 
Mosquitoes are carriers of various pathogens that cause disease in human, 
including Dengue, Chikungunya and West Nile fever. An estimated two 
billion people live in areas where these diseases persist. Co-infection 
among these diseases is possible in geographical locations where the 
respective vectors co-exist.
Arboviral infections and malaria are acute vector-borne diseases, 
representing the most common arthropod-borne diseases with febrile 
symptom in humans. Concurrent infections are widely under-reported 
in sub-Saharan Africa. Arboviral infections are often misdiagnosed with 
malaria due to their similar clinical presentation. 
WNV fever is a widespread mosquito-borne zoonotic arbovirus of global 
importance, and concurrent infections are a factor in regions where their 
endemic areas overlap extensively. WNV is a Flavivirus single-stranded 
RNA virus with two genetic lineages. Lineage 1 has three clades (1a, 1b, 
1c) and infects humans, birds, mosquitoes, horses and other mammals.
WNV was first isolated in the West Nile district of Uganda. In 1950 the 
ecology of the disease was studied in Egypt. Additional outbreaks occurred 
in 1951 – 54 and 1957 in Israel; in 1962 and 2000 in France; in 1973 – 74 
in South Africa; in 1996 in Romania; and in 1998 in Italy. WNV represents 
one of the commonest agents of febrile illness. In its most common forms, 
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WNV resembles influenza. Most infections resolve within two to six days, 
but persistent fatigue can occur.
Malaria is currently endemic in more than 100 countries worldwide and 
the leading cause of illness in Africa and tropical countries. The global 
burden of disease is formidable. WNV, malaria and febrile illness have an 
overlapping geographic distribution in sub-Saharan Africa. There is limited 
knowledge of the effect of co-infection on the host immune response. WNV 
and malaria are usually implicated as aetiologies of acute febrile illness 
in some African countries apart from Nigeria. There was an inconsistent 
sero-survey of WNV/malaria co-infection in Nigeria.
The presentation described a study of WNV/malaria co-infections in 
patients with acute febrile illness attending the University of Abuja Teaching 
Hospital, its prevalence and associated risk factors. The following research 
questions were set for the study:
• What is the prevalence of WNV/malaria infections and associated risk 
factors among patients with acute febrile illness?
• What is the clinical and epidemiological significance of diagnosing 
WNV in a setting endemic with malaria?
The study was a hospital-based cross-sectional study. Purposive random 
sampling was used to assemble a sample of 162 participants. The inclusion 
criteria were those who present with febrile illnesses regardless of onset 
and duration of illness, and consent to participate voluntarily in the study. 
The exclusion criteria included apparently-healthy individuals without any 
trace of ongoing febrile illness in the last three weeks, as well as critically 
ill individuals.
For each participant, 3 mL of venous blood was collected in tubes without 
anticoagulant and centrifuged at 3000 rpm for 15 minutes to obtain the 
serum. The sera were separated and used for the IgM Elisa assay. 
The results generated from analysis and data obtained from the questionnaire 
were analysed. The chi-square test was used to determine the level of 
significance in the occurrence of malaria parasitemia and WNV IgM 
in association with categorised variables at a CI of 95%. P-values were 
reported to be statistically significant at <0.05.
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Of the 178 samples studied, 113 (prevalence of 66.1%) were seropositive 
for WNV virus IgM. Of these 113, 38 (33.6%) were co-infected with WNV 
and malaria parasites. The prevalence of malaria in this study was 28.07%. 
All malaria parasites were P. falciparum. 
Based on demographic factors, 62 of the 113 positive cases of WNV IgM 
were female participants with a prevalence of 62/113 (54.9%), which was 
higher than that of their male counterparts. Seropositivity was observed 
to increase from participants who were within the age range of 25 – 36 
years (36%). Regarding occupation, IgM to WNV was detected in the 
highest prevalence (20/23) among farmers, while the lowest prevalence 
(16/47) was recorded among the unemployed participants.
The concerted efforts by WHO to combat malaria have resulted in its 
mortality falling by 42% globally. However, the issue of the involvement 
of co-infection with one or more arboviruses has called for taking febrile 
conditions more seriously than before. 
WNV currently poses a significant threat to human populations in Africa 
as well as the entire globe, and vector habitats appear to be increasing; 
therefore, new epidemics of WNV could be looming. The prevalence of 
malaria and WNV co-infection in this study is an indication of poor vector 
control measures against mosquito vectors in the community. There is a 
high sero prevalence of WNV in the study area being sampled, which 
might be indicative of an ongoing infection. The seasonality in the activity 
of the mosquito vector (Culex spps) has a large influence on the activity 
of WNV.
This study recommended that: 
• In the absence of a vaccine, the only way to reduce infection is by 
raising awareness of the risk factors and educating people about the 
measures they can take to reduce exposure to the virus.
• Clinicians and public health physicians should be sensitised on the 
proper management, diagnosis of WNV infection and the role they 
play in acute febrile illnesses.
• Public health educational messages should focus on reducing the risk 
of mosquito transmission.
• Integrated mosquito surveillance and control programmes should be 
carried out in this area.
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• Further studies should identify the local mosquito species that play a 
role in WNV transmission, including those that might serve as a bridge 
from birds to human beings.
Discussion
Question (Ms Alison Lubisi): In terms of surveillance, do you involve people 
who look at birds?
Response (Mr Aina Kehinde Oluwasegun): No, the study only involved 
febrile patients. There is no intention to involve people working on birds.
Question: What is the next step in your research as a young researcher?
Response (Mr Aina Kehinde Oluwasegun): The research suffers from a 
lack of diagnostic facilities to confirm the presence of virus in samples. It 
is hoped that collaboration and funding can be found for this research.
Lipids Go Viral: Deciphering the Function of Lipids and Lipid Droplets 
in HCV Infection (Dr Eva Herker, Leibniz Institute for Experimental 
Virology, Germany)
The global hepatitis C virus (HCV) rate has reached epidemic proportions 
with an estimated 150 million people infected, which represents 3% of 
the world population. Infection rates vary from below 1% to over 10% in 
different parts of the world. Better treatment has become available for 
HCV, but worldwide only 5% of people are aware that they are infected, 
and of those only 5% are treated, and most are treated with old medicines, 
since the new antivirals are generally too costly for most people to afford. 
Even when people are treated, there is still the risk of disease progression 
or reinfection. 
HCV replication is closely tied to the host cell lipid metabolism. Lipid 
droplets have emerged as key organelles for HCV replication, and it has 
been proposed that they serve as virion assembly platforms. The viral 
capsid protein core localises to lipid droplets, recruits viral RNA replication 
complexes, and initiates the assembly of progeny virions at lipid droplet-
associated membranes of the endoplasmic reticulum. It has previously 
been shown that a host protein involved in lipid droplet biogenesis serves 
as a key regulator of viral replication. The fact that HCV selectively targets 
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a subset of lipid droplets points to hitherto unrecognised specificity. 
However, the virus targets lipid droplets and the mechanistic details of the 
late stages of HCV replication are still ill defined. Proteomic and lipidomic 
approaches are used to elucidate in molecular detail the role of lipids 
and lipid droplets in HCV replication.
Discussion
Question (Prof Thomas Mettenleiter): Did you test any of the other Flaviviridae 
viruses and find similar results?
Response (Dr Eva Herker): The vasicular structures induced by other 
Flaviviridae viruses look different from HVC. It seems that specific lipids 
are required. This will be investigated. 
Question (Prof Thomas Mettenleiter): Will you look at inhibitors?
Response (Dr Eva Herker): We would try, but unfortunately we do not 
have inhibitors for the fatty acid elongases.
Question (Prof Anna Kramvis): Would there be competition between 
HVC and HVB?
Response (Prof Eva Herker): There would perhaps be competition over 
host cell resources; the fittest virus would use the resources.
Prevalence of Human Papilloma Virus and Factors Associated with 
oral and Oropharyngeal Squamous Cell Carcinoma Among HIV-1 
Infected Patients Attending Mulango Hospital, Uganda (Dr Annah 
Margret Biira, Makerere University, Uganda)
Human papilloma viruses (HPVs) are a heterogeneous group of small 
non-enveloped epitheliotropic DNA viruses. HIV-1 infected individuals 
have two to three times higher chance of prevalent oral HPV infection 
compared to non-HIV counterparts.
Dr Biira’s research determined the prevalence of HPV 16, 18 and factors 
associated with oral (OSCC) and oropharyngeal squamous cell carcinoma 
(OPSCC) among HIV-1 infected patients attending Mulago Hospital.
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The study confirmed the role of HPV 16 and 18 in OSCC and OPSCC 
pathogenesis in the Ugandan population. The results suggest that HPV 
is an aetiological factor responsible for the high occurrence of oral and 
oral pharyngeal squamous carcinoma in HIV infected people.
A bigger study is underway, where all HPV genotypes will be assessed and 
other sociodemographic factors considered using a higher statistical power.
Facilitator: Prof Stefan Kaufmann, Director, Max Plank Institute for Infection 
Biology, Germany
The Development of a Nanomedicine-Based Drug Delivery System 
with the Potential to Improve Tuberculosis Therapy (Dr Madichaba 
Chelopo-Mgobozi, North-West University, South Africa)
TB treatment challenge
TB is still a major health threat that burdens a large number of poor 
communities in the developing world and is one of the major causes of 
death amongst a group of infectious diseases even though there are 
effective drugs approved for its treatment. 
Poverty-related diseases are the major cause and consequence of 
considerable poverty in developing countries, particularly those in sub-
Saharan Africa. South Africa is a TB high-burden country. Fighting these 
diseases remains one of the most effective ways to alleviate poverty and 
promote economic progress in these countries.
Current treatment comprises a fixed dose combination of the following 
four potent drugs: RIF, isoniazid (INH), pyrazinamide and ethambutol, 
approved by WHO, to be taken daily for a period of up to six months.
The failure to control or reduce the number of TB cases is aggravated by 
the high dosage, long treatment duration, development of side effects 
and poor patient compliance, typically leading to the development of 
drug-resistant TB strains that present yet more challenges in the treatment 
of TB.
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The use of drug delivery systems
Along with all the strategies used to reduce the burden of TB, it should be 
mentioned that the existing anti-TB drugs are still effective. 
Overcoming technological drawbacks of these therapeutic agents 
and improving the effectiveness of the drug by targeting the infection 
reservoirs remain the central aims of pharmaceutical technology. The 
formulation of potent anti-TB drug within suitable drug delivery systems 
(DDS) appears to be one of the most promising approaches for the 
development of a more effective treatment, with which patients can 
comply. A DDS is a formulation that assists the transport of a drug in the 
living body and enhances its efficacy and safety through the control of 
the time and location of its release. Such systems generally overcome 
the disadvantages of free drugs and enhance their activity.
Developing and designing a suitable DDS is a key area of extensive 
research and takes into consideration many factors, such as the target 
tissue and the type of drug being transported. The question is whether 
it can reach the target tissue and protect the drug from undesirable 
degradation in the body.
The goal in the use of drug delivery formulations is modulation of 
the pharmacological profiles, namely the pharmacokinetics and 
pharmacodynamics of the therapeutic agents to ensure clinical potential. 
Therefore, to design an efficient delivery system, important principles such 
as drug stability, drug solubility, drug safety, biocompatibility, therapeutic 
efficacy and industrial scale-up need to be taken into consideration.
The field of DDS dates back to the 1950s. After the emergence of 
nanotechnology in the 1970s, it became the main driver in the growth of 
DDS and led to the availability of various delivery platforms that exist in 
the nanoscale. Nano-size particles possess distinct chemical and physical 
properties that offer a number of unique advantages over micrometre-
sized particles, particularly in drug delivery. Nano-size particles also have 
very high surface area per unit volume, and this has had a significant 
influence in the field of drug delivery, where most drugs with generally 
poor bioavailability attained significantly improved bioavailability when 
encapsulated in nanoparticles (NPs). This attribute of cellular uptake is 
essential for the treatment of intracellular pathogens, such as TB infection. 
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Nano-based DDS have brought transformation to the field of pharmaco-
therapy through their capability to modify the pharmacokinetics properties 
of conventional drugs, which includes the extension of the drug circulation 
time, increased half-life of the drugs and reduced toxicity. 
Several DDS have been explored for TB therapy and had the following 
results in rodents:
Polylactic-co-glycolic acid (PLGA) NPs with anti-TB drugs: This system 
improved the bioavailability, controlled the release of drugs, reduced 
the drug dosage, and was easily taken up by alveolar macrophages.
• Liposomes with anti-TB drugs: This system showed overall increases in 
anti-TB activity with a significant decrease in toxicity, but cannot be 
administered orally;
• Pheroid® vesicles with anti-TB drugs: This system exists in both the micro 
and nano ranges. The systems improved intestinal absorption of drugs, 
increased their half-life, enhanced the bioavailability of drugs, and 
can be administered orally.
However, uncertainty over safety and toxicity, high costs and challenges 
of scaling up production made pharmaceutical industries reluctant to 
develop them for poverty-stricken countries. These drawbacks apply to 
many other DDS. There has been a lack of human trial studies to evaluate 
the effect of polymeric NPs on anti-TB drugs. 
Despite the effectiveness of polymeric NPs and lipid-based DDS for 
anti-TB drugs, sufficient data from clinical trials is still required in order 
to pave the way to bring them into the market. It was predicted that 
the use of nanomedicine to deliver effective conventional therapeutic 
agents would facilitate a faster transition of effective DDS-formulated 
therapy to clinics for better control of poverty-related infectious diseases. 
However, the advancement of these DDS for TB is limited by pitfalls such 
as bioaccumulation, cumulative toxicity and side effects associated with 
these nanomedicines. The lack of extensive research studies on safety and 
long-term stability hinders the progress of new medicine formulations to 
human trials. Other major hurdles in advancing these delivery technologies, 
especially for the improvement of TB therapy to the clinical stage, include 
the high cost of the drug-delivery materials, the inability to conduct large-
scale production and the removal of residual organic solvents. 
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The high cost of developing effective drug-loaded DDS for poverty-related 
infectious diseases leads to reluctance by pharmaceutical industries to 
advance them to the market. Although new potential DDS continue to 
be proposed for the improvement of PK for current anti-TB drugs, novel 
strategies such as the combination of two effective DDS do not seem to 
have been explored yet. 
Hybrid DDS
Hybrid delivery systems combine the advantages of polymeric NPs and 
lipid-based systems and have emerged as a robust and promising delivery 
platform, resulting in potentially robust drug delivery technology, with 
excellent stability, sustained drug release and enhanced drug delivery.
Dr Chelopo-Mgobozi developed a hybrid DDS comprising three major 
components, namely the drug, PLGA and a lipid bilayer shell. A hybrid 
system makes the most of the unique attributes of each technology, with 
the advantages of improved stability, enhanced compatibility and more 
superior in vitro cell efficacy. 
The recent approach in dealing with the TB problem has therefore been to 
focus on DDS that have previously been investigated (independently) to 
improve the current TB therapy to reduce dosing frequency and shorten 
the treatment period. 
The combined PLGA NP-Pheriod® hybrid DDS was hypothesised to create 
a powerful novel system to more effectively improve PK than individual 
systems, in which the drug would be absorbed faster and then be slowly 
released in a living organism:
• Polymeric NPs are composed of biodegradable PLGA polymers and 
demonstrate outstanding structural stability and controlled drug-release 
mechanism;
• Pheroid® technology is a lipid-based method of delivering drugs. It 
is a submicron emulsion consisting of essential fatty acids and has 
exceptional ability to enhance the absorption of numerous drugs.
This work was a collaborative initiative between the NWU and the Council 
for Scientific and Industrial Research (CSIR).
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Preparation methods and characterisation
The preparation was based on making an emulsion, and solid NPs were 
produced. Double emulsion followed using a spray-drying technique to 
produce solid NPs. The polymer is usually dissolved in the first or internal 
emulsion; depending on the solubility of the drug, which could be either 
in the O or W phase. The addition of excipients ensures better surface 
properties of the drug such as its shape and surface charge. The final 
double emulsion is subjected to a spray-drying technique. To produce 
the Pheroid® vesicles, single nitrous oxide saturated water with FA oil was 
homogenised to form an emulsion. 
Various combination methods were explored
• In the post-mix, preformed Pheroid® vesicles were combined with the 
preformed NPs through vortex to obtain the hybrid system.
• The pre-mix method involved adding preformed NPs to at least one 
constituent of the Pheroid® vesicle prior to their production. 
Characterisation showed that the pre-mix method resulted in a more stable 
hybrid system with higher zeta potential (ZP) than using the post-mix method. 
In the pre-mix method, electrostatic interaction was responsible for the 
successful combination of NPs and Pheroid®. In addition to measuring size 
and ZP, visual analysis was done through transmission electron microscopy 
(TEM) and confocal microscope.
Pharmacokinetic studies and results
In PK studies, healthy BALB/c mice were used and were divided into three 
per drug, administered via oral gavage. The first group received the free 
drug; the second group received the drug formulated in a NP; and the 
third group received the drug formulated in the hybrid DDS. The aim of 
the hybrid system was to entrap the anti-TB drug (INH or RIF) within hybrid 
DDS and evaluate its PK parameters in vivo. The mice were euthanised 
at ten different time points. Plasma and various organs or tissue were 
collected and analysed with LC tandem mass spectrometry to establish 
the drug levels. 
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The following PK results were obtained:
• There was found to be no statistically significant difference between the 
PK parameters – Cmax (maximum concentration of the drug achieved 
in the plasma following dose administration); AUC (area under the 
plasma drug concentration-time curve); Tmax (time at which Cmax, is 
attained) and t1⁄2 (half-life) for both INH and RIF formulations. However, 
the probability of superior PS values showed that the hybrid (NP-Pheroid®) 
formulation had an effect on t1/2, AUC and Cmax compared to free RIF 
and NPs by medium practical significance. 
• There were no statistically significant variations caused by the RIF hybrid 
system on either AUC and Cmax. However, the PS values indicated that 
the RIF hybrid system had a large effect sizes (PS > 0.71) on the AUC, 
Cmax and t1/2 in the liver, intestines and kidneys.
• The RIF hybrid formulation significantly increased t1/2 of free RIF from 
four to 16 hours in the kidneys (P = 0.042). The effect size of RIF hybrid 
formulation on t1/2 is also large in comparison to both RIF NPs and free 
RIF.
Another study was conducted to measure the effect sizes, which provided 
a different perspective on the results, showing a medium effect in the 
plasma on the PK parameters and the potential positive outcome of 
hybrid systems.
Conclusion 
The design of effective DDS is a key to ensuring improved activity of 
current TB treatment and reducing the risk of developing resistant strains.
The fabrication of the hybrid PLGA NP-Pheroid® DDS through the pre-mix 
method proved to be more stable through electrostatic interaction. 
Co-localisation was proved by sizing technique, TEM and confocal laser 
scanning microscopy (CLSM). 
NP-Pheroid® did not show any significant statistical difference on the PK 
parameters of the INH and RIF drugs in the plasma. However, this novel 
hybrid DDS reduced RIF Tmax and increased the retention of RIF in the lungs.
The estimated probabilities that the hybrid system improved certain of the 
PK parameters in comparison to the free drug and drug in NPs served as 
effect sizes to establish the practical or clinical relevance that the system 
could have.
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Discussion
Question (Dr Alison Lubisi): Some drugs have specific prescriptions for 
administration (e.g. to be taken after a meal) to optimise their efficacy. 
Could a DDS circumvent such prescriptions and ensure that the drug is 
properly absorbed whenever it is taken. 
Response (Dr Madichaba Chelopo-Mgobozi): This has not been investigated 
but should be. It might be possible to design a DDS to address these 
challenges.
Question (Genevieve Mezoh): There have been many papers about DDS. 
Are any such systems being used?
Response (Dr Madichaba Chelopo-Mgobozi): DDS are being used for 
cancer but not for infectious diseases. There are some DDS in clinical trials.
Question (Dr Norbert Heinrich): It was mentioned that the novel hybrid 
increases the retention of RIF in the lungs. Is there any idea of where, or 
in which compartment cell in the lungs the RIF is retained? 
Response (Dr Madichaba Chelopo-Mgobozi): The study only looked at the 
tissue of the lung as a whole, not at the exact compartment. This would 
require a further study. It would go into the macrophages. 
Question (Dr Norbert Heinrich): RIF is highly bioavailable. Have you 
considered working with drugs that have problems with bioavailability 
(e.g. injectable drugs are not orally bioavailable; and some of the drugs 
in development that need formulation to make them bioavailable).
Response (Dr Madichaba Chelopo-Mgobozi): The study investigated 
only two drugs (INH and RIF), which is not representative of all the drugs 
available to treat TB. Investigating DDS for other drugs would be a possibility 
for the future.
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Importance of Human Proteins for Survival of Human Malaria Parasite 
P. falciparum: An Unexpected Achilles Heel (Dr Jude Przyborski, 
Heidelberg University Hospital, Germany)
Dr Przyborski presented some of his unpublished work, about which he 
was very excited.
The presentation would look at the way in which the parasite communicates 
with the host cell, and how this potential weakness could be used to 
attack a parasite. 
When a parasite invades and proliferates in human erythrocytes, knob 
structures form on the surface of the infected erythrocyte. The parasite 
changes the biochemical and physiological properties of the host cell in 
order to live within the host cell, which is usually enucleated, does not carry 
out any protein synthesis, and is poor in nutrients. Another modification of 
the host cell is the formation of knob structures on its surface, within which 
there are a number of parasite-encoded proteins, the most important of 
which is Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). 
These proteins stick to various receptors on the endothelial cells in various 
tissues of the body and within blood vessels, leading to blockage of the 
blood vessels with infected erythrocytes. Non-infected erythrocytes are no 
longer able to continue to perform their function of transporting oxygen. 
Patients become hypoxic and ultimately die, especially if this occurs in the 
brain. Protein transport is responsible for the pathology of malaria when 
the parasite transports proteins to the surface of the cell. 
The parasite exports over 400 proteins to the host cell, but the function of 
a large number of these proteins is unknown. Dr Przyborski’s laboratory 
studied host cell modifications; how proteins travel to their destination; 
the signals that direct them in that direction; what molecules are involved 
in the process; and what functions they carry out once they get there. 
Parasites have to devise new mechanisms to deal with new situations, 
all of which are a potential Achilles heel that researchers could target to 
combat the disease. 
The parasite places itself in a difficult situation when it invades an 
erythrocyte. If the basic secretory system of a large number of eukaryotic 
cells is studied, it is found that proteins insert ER carried in vesicles to the 
Golgi, where they are spat out or inserted into the plasma layer. 
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When the parasite invades blood cells, it surrounds itself with a third 
membrane, the parasitophorous vacuolar membrane. Any parasite protein 
that wishes to move to the surface of the cell has to cross the membrane. 
Additionally, once the parasite protein reaches the erythrocyte, it cannot 
carry out any protein transport itself, so the parasite has to export a secretory 
system into the host erythrocyte to carry out this function, or the parasite 
needs to use the proteins that are already there. 
The first research question that Dr Przyborski started to address several years 
ago was how parasite proteins get across the parasitophorous vacuolar 
membrane. It is now known that a parasite-encoded translocon sits within 
the membrane and forms a conduit through which exported proteins can 
travel. The exact mechanism is not certain, but it seems to be important. 
It was also known from experiments that Dr Przyborski did at Marburg that 
to get through the translocon, called PTEX, parasite proteins need to be 
unfolded, which is common for many protein translocons. 
The question thus arises what will happen to the unfolded protein when it 
reaches the other side of the membrane, since proteins need to be folded 
correctly in order to carry out their biological function. The proteins have 
to be refolded, and probably need some other factor that blows them 
through the translocon. 
The factors required on the trans side of the parasitophorous vacuolar 
membrane were then investigated. In order to study this, the existing 
GDP assay was improved (GDP is an exported protein that is used as a 
surrogate for protein export). Tetanolysin was used, which inserts itself into 
the erythrocyte as a membrane and lyses it so that all the erythrocyte 
contents can be sucked out. The erythrocyte contents are washed to get 
rid of the residual protein. This allows the composition of the cell to be 
changed through the media placed on top. The composition of the trans 
side of the parasitophorous vacuolar membrane can thus be changed. 
By doing so, it was hoped that factors on the trans side of the membrane 
could be identified that were required for protein translocation. 
The first experiment was to use erythrocyte cytosol derived from non-
infected erythrocytes. This was incubated and then separated into the 
pellet fraction (the non-exported fraction) and the exported fraction. It 
was found that there is a factor in non-infected erythrocyte cytosol that is 
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required for protein translocation. This would have to be a human factor 
and is likely to be a protein.
The next experiment was to trypsinize erythrocyte cytosol to kill the activity 
of proteins, and then to put it back on to the cell system. It was found 
that the translocation efficacy was lost from the fraction. It could thus be 
concluded that there is a human protein within erythrocyte cytosol that 
is required for protein translocation. Further experiments showed that the 
protein requires hydrolysed ATP for its activity. The unknown protein has to 
be located on the outside of the parasitophorous vacuolar membrane 
in order to pull proteins through. 
Other experiments found that human HSP70 associates very strongly with 
the outer surface of the parasitophorous vacuolar membrane. This was 
interesting, because human HFP70 fulfils all the other identified criteria (i.e. 
it requires hydrolysed ATP, is present in non-infected cells and is trypsin-
sensitive). 
Recombinant HSP70 can be generated either in a wild type or a dominant-
negative form. This was pipetted into the translocation mixture; human 
HSP70 was added in the dominant-negative form. It was found that if 
dominant-negative HSP70 is added on top of red blood cell cytosol, 
there is a 75% reduction in protein translocation to the host cell. It was 
concluded that HSP70 is definitely involved in the process, and there is a 
search for the other molecules that help it to carry out its function (e.g. 
HSP40 or nuclear-type exchange factors). 
Further work was done by lysing red blood cells under certain conditions, 
resealing them and getting them to go back. While they are going back, 
it is possible to put other things in. In the experiment, dominant-negative 
HSP70 was inserted. The cells were resealed and the parasites were 
allowed to infect them. Controls were also carried out. When wild type 
HSP70 is added, there is some drop in the growth of the parasite, probably 
because the endogenous chaperone system is unbalanced. When 
dominant-negative HSP70 is added, there is a 75% drop in translocation. 
This shows that HSP70 is not only involved in protein translocation, but 
also in parasite survival. It is not known whether there is an effect on the 
host cells (e.g. whether it stops the host cell being able to be invaded 
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by parasites), or whether the parasites need it directly. Further work is 
ongoing to establish this.
In summary, human protein is required for host cell modification and 
thus parasite survival. Inhibiting human protein has already been used in 
other contexts. For example, cancer cells are comparable to a parasite 
in that they are fast replicating, have an extremely high metabolism, 
and are dependent on a protein that normally replicating cells are not. 
Cancer cells have been inhibited using, among other things, inhibitors of 
molecular chaperones. 
Even more importantly, if human proteins are inhibited, the parasite has 
no way to get around this. The parasite cannot change the composition 
of the human protein within the erythrocyte. This approach is thus not 
likely to be subject to parasite-driven resistance. 
The parasite exports about 400 proteins into the host cell, but the function 
of most of these proteins is not known. It is suggested that they are likely 
to interact with human proteins, otherwise there is no reason for them to 
be present. It is thought that there is close interaction between parasite-
exported proteins and human proteins, which is likely to be essential for the 
growth of the parasite. It is thus likely that there are other human targets 
to be discovered, and this is being investigated.
Dr Przyborski encouraged African delegates to explore the opportunities 
offered by the Deutsche Forschungsgemeinschaft (German Research 
Foundation) programme known as the German-African Cooperation 
Projects in Infectiology, which is designed to foster collaboration between 
German and African countries. The funding pays for one PhD student 
per group as well as consumables, staff travel and exchange between 
countries, and investment in infrastructure in Africa. The programme 
started in 2010, and 20 African countries have thus far been involved. The 
next round of pre-proposals opens in June and runs until November 2018.
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Polymorphisms in HIV-1 NEF and TAT Associated with Endothelial 
Dysfunction (Ms Genevieve Mezoh, University of the Witwatersrand, 
South Africa)
Sub-Saharan Africa has a high prevalence of HIV. Africa accounts for 
about 70% of people living with HIV worldwide, and the rate of infection 
is growing the fastest in Africa. 
Ms Mezoh posed the question of whether HIV is treatable, or curable. HIV 
is known to be transmitted from human to human. The virus is treatable 
using ARVs, but there is growing resistance among HIV-infected patients 
to taking the drug. Several strategies have been proposed with regard 
to an HIV cure, some of them being bogus:
• Traditional healers claim to be able to cure HIV in Africa. This affects 
the way in which the African population perceives information about 
HIV infection. This could perhaps account in part for the growing HIV 
prevalence in Africa. 
• Myths abound, for example, that having sex with a virgin will cure HIV. 
People need to be sensitised about how HIV is spread, and the fact 
that there is no cure available yet.
• HIV vaccines have been proposed as a functional cure, but it will need 
to be established how efficient the vaccines are and what percentage 
immunity they will offer.
• It has been suggested that ultimately, humankind may exist in harmony 
with HIV.
Since the advent of ARVs, HIV-infected people are living much longer, 
and there has been a decrease in the incidence of opportunistic diseases. 
CVD have now emerged as an important cause of death among the 
HIV-infected population. Several studies have been released showing 
that the prevalence of CVD is higher in the HIV-infected population, but 
the pathophysiological process involved is not known.
Several studies have been conducted in the West looking at the prevalence 
of CVD in the HIV-infected population, but the emergence of CVD in the 
HIV-infected population in Africa has not been studied. There has been 
a proposal to investigate HIV and the risk of CVD in sub-Saharan Africa 
through the Ndlovu cohort study.
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A healthy endothelium is the first line of defence against a pathogenic 
invasion because it is in contact with circulating pathogens. Ms Mezoh 
was investigating the hypothesis that unique polymorphisms observed 
in the HIV-1 nef and tat sequences may be associated with endothelial 
dysfunction in the HIV-infected population. The aim of the study was to 
assess endothelial dysfunction in the black South African HIV-infected 
population by measuring levels of blood markers of endothelial dysfunction 
and inflammation, and to assess the association of nef and tat gene 
variants with endothelial dysfunction.
For each biomarker, subjects were divided into two groups based on the 
median value for the biomarker. The frequency of each variant in these 
two groups was compared using a contingency table and two-tailed 
Fisher’s exact test. Biomarker levels of the subjects possessing the identified 
variant were compared using a student’s t test.
The study reached the following conclusions:
• There is evidence of endothelial dysfunction in the black South African 
HIV-infected population.
• The study found several mutations in HIV nef and tat associated with 
markers of endothelial dysfunction, confirming a role for these viral 
proteins in impacting endothelial function. 
• Targeting HIV nef and tat is a potential therapeutic strategy to circumvent 
the development of CVD in HIV-infected patients.
Discussion
Comment (Dr Jude Przyborski): Stronger association might be found if 
patients with multiple genotypes were excluded. 
Response (Ms Genevieve Mezoh): Because she was looking at the highest 
measurements it would not be possible to exclude patients with more 
than one variant.
Comment (Prof Anna Kramvis): The title of this session was The Big Four: 
HIV, TB, Malaria, HCV. It should have been ‘The Big Five’ and included 
hepatitis B, which needs to be included in surveillance because hepatitis 
B virus (HBV) is responsible for 90% of hepatitis in Africa, and there are 1.4 
million deaths annually from HBV worldwide, which is equivalent to the 
death rate from HIV.
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WRAP-UP, VOTE OF THANKS AND CLOSING OF THE SCIENTIFIC 
CONFERENCE
Prof Stefan Kaufmann, Director, Max Planck Institute for Infection 
Biology, Berlin, Germany
The first joint conference on infectious diseases between Leopoldina and 
ASSAf was held in October 2016 at the Max Planck Institute for Infection 
Biology in Germany. That meeting was a great success, but the present 
conference has been even more successful. Scientific information was 
shared, new friends were made, potential collaborators were identified, 
and researchers found ideas for new projects. 
Prof Stefan Kaufmann conveyed the thanks of Prof Jörg Hacker, President 
of the Leopoldina, who had only been able to attend on the first day. It 
was particularly rewarding that Prof Hacker and Prof Jansen, President 
of ASSAf, had extended the MoU on cooperation between Leopoldina 
and ASSAf for another five years.
The conference included sessions on comorbidities, AMR, diagnostics, 
vaccines, drugs, patient-centred activities, management surveillance 
and response, and guidelines for the future.
Prof Kaufmann commended the title of the conference (Surveillance 
and Response to Infectious Diseases and Comorbidities: An African and 
German Perspective) for several reasons:
• Response is important from the WHO perspective.
• Comorbidities of infectious diseases with non-infectious diseases are 
becoming more frequent.
• The title places ‘African’ first before ‘German’, which reflects a meeting 
of the partners on an equal level.
Another positive aspect of the conference was that there was almost 
equal participation of men and women.
For future conferences on this topic between the partners, Prof Kaufmann 
would like to see the term ‘integrated response’ appear in the title. 
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Prof Kaufmann was glad to see initiatives in bioinformatics as a field for 
the future. His dream for the future was to have a disease epidemiology 
forecast. The response to the listeria outbreak in South Africa, for example, 
could have been considerably shortened through an information system 
that localised the occurrence of the disease and showed the supermarkets 
where the disease victims had bought their food. Attention would need 
to be paid to attract information technologists to develop these areas.
Prof Kaufmann thanked everyone responsible for organising the conference.
Mr Christian Acemah, Executive Secretary, Uganda National 
Academy of Sciences, Uganda
Mr Acemah commended the excellent balance at the conference 
between the German and African perspectives. He thanked everyone 
responsible for organising the conference. Unfortunately the scientific 
coordinator of UNAS, Prof David Serwadda, was not able to attend.
Prof Quarraisha Abdool Karim, Associate Scientific Director, CAPRISA, 
South Africa
Prof Karim echoed the thanks of the previous speakers to all those 
responsible for the partnership. Planning for the conference began in Berlin 
in 2016. There was a discussion of who to include, and particular interest in 
involving young investigators. The scope could have been limited to the 
partnership between Germany and South Africa, but it was decided to 
use the opportunity to try to make this a pan-African effort, and to widen 
the scope of German research institutions beyond Max Planck. 
Senior scientists have a lot to offer at a conference such as this. They have 
been magnanimous in sharing their life-long experience and wisdom related 
to their successes and failures, projects, institution-building, programmes 
and peer collaboration.
The conference involved a good mix of senior scientists, mid-level 
researchers and junior investigators (or rising stars). Africa is unique in that 
65% of the population of the continent is under the age of 35 years. In Africa, 
young people are not the future, but the present. The present generation 
of young people are growing up with technology and a worldview 
related to access to information that was previously inconceivable, and 
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which eliminates many of the disparities between the global North and 
South, and between industrialised and non-industrialised nations. Young 
investigators must not be underestimated; they have much to teach the 
older generation, and the older generation as much to share with them, 
in a synergistic relationship.
In the 21st century, there are possibilities of altering trajectories with respect 
to allowing people to live longer, healthier and more meaningful lives. 
Science is important for social and economic transformation. What 
humanity has already achieved is only the beginning. When men and 
women contribute equally, and when we can join forces globally, the 
possibilities on Earth and beyond are tremendous and are limited only 
by our imagination.
Surveillance
The Surveillance session did not take place the previous evening, so Prof 
Karim shared some ideas on this topic. 
Epidemics tend to have a two-year delay before they are identified as 
an epidemic, whether category 1 or 2. Once the epidemic has been 
identified, there is media attention, huge investment and some level of 
public hysteria, but once the epidemic is over, amnesia sets in.
Those working with infectious diseases and disaster management need to 
be smarter during the inter-epidemic period to build on the momentum 
created by the epidemic. During the inter-epidemic period, we need to 
nurture relationships with the media and increase awareness among the 
general public. Popularisation of knowledge is important and does not 
receive enough attention, especially in Africa. 
Epidemics start in communities, and communities are the first to know 
about the disease. They need to be informed how to respond when 
they observe common patterns and death. More advocacy efforts are 
needed at community level, linked to media efforts, whole government 
accountability, and more rapid responses. Good-quality, consolidated 
data and communication are important. There are many lessons to be 
learnt from each epidemic that can be applied to subsequent epidemics 
in order to develop a critical mass of individuals with knowledge, expertise 
and ability for rapid responses.
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Prof Karim thanked the leaders and organisers responsible for convening 
the conference, the speakers and the participants. She acknowledged 
the sponsors: ASSAf, Leopoldina, ICSU ROA and the South African DST. 
Prof Karim invited participants to email suggestions for the evolving 
partnership.
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APPENDIX A: LIST OF ACRONYMS
3TC Lamivudine
ABR Antibiotic resistance
AiBST African Institute of Biomedical Sciences and Technology
AIDS Acquired immune deficiency syndrome
AMR Antimicrobial resistance
ARC Agricultural Research Council
ARV Antiretroviral
ASSAf Academy of Science of South Africa
ATP Adenosine triphosphate
AZT Azidothymidine
BCG Bacillus Calmette-Guérin vaccine
Bdq Bedaquiline
BSL Biosafety level
BTZ043 Benzothiazinone
BV Bacterial vaginosis
CAPRISA Centre for the AIDS Programme of Research in South 
Africa
CARE Collective Action and the Risk Ecosystem
CDC Centre for Disease Control and Prevention
CDDEP Centre for Disease Dynamics, Economics and Policy
CIDRZ Centre for Infectious Disease Research in Zambia
CLSM Confocal laser scanning microscopy
CSIR Council for Scientific and Industrial Research 
CVD Cardiovascular disease
CYP Cytochrome P450
DAAD German Academic Exchange Service
DDS Drug delivery system
DFID Department for International Development
DHN Dihydroxy naphthalene
Surveillance and Response to Infectious Diseases and Comorbidities
Proceedings Report 12 – 13 April 2018
119
DKA Diabetic ketoacidosis
Dlm Delamani
DM Diabetes mellitus
DNA Deoxyribonucleic acid
DoH Department of Health
DRC Democratic Republic of Congo
DST Department of Science and Technology
EDCTP European and Developing Countries Clinical Trials 
Partnership
EDIS Extended Dose Interval Study
EFV Efavirenz
EID Early Infant Diagnostic
ErC Erinacine C
EU European Union
FAO Food and Agriculture Organisation
FTC Emtricitabine
G77 Group of 77 at the UN, a coalition of developing nations
GARD Global Alliance Against Chronic Respiratory Diseases
GARP Global Antibiotic Resistance Partnership
GDP Gross domestic product 
GIS Geographic information system
GLASS Global Antimicrobial Resistance Surveillance System
GOARN Global Outbreak Alert and Response Network
HCV Hepatitis C virus 
HDSS Health Research Centre (Manhiça, Mozambique)
HIV Human immunodeficiency virus
HPLC High-performance liquid chromatography
HPV Human papillomavirus
HSV Herpes simplex virus
ICSU International Council for Science
ICSU ROA ICSU Regional Office for Africa
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IDI Infectious Diseases Institute, Uganda
IFS International Foundation for Science
IMAI Integrated Management of Adolescent and Adult Illness
IMCI Integrated Management of Childhood Illness
INGSA-
Africa
International Network for Governmental Science Advice 
– Africa
INH Isoniazid 
IPC Infection prevention and control
LC Liquid chromatography
LC-HRMS Liquid chromatography-high resolution mass spectrometry
LMICs Low and middle-income countries
Lzd Linezolid
MBC Minimum bactericidal concentration
MD PhD Doctorate of Medicine and of Philosophy
MDR-TB Multiple drug-resistant TB
MERS Middle East respiratory syndrome
MIC Minimum inhibitory concentration 
MoU Memorandum of understanding
MS Mass spectrometry
Mtb Mycobacterium tuberculosis
NAP National action plan
NCD Non-communicable disease
NGO Non-government organisation
NIH National Institutes of Health
NMIMR Noguchi Memorial Institute for Medical Research
NMR Nuclear magnetic resonance spectroscopy
NNRTI Non-nucleoside reverse transcriptase inhibitor
NP Nanoparticle
NRF National Research Foundation
NSP National Strategic Plan
NVP Nevirapine
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NWU North-West University
OECD Organisation for Economic Co-operation and 
Development
OiE World Organisation for Animal Health
OPSCC Oropharyngeal squamous cell carcinoma
OSCC Oral squamous cell carcinoma
PCR Polymerase chain reaction
PEN Package of Essential Non-communicable Intervention 
Tools
PEPFAR US President's Emergency Plan for AIDS Relief
PfEMP1 Plasmodium falciparum erythrocyte membrane protein 1
PhD Doctor of philosophy
PID Pelvic inflammatory disease
PLGA Polylactic-co-glycolic acid
PMTCT Prevention-of-mother-to-child-transmission
R&D Research and development
RIF Rifampicin
RNA Ribonucleic acid
RR-TB Rifampicin-resistant TB
RISLNET Regional Integrated Surveillance and Laboratory Network
RVF Rift Valley fever
SAMRC South African Medical Research Council
SARChI South African Research Chairs Initiative
SARS Severe acute respiratory syndrome
SATVI South African Tuberculosis Vaccine Initiative
STI Sexually transmitted infection
TB Tuberculosis
TDF Tenofovir disoproxil fumarate
TEM Transmission electron microscopy
TLC Thin layer chromatography
TWAS The World Academy of Sciences
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UK United Kingdom
UNAS Uganda National Academy of Sciences
USA/US United States of America
UV Ultraviolet
VHF Viral haemorrhagic fever
VPM Vakzine Projekt Management
WHO World Health Organisation
WHO-
AFRO
WHO Regional Office for Africa
WNV West Nile virus
XDR-TB Extensively drug-resistant tuberculosis
ZP Zeta potential
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APPENDIX B: LIST OF PARTICIPANTS
NAME SURNAME TITLE INSTITUTION/COMPANY
Quarraisha Abdool Karim Prof CAPRISA
Salim Abdool Karim Prof CAPRISA
Christian Acemah Mr UNAS 
Alicia Aron Dr Department of Health
Patrick Arthur Dr University of Ghana
Annah Margret Biira Dr       Makerere University
Axel Brakhage Prof Leibniz Institute 
Siyavuya Bulani Dr Academy of Science of 
South Africa 
Madichaba Chelopo Ms North-West University
Karen Cloete Dr iThemba LABS
Dina Coertzen Dr University of Pretoria
Halima Dawood Dr Greys Hospital 
Nokwanda Depargo Mrs CAPRISA
Daniel DeSanto Mr AHRI
Roseanne Diab Prof Academy of Science of 
South Africa 
Linda Dlamini Mrs Department of Health
Sabiha Essack Prof University of KwaZulu- 
Natal
Dorcas 
Oladayo
Fatoba Mrs University of KwaZulu-
Natal
Lindiwe Faye Ms Nelson Mandela 
Academic Clinical 
Research Unit
Glenda Gray Prof South African Medical 
Research Council 
Sherika Hanley Dr CAPRISA
Rose Hayeshi Prof North-West University
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NAME SURNAME TITLE INSTITUTION/COMPANY
Jörg Hecker Prof German National 
Academy of Sciences 
Leopoldina
Norbert Heinrich Dr University Hospital LMU 
Munich
Eva Herker Dr Leibniz Institute for 
Experimental Virology
Shevin Jacob Dr Infectious Diseases 
Institute/Liverpool School 
of Tropical Medicine
Graeme Jacobs Dr Stellenbosch University
Jonathan Jansen Prof Academy of Science of 
South Africa 
Stefan Kaufmann Prof Max Plank Institute for 
Infection Biology
Aina Kehinde Mr Llion University
Ayesha Kharsany Prof CAPRISA
Marina Koch-Krumrei Dr German National 
Academy of Sciences 
Leopoldina
Lenadine Koza Ms South African Medical 
Research Council
Alison Lubisi Dr Agricultural Research 
Council
Andriy Luzhetskyy Prof Helmholtz Institute 
for Pharmaceutical 
Research
Tebogo Mabotha Dr Academy of Science of 
South Africa
Steven Manzi Mr Vaal University of 
Technology
Stanley Maphosa Mr Academy of Science of 
South Africa
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NAME SURNAME TITLE INSTITUTION/COMPANY
Tebogo Maphosa Mr Kaboentle Centre for Life
Lungile Maphumulo Ms CAPRISA
Jackson Marakalala Dr University of Cape Town
Collen Masimirembwa Prof AiBST
Silindile Mbhele Ms CAPRISA
Thomas Mettenleiter Prof Federal Research 
Institute for Animal 
Health
Genevieve Mezoh Ms University of the 
Witwatersrand
Ntombizodumo Mkwanazi Ms University of the 
Witwatersrand
Koleka Mlisana Prof University of KwaZulu-
Natal
Martha Mokwena Miss Kaboentle Centre for Life
Louell Moonsamy Dr CAPRISA
Thumbi Ndumg'u Prof University of KwaZulu-
Natal
Jan Nilsen Dr German National 
Academy of Sciences 
Leopoldina
Oladoyin Odubanjo Dr Nigerian Academy of 
Sciences 
Olatunde Olayanju Dr University of Cape Town
Charles Osunla Mr Fort Hare University
Sean Patrick Dr University of Pretoria
Jude Przyborski Dr Heidelberg University 
Hospital
Caroline Pule Ms Stellenbosch University
Kristina Roesel Dr International Livestock 
Research Institute
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NAME SURNAME TITLE INSTITUTION/COMPANY
Gayle Sherman Prof National Health 
Laboratory Service
Alex Sigal Dr Africa Health Research 
Institute 
Izukanji Sikazwe Dr Centre for Infectious 
Disease Research in 
Zambia
Sydney Sproul Mr Uganda National 
Academy of Sciences 
Renee Street Dr South African Medical 
Research Council
Elizabeth Streicher Dr Stellenbosch University
Joseph Tchamgoue Mr University of Yaounde I
Renate Venier Ms Academy of Science of 
South Africa
Marietjie Venter Prof University of Pretoria
Delfino Vubil Mr Manhica Health 
Research Centre
Henriette Wagener Ms Academy of Science of 
South Africa
Kathrin Wittstein Dr Helmholtz Centre for 
Infection Research
Charles Wiysonge Prof South African Medical 
Research Council
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